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Summary 
Schistosomiasis is a neglected tropical disease caused by Schistosoma spp. 
parasites. It affects more than 200 million people and 700 million more are at risk. 
Over 10’000 people die every year because of the disease, but this number might be 
a big underestimation. While the disease is endemic in 78 countries and affects mostly 
poor communities without access to clean water, the highest prevalence for the 
disease is found in sub-Saharan Africa with over 85% of the overall occurrences. 
Children are at especially high risk of exposure through activities such as playing or 
bathing in infested water bodies. 
Schistosomiasis is a debilitating disease; the loss of productivity and mortality 
associated with the disease have a negative effect on the emerging countries' 
economies, which causes people to be stuck in a negative feedback loop of poverty 
and public health problems. Poor sanitation and unawareness of the general 
population are the main reasons for the transmission of schistosomiasis. The first 
symptoms of the disease are red bumps on the skin, usually appearing a few hours 
after infection and sometimes followed by mild fever and nausea. However, the chronic 
effects are more serious. In fact, children affected by the disease often show 
developmental delays and adults may develop chronic hepatic damage and 
eventually liver failure. There is only one drug available for mass drug administration 
(MDA) campaigns: praziquantel. There is growing evidence of a decreasing 
efficacy of praziquantel against Schistosoma spp. There is no vaccine available 
and the drug pipeline to treat schistosomiasis is empty. 
The overwhelming prevalence of schistosomiasis in the developing world and the 
absence of novel drug candidates against the disease are provoking fear of resistance 
emergence among the handful of laboratories involved in the fight against this 
neglected tropical disease (NTD). The research of novel compounds moves slowly 
and one of the main reasons for this is the difficulty in finding a reliable and faster drug 
screening method that would increase the drug screening output and the concordance 
between laboratories involved in the drug screening process. 
During my PhD, I worked on different projects tackling schistosomiasis, searching for 
ways to speed up drug screening processes and to contribute to the currently empty 
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drug pipeline. I worked on a protocol, in which we detail all the aspects of the drug 
screening procedure, with the aim to familiarize new laboratories with the procedures 
as we do them here at Swiss TPH, in order to decrease the methodological 
fragmentation in the field. I worked on the development of novel drug screening 
platforms and new methods to identify potential drug candidates. In collaboration with 
the Department of Biosystems Science and Engineering (D-BSSE) of ETH located in 
Basel, we developed a novel platform for antischistosomal drug screening based on 
microfluidic electrical impedance spectroscopy (EIS). Also, I worked on a human liver 
microtissue-based system to assess the liver metabolism for extending the standard 
drug screening assays in vitro on NTS to prodrugs, and to evaluate the liver 
metabolism's effect on the compounds’ activity on NTS in vitro. I first validated 
the system with praziquantel and then quantified the amount of compound 
metabolised and tested the effect of the liver metabolites on NTS in vitro with other 
compounds that are approved for human medicine. Finally, in an attempt to 
resolve the issue of praziquantel's low solubility, I collaborated with the 
University of Trieste in the development and testing of a novel formulation 
of praziquantel. This novel praziquantel formulation was based on a 
polymorph co-crystal provided by the University of Trieste. I tested this formulation 
derivative in vivo and in vitro to compare it to the standard praziquantel to 
evaluate its activity. I quantified praziquantel enantiomers by LC-MS/MS in mice 
plasma and compared the pharmacokinetics of the standard praziquantel with the 
polymorph praziquantel derivative. In this thesis, all of the above-mentioned projects 




Schistosomiasis is a neglected tropical disease and it is a morbidity associated with 
Schistosoma spp. infections. Schistosomes are the only known trematodes which 
possess dioecious reproduction and are able to reproduce sexually in the definitive 
host, while they reproduce asexually in the intermediate host (McManus et al., 2018). 
There are five main human Schistosoma species, which are commonly associated 
with the disease, namely: Schistosoma haematobium, S. mansoni, S. japonicum, S. 
mekongi and S. intercalatum, although the first three account for more than 90% of all 
the schistosomiasis cases (Gryseels et al., 2006). It is estimated that more than 779 
million individuals in 78 countries are at risk of contracting the disease (Keiser, 2010, 
Utzinger et al., 2011). The most endangered countries are the ones in sub-Saharan 
Africa with over half of all the schistosomiasis infections (Colley et al., 2014, Gryseels 
et al., 2006, Holding, 2003, Keiser, 2010, King, 2017). In sub-Saharan Africa, it is 
estimated that more than 10,000 deaths per year are due to schistosomiasis. The main 
reasons for the disease endemicity in these countries is the lack of sanitation-
infrastructures and the presence of uninformed individuals and unawareness 
(Gryseels et al., 2006).  
According to the Global Burden of Disease Study, schistosomiasis caused a loss of 
1.4 million disability-adjusted life years in 2017 (GBD 2017). The individuals 
infected with the disease, in most cases, will survive, but the liver damage can be 
dramatic, leading to hepatic cirrhosis and an increased risk of contraction of other 
diseases (Feldmeier et al., 1994). On top of this co-morbidity, schistosomiasis 
can lead to infertility, haematuria, impaired growth, anaemia and mental retardation 
(Tucker et al., 2013, Lewis and Tucker, 2014, Colley et al., 2014).  
The main cause for the disease is the presence of eggs released by the female 
schistosomes that remain embodied in the host organs, mostly the liver. Those eggs 
are released by the parasites in the order of a few dozens to hundreds per day, 
depending on the Schistosoma species; many of those eggs are excreted by the host 
but the ones remaining embedded are the cause of the disease (McManus et al., 2018, 
Elbaz and Esmat, 2013). The eggs have a specific morphology that helps the 
microscopic distinction of the species during diagnostic screenings (Gray et al., 2011). 
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Every species has a specific localisation of the adults, which also helps the 
identification of the parasite species. However, the parasite localisation can vary 
depending on the animal model used (Keiser, 2010).  
1.1.1. Schistosoma mansoni life cycle 
Schistosoma are dioecious, digenetic, parasitic flatworms, and have a syncytial 
tegument and a ventral and oral sucker (Olson et al., 2003). The adult worms are about 
1-2 cm long, and possess a blind digestive tract, reproductive organs and a primitive
neuromuscular system. Sexual dimorphism is evident: the male is wide with a 
tegument patterned by distinct tubercles, while the female is longer and streamlined 
(Hockley, 1973, Buchter et al., 2018). The life cycle of the parasite is a complex one 
and only a few institutions worldwide have it in-house (Keiser, 2010). The life cycle 
includes both asexual and sexual reproduction in an intermediate and definitive host, 
respectively.  
Figure 1 Schematic representation of the S. mansoni life cycle. Figure adapted from 
yourgenome.org/facts/what-is-schistosomiasis. 
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Flagellated, fork-tailed cercariae, the infectious freshwater swimming stage of the 
parasite, are chemotactically attracted by the human’s (definitive host) skin due to its 
release of L-arginine (Haas et al., 2002) and/or skin lipids (Shiff et al., 1972). The 
cercariae can survive in fresh water for 24-48 hours without feeding due to their 
glycogen reserves (Morley, 2011). Once the cercariae reach the host, the parasites 
penetrate the host’s skin, which activates a series of biochemical mechanisms causing 
them to shed their tail and their glycocalyx (McKerrow and Salter, 2002). They are 
from this moment on known as schistosomula. The schistosomula enter the blood 
circulation and, driven by the blood pressure, reach the lungs and the heart. 
Schistosomula will mature for up to 3 weeks in the lungs. Eventually, from here the 
schistosomula will reach the liver, where, over a period of about 7 weeks, they mature 
into a sexually dimorphic species and pair, living in constant copula, which can last for 
many years (Gryseels et al., 2006, Jamieson, 2017) . Once this stage is reached, the 
paired adults leave the liver through the portal vein and parasitize the mesenteric 
veins. 
There are reports indicating that Schistosoma spp can live up to 30 years in the 
human host (Tucker et al., 2013, Lewis and Tucker, 2014, Colley et al., 2014, Gryseels 
et al., 2006).  
The adult schistosomes feed on blood; the ingested volume is ∼100 nL for males and 
∼900 nL for females per day (Skelly et al., 2014). Ingested erythrocytes are lysed by
gut proteases present in the digestive tract. Proteomic analysis of the gut identified an 
amino acid transporter, ion, and lipid transporters (Skelly et al., 2014). Specialised 
channels on the surface of the parasites acquire glucose. The catabolic product of the 
haemoglobin degradation is heme, which could be toxic for the parasites (Skelly et al., 
2014). Consequently, a not very well understood process of regurgitation excretes 
heme back into the host circulation, since schistosomes lack the anus (Skelly et al., 
2014).  
The females of Schistosoma spp. shed eggs that extravasate the mesenteric veins, 
pass through the wall of the intestines via the Peyer’s patches to the intestinal lumen 
and eventually end up in the feces (Turner et al., 2012). Due to poor sanitation and 
hygiene standards in the affected countries, the eggs end up contaminating water 
bodies. Ciliated miracidia develop inside those eggs and once favourable conditions 
are present, they hatch. The ciliated miracidia are chemotactically attracted by their 
intermediate host, the Biomphalaria glabrata water snails and penetrate them. Once 
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inside the intermediate host, the miracidia transform into sporocysts and reproduce 
asexually, leading to shedding of thousands of sporocyst every day, which eventually 
develop into cercariae, the infectious stage of the schistosomes' life cycle (Jamieson, 
2017). Cercariae can survive in open water for a period longer than 24 hours and 
eventually infect their definitive host, thereby completing the cycle (Figure 1) 
(Jamieson, 2017, Morley, 2011). 
The replication of the life cycle of the parasite in a laboratory setting has been an 
essential achievement for a better understanding of the host-parasite dynamics and 
is a fundamental pillar for the research on novel compounds that would deter 
schistosomiasis (Keiser, 2010, Lombardo et al., 2019). In a laboratory environment 
the entire cycle requires about 4 months to be completed, and at that point, it can also 
be reproduced every month by having numerous batches simultaneously (Lombardo 
et al., 2019).  
1.1.2. Epidemiology 
One of the objectives set by the WHO is the elimination of schistosomiasis within the 
year 2020. The objective will not be reached, but the overall prevalence in many sub-
Saharan countries has been decreasing steadily, in some settings dramatically 
(Rollinson et al., 2013). The reason for this partial success were the mass drug 
administration (MDA) campaigns, started in early 2000, which distributed hundreds 
of millions of therapeutic doses (of praziquantel) over the years (Wang and Liang, 
2015). Although the MDAs do not prevent helminthic reinfection, the overall 
prevalence has decreased, for example by ~30% in Mali between 2003 and 2010, 
and in Lebanon schistosomiasis transmission has been eliminated (Miguel and 
Kremer, 2004, Rollinson et al., 2013) (Figure 2). Some endemic countries, such as 
Zanzibar, will most likely reach the goal of disease elimination as soon as 2025 
(Knopp et al., 2019). A more realistic goal for the elimination of transmission is 2030 
(Fenwick and Jourdan, 2016).  
7
Figure 2: Distribution of schistosomiasis in the world and the countries that have been 
determined to have achieved the elimination of the burden (Rollinson et al., 2013) 
The countries in which the prevalence of the disease is still high are usually lacking 
adequate sanitation infrastructures and have poor healthcare systems (Figure 2). This 
poverty-loop makes the infection and eventually reinfection extremely likely to happen, 
especially in children 5-12 years old (Bustinduy et al., 2017, Coulibaly et al., 2017). 
However, there is an overall increase of interest as well as a growing awareness of 
the disease and health education (Miguel and Kremer, 2004). There are also global 
initiatives, such as Water, Sanitation and Hygiene (WASH), which help alleviate the 
poverty cycle caused by schistosomiasis (McMichael, 2019, McManus et al., 2018). In 
endemic areas, schistosomiasis can also be associated with other parasitic infections. 
Such a condition is known as polyparasitism, and it can lead to exacerbation of the 
symptoms (Ezeamama et al., 2008, McKenzie, 2005). Overall, the contribution of the 
MDAs was important in the reduction of schistosomiasis prevalence. However, more 
work has be conducted to eliminate the disease.  
1.1.3. Pathology 
The cercariae penetrate the host’s skin within an average of seven minutes after 
contact (Haas and Haeberlein, 2009, Gryseels et al., 2006). Within one hour after 
cercarial penetration through the skin, there is generally an ectodermal manifestation 
characterized by general rash with maculopapular lesions, known as “swimmer’s itch” 
(Bouree and Caumes, 2004). This is characterized by sensation of itch and red swollen 
regions of the skin. Once the schistosomula successfully penetrated the human skin, 
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an acute, then a chronic phase follows. The acute phase, called also Katayama 
syndrome, provokes general flu-like symptoms such as myalgia, fever, fatigue, 
nausea, abdominal pain, urticaria and eosinophilia, but sometimes the acute phase 
can be asymptomatic (de Jesus et al., 2002, Maizels and Yazdanbakhsh, 2003). In 
the animal model, those symptoms are hardly detected. These symptoms are caused 
by the immune system reacting to the parasite and are generally short-term and mild. 
Symptoms of acute schistosomiasis can develop a few weeks after the schistosome 
parasite first burrows into the skin of the human host, when the first parasite eggs are 
trapped in the liver and spleen. Those symptoms arise due to the activity of elements 
of the humoral immunity such as macrophages and basophils. The incremental 
differentiation of the CD4 T cells into Th2 T cells drives the macrophages to exacerbate 
the inflammatory microenvironment and causes fibrogenesis in the Schistosoma eggs 
milieu in the liver by upregulation of Fizz1, Ym-1 and Arg-1 (Wilson et al., 2006).  
In the chronic phase of schistosomiasis, symptoms can persist for years. Symptoms 
of chronic schistosomiasis include: abdominal pain, hepatomegaly, haematochezia or 
haematuria (Gryseels et al., 2006). In rare events, eggs have been found in the brain 
or the cerebrospinal fluid (CSF) causing inflammation and seizures. This condition is 
known as neuroschistosomiasis; in most cases it is due to ectopic egg 
dissemination of Schistosoma japonicum (Ross et al., 2012). 
S. haematobium is localised in the blood vessels surrounding the bladder. A common 
complication is an increased risk of co-morbidities, especially in women, such as 
haematuria and increased risk of contracting HIV (Feldmeier et al., 1994). Moreover, 
chronic infection with S. haematobium increases the risk of chronic inflammation that 
could eventually lead to squamous cell carcinoma of the bladder (SCC), due to the 
eggs trapped in the tissue.  
Schistosoma mansoni has not been associated with increased risk of developing 
hepatocarcinoma, but it is well known to cause periportal fibrosis and consequent 
hepatosplenomegaly (Nacif-Pimenta et al., 2019). Recently, a correlation between the 
levels of splenomegaly could be predicted by the altered proportion of blood elements, 
such as the proportion of leukocytes. The enlargement of the spleen is directly 
proportional to the level of leukopenia (Vasconcellos et al., 2018). 
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1.1.4. Diagnosis, treatment and prevention 
Routine screening for schistosomiasis is usually conducted by analysis of stool smear 
specimens (2-10 mg) based on methods such as Kato Katz or urine filtration and by 
optical microscopy to identify eggs (Gray et al., 2011). This allows the identification of 
the infecting Schistosoma species due to the morphological distinguishing trait of the 
eggs’ spine (Gray et al., 2011). However, trained operators are required for the stool 
analysis. The stool based analysis method can introduce an operator bias, and it can 
be laborious. The Kato-Katz and urine filtration methods are recommended by 
WHO for schistosomiasis when the intensity of infection is high, but their 
sensitivity varies with prevalence and intensity of infection, because if less eggs are 
present in the sample they can go undetected by the operator, leading to an 
underestimation of the infection level (Gray et al., 2011). A sensitive PCR 
based assay has been developed for the detection of Schistosoma spp. DNA in 
biological samples from feces and plasma. This approach has the potential to 
provide a test for diagnosing schistosomiasis in all phases of infection 
(immediate, acute or chronic phase of infection). This diagnostic test is particularly 
important because egg detection can take up to two months post infection (Gray et 
al., 2011). There are also other techniques such as ELISA that allow the detection 
of IgG, IgM, or IgE against soluble worm antigen or soluble egg antigen, indirect 
haemagglutination, or immunofluorescence (Gray et al., 2011). However, these 
techniques are less sensitive and specific than PCR and stool or urine sample 
analysis (Gray et al., 2011). The circulating cathodic antigen (CCA) and the 
circulating anodic antigen (CAA) are both applied to diagnose active infections and 
for evaluation of drug efficiency. There are emerging detection methods based on 
point-of-care-circulating cathodic antigen (POC-CCA) on biological samples, 
which have been shown to be sensitive in field settings in high and middle endemic 
areas. However, the performance of the POC is still debated in low endemic areas 
(Kittur et al., 2016).  
Preventive chemotherapy against schistosomiasis has been going on since the early 
2000 (Inobaya et al., 2014). The WHO organises annual or biannual MDA 
campaigns for preventive chemotherapy. MDAs aim to reduce the morbidity 
and mortality associated with the infection with Schistosoma spp. and to prevent 
new infections by limiting the transmissions by reduction of the overall 
prevalence in the population 
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(Inobaya et al., 2014). Over 200 million doses are distributed each year to the 
schistosomiasis endemic countries (Inobaya et al., 2014). MDAs are often 
implemented in combination with other strategies, such as intermediate host 
control. Using molluscicides is a common method for elimination of the intermediate 
host. One of the main chemicals used for this purpose is niclosamide, which is also 
the only WHO recommended molluscicide (Inobaya et al., 2014). 
Praziquantel has always been the drug of choice for these administration campaigns, 
because of the low cost of the therapy and the well-known efficacy of this drug as well 
as the ease of administration and the minor side effects (Inobaya et al., 2014). The 
preventive chemotherapy is based on a single dose of 40 mg/kg of praziquantel. This 
drug regimen has 66-95% efficacy for MDA programs, egg reduction rate (ERR) 
above 90% and cure rate (CR) above 70% (Gryseels et al., 2006). However, double-
dose praziquantel treatments achieved ERR above 95% and CR above 90% (Munisi 
et al., 2017). The WHO recommends a dosage regimen of 60 mg/kg orally for S. 
japonicum and S. mekongi and a 40 mg/kg praziquantel dose for S. mansoni, S. 
haematobium, and S. intercalatum (Gryseels et al., 2006). There is still a debate 
whether a double dose with 40-60 mg/kg praziquantel therapy could provide some 
benefit over a single dose treatment. King et al. suggested in a systematic review that 
a double dose of praziquantel administered 2-8 weeks after the first dosage would 
justify the additional costs sustained by increasing the cure rates of the treatment in 
the case of S. mansoni infection, but in the case of S. haematobium this is still unclear 
(King et al., 2011). This increased cure rate after double therapy could be due to the 
development of the parasites in infected individuals, who had juvenile stage parasites 
(which are not susceptible to praziquantel) at the time of administration of the 
first dose, which had developed into susceptible developmental stages by the 
time of administration of the second dose (Cioli et al., 2014). However, because 
praziquantel is not effective for the prevention of reinfection, because it does not 
kill the young parasites and because many of the people infected are still not 
reached by the MDAs, the disease elimination objectives could not be reached 
(Inobaya et al., 2014). In addition, praziquantel drug efficacy is decreasing, making 
the research for novel drug candidates necessary (Doenhoff et al., 2008). 
A problem related to the current treatment with praziquantel is the bitter taste and the 
size of the oral pills (600 mg). Those two issues make the praziquantel paediatric 
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compliance difficult. Because children (10-13 yrs.) are the most exposed population to 
the infection in schistosomiasis endemic countries (Hajissa et al., 2018), there are 
currently some efforts to make the formulation more child friendly, for example by 
removing the inactive stereoisomer S-praziquantel from the current formulation, 
thereby reducing the pill size (Cioli et al., 2014). 
1.1.5. Praziquantel 
Praziquantel has an interesting history. It is the only drug available today as effective 
treatment against schistosomiasis, next to oxamniquine, which has seen the 
insurgence of resistant parasite strains and is therefore no longer used. Praziquantel 
is listed by the WHO as essential medicine and it has been recommended for MDA 
since the mid-80s (Colley et al., 2014). It was discovered in 1971, from a collaboration 
between Bayer and Merck, in Germany. When the compound was first discovered 
among a library of about 400 pyrazinoisoquinolines as potential tranquilizers, it was 
used for veterinary practice. A few years later, its broad-spectrum activity against 
several helminths and cestodes was discovered and human clinical trials established 
that the drug was indeed safe and effective for use in human medicine (Campbell 
and Rew, 2013). The drug was very expensive at first, but it rapidly became cheaper 
and cheaper with the increased competitive chemical power of China and 
Korea. Praziquantel is the latest cornerstone against schistosomiasis. Nowadays, 
hundreds of millions of doses of praziquantel are used routinely every 
year to treat schistosomiasis in human and veterinary medicine. The fact that this 
drug is used for both human and animal medicine implies an increased risk of 
resistance development, because of the high evolutionary pressure posed on the 
Schistosoma spp parasites. Praziquantel’s mechanism of action is not yet 
completely understood, but the most accredited opinion is an effect on the 
calcium channels on the tegument of the parasites (Olliaro et al., 2014). 
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Figure 3 Molecular structure of praziquantel with its stereocentre (Gouveia et al., 
2018). The stereocentre is highlighted in blue. The two enantiomers have different 
biological effects. R-praziquantel is biologically active while S-praziquantel is less 
active. 
Voltage-gated Ca2+ channels (VGCCs) and in particular the beta subunits of the VGCC 
are known as one of the potential molecular targets of praziquantel (Jeziorski and 
Greenberg, 2006). It has been demonstrated that, if these channels are specifically 
antagonized by nicarpidine and nifedipine, the adult worms survive doses of 
praziquantel otherwise lethal (Doenhoff et al., 2008).  
Praziquantel is a safe drug with a good safety window, but it also has drawbacks, such 
as poor efficacy against juvenile stages of the parasites, poor formulation compliance 
in children due to bitter taste and tablet size and very erratic pharmacokinetic profiles. 
In consequence, rounds of multiple doses are necessary to clear the infection 
(Doenhoff et al., 2008, Cioli and Pica-Mattoccia, 2003). 
The commercial formulation of praziquantel is a racemate (both the R- and S- 
enantiomers are present each in 50%) (Figure 3), since the active pharmaceutical 
ingredient (API) possesses a stereocentre. Maximum concentrations are reached at 
about 60-120 minutes post oral intake with an overall bioavailability of about 80%. Only 
Biologically active 
Biologically less active 
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R- praziquantel is the active component (Figure 3). However, some authors claim 
that S- praziquantel has some activity in vivo against S. haematobium (Kovac et al., 
2017, McManus et al., 2018). The drug undergoes extensive liver first pass 
metabolism and is later processed into the inactive main human metabolites trans-4-
hydroxy-praziquantel and cis-4-hydroxy-praziquantel by the two P-450 isozymes 2B1 
and 3A that oxidise xenobiotics (Doenhoff et al., 2008, McManus et al., 2018).  
1.2. Current challenges in the field 
Schistosomiasis is a global disease, which affects over 200 million individuals, yet 
there is only one treatment currently available and the drug pipeline is empty. There 
is no vaccine available (Lewis and Tucker, 2014, Ricciardi and Ndao, 2015) and the 
research for new antischistosomal vaccines or drugs relies on a handful of academic 
laboratories (Keiser, 2010). However, in the last ten years, global awareness of the 
disease has been increasing and some new public and private partnerships (PPP), 
such as Drugs for Neglected Diseases Initiative (DNDi) and Medicine for Malaria 
Venture (MMV) and collaboration programs are being established in a number of 
academic settings (Chatelain and Ioset, 2011, Nwaka and Hudson, 2006).  
Nonetheless, finding alternative drugs against schistosomiasis is not an easy task. 
There are many challenges related to the complex nature of the parasite’s life cycle, 
which requires two hosts, and to the biology of the parasite, which is so variable 
depending on the parasite stage (Lombardo et al., 2019). There are problems 
regarding the availability of parasites, which at this point, is still too limited to perform 
high throughput drug screenings (Lombardo et al., 2019).  
In addition, the current gold standard for drug screening is based on phenotypic 
assessment by microscope visual scoring (Ramirez et al., 2007). This method does 
not allow medium or high throughput and it suffers from operator bias, which makes 
this screening method slow and subjective (Lombardo et al., 2019). It has been 
reported that less than 20% of drug hits identified by a lab are confirmed by other 
laboratories (Panic et al., 2015b, Mansour et al., 2016).  
Many alternatives to the standard drug screening method have been proposed, but 
none of these technologies spread. NTS drug screening methods based on 
microthermal calorimetry (Manneck et al., 2011), colorimetric assay (Panic et al., 
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2015a), as well computer aided image recognition and photogram-image subtraction 
(Paveley et al., 2012) have been proposed. Each of these methods has some 
drawbacks and the lack of other laboratories using the same technique is a cause of 
conflicting results, variance and fragmentation in the field. In the case of the 
calorimetric assay, one of the main limitations was the high number of parasites 
needed, which made this technique difficult to implement (Manneck et al., 2011). Also, 
calorimetric assays are often based on expensive dyes, therefore low-resource 
settings could not afford them (Panic et al., 2015a, Lalli et al., 2015). This is also a 
problem with the computer aided phenotypic screenings on NTS, which are based on 
high computational power and sophisticated algorithms and/or devices that can be 
costly and difficult to implement (Paveley et al., 2012).  
1.3. Anti-schistosomal drug screening 
It is not known, at the moment, if the sex of the adult worm is already determined at 
the level of the eggs, as suggested by some authors (Sotillo et al., 2015). However, 
some authors reported a genetic trait at the cercarial stage that is essential for the 
development of female parasites (Spotila et al., 1987). There are also authors 
suggesting that it is the presence of schistosomes of the opposite sex, which makes 
the parasites develop into sexually mature adults (Hernandez et al., 2004). Another 
theory assumes that the maturation into male or female is determined by components 
of the definitive host’s immune response (Hernandez et al., 2004).  
NTS represent an important stage for the entire drug discovery procedure, as 
illustrated in (Chapter I) of this thesis. Because NTS can be obtained in high numbers 
(in contrast to the adult stage parasites that are isolated from animal hosts in the range 
of dozens per mouse (Lombardo et al., 2019)), they are considered an important 
organism for drug discovery and drug development. Ideally, a drug that is effective in 
vitro on NTS would be active on adult stage parasites in vitro and hopefully in vivo. 
This ideal drug would lower the risk of reinfection, since the drug would be active 
against the juvenile stages of the parasites that are not targeted by praziquantel 
(Cioli et al., 2014). NTS are obtained by mechanical transformation, by passing snail-
shed-cercariae through a pair of 10 mL syringes connected by a plastic Luer-Lok 
connector. During this coerced passage, the cercariae become tailless. At this point, 
the genetic profile of the NTS is very different from the one of naturally occurring 
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schistosomula after skin penetration. For this reason, some researchers analysed 
the transcriptomic difference between those mechanically and the naturally 
obtained schistosomula. Protasio et al. (Protasio et al., 2013) noticed that the profile 
differs in the expression of some proteases, which are expressed in naturally 
occurring schistosomula, but not in the mechanically obtained ones (Protasio et al., 
2013). However, after 12-24 hours incubation, the expression profiles of the 
mechanically transformed schistosomula become similar to the ones of naturally 
occurring schistosomula (Protasio et al., 2013). 
New drug candidates are tested in vitro at first on NTS at 10 µM and then the ones, 
which showed efficacy, called hits, are tested on adult Schistosoma again at 10 µM. 
IC50 curves are calculated to evaluate the potency of the compounds (Chapter I). 
During the drug screening on NTS and adult stage parasites, a trained operator gives 
scores from 0 to 3 depending on the morphology and the behaviour of the parasites 
after drug testing. When the operator assigns a 0, this score indicates that the 
compound tested was active leading to parasite death. If the operator assigns a score 
of 3, the parasites are viable with an optimal behaviour, indicating that the compound 
tested was not active against the parasites (Lombardo et al., 2019). Those lead 
compounds can at this point be tested in mice harbouring S. mansoni infection, in 
order to evaluate the potential effect in vivo, generally at 200 mg/kg (Chapter I). 
Unfortunately, many compounds that are active in vitro, fail to show activity in vivo or 
they show high toxicity (Pasche et al., 2018, Panic et al., 2015b, Panic and Keiser, 
2018).  
An approach to identify novel active compounds is to test “brute-force” libraries with 
huge numbers of compounds within the shortest time possible to observe a change in 
the phenotype of the target cell or organism (phenotypic screening). Many pharma-
companies are currently using this approach to test millions of compounds in a limited 
amount of time (Swinney, 2013). Generally, these approaches are relying on high-
throughput (HTS) screenings and automatized methods (Wildey et al., 2017). These 
large-scale approaches can hardly be applied to the drug screening against 
schistosomiasis, because of the complexity of the parasite's life cycle and because, at 
the moment, it is not possible to grow the parasite stages in vitro without the 
intermediate and definitive host. 
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A more recent approach for drug screenings consists of in silico drug prediction for 
both phenotypic drug screenings and target-based drug screenings. Thanks to the 
advances in computer technologies, life sciences and increased understanding of the 
parasites’ biology, the acquired knowledge from decades of drug screenings 
and structure identification led to the availability of millions of molecular structures, 
now stored in freely available online databases (Liu et al., 2013, Wishart et al., 
2006, Terstappen and Reggiani, 2001). Computer algorithms can scan these 
databases in a short time in order to identify possible molecular fits against 
molecules and vice versa. Each in silico fit can be subsequently tested and 
verified. With the recent advances in machine learning algorithms or neural 
networks, it is also possible to generate a molecule from the target by molecular 
computer-aided design (mol-CAD). This latter approach is estimated to be the 
next generation for drug screening procedures (Olivecrona et al., 2017). This 
could be useful in settings with low resources such as the field of neglected 
tropical diseases (NTDs) and rare diseases, both underfunded. These approaches 
could reduce the amount of drug screenings necessary to obtain interesting drug 
candidates, because the molecules are produced to fit to specific molecular targets 
or specific molecular targets are identified from known chemical structures (Plouffe 
et al., 2008). 
1.3.1. Drug repurposing 
Drug repurposing is a very interesting aspect of drug development. It is based on the 
idea of “recycling” established drugs by employing them against other diseases or 
against other organisms than they were originally intended for. Drug repurposing has 
important advantages, such as reducing the costs associated with the research and 
the development of a drug ex novo as well as reducing the time-to-market for potential 
lead candidates (Panic et al., 2014). Moreover, additional information, such as 
chemical, pharmacokinetic and analogue properties have already been determined 
and are usually available (Oprea et al., 2011). In addition, computer aided screening 
can facilitate this process, by finding other molecular targets for already marketed 
drugs in publicly available databases (Liu et al., 2013). For example, thalidomide was 
initially marketed in the 50s-60s’ to treat morning sickness during pregnancy, but was 
re-used as therapy against brain tuberculosis (Buonsenso et al., 2010) and as cancer 
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drug (Liu et al., 2013). Due to the limited resources funding the research of novel 
candidates in NTDs, drug repurposing has become an essential part of the drug 
development process. In our laboratory, many compounds come from a series of 
potential drug candidates for other diseases and/or conditions. These compounds 
were tested for their effects against schistosomiasis and in many cases interesting 
compounds were identified (Cowan and Keiser, 2015, Panic et al., 2014, Panic and 
Keiser, 2018, Gouveia et al., 2018, Panic et al., 2015b).  
1.4. Polymorphism 
Polymorphism is a characteristic that is intrinsic in the structure of compounds. Every 
compound has a specific number of possible conformations (Figure 4), in which the 
crystalline structure can be set. Those altered special dispositions of the constituents 
of the crystal lattice make it possible to generate new versions of a compound with 
modified chemical and physical properties, but keeping its molecular formula. 
Figure 4: In this schematic the various configurations of a compound are reported. 
Figure from https://newdrugapprovals.org/category/polymorph/ 
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Polymorphs differ in numerous important drug properties such as drug efficacy, 
bioavailability, and even toxicity (Raza, 2014). For example, the praziquantel 
polymorph we used in this work (Chapter IV) has been shown to possess double the 
solubility of the standard praziquantel (Beatrice et al., 2017, Zanolla et al., 2018b).  
Compounds can be of amorphous structure without a crystalline reticulate and they 
can undergo a series of chemo-physical rearrangements of their reticule in order to 
increase their stability. Polymorphs are an example of such a transition. Polymorphism 
can be of two types: monotropic and enantiotropic. In the monotropic type, the stability 
of one of the polymorphic forms is stable at temperatures below the melting point of 
the drug. In contrast, an enantiotropic polymorph can have several stable forms at 
different temperatures. Gibbs free energy (ΔG) determines the relative stability and it 
is the driving force for the polymorphic transformations at constant temperature and 
pressure (Figure 4). 
There are some examples of important marketed polymorph drugs: Axitinib is a drug 
marketed for treatment of renal cell carcinoma (RCC) with over 200 reported 
polymorphic forms. The drug is an inhibitor of the vascular-endothelial-growth-factor-
receptors (VEGFRs) kinase, expressed mostly in endothelial cells. However, the most 
thermodynamically stable form of the API is the polymorphic form, known as XLI; this 
drug is currently marketed as polymorph with the name Inlyta (INN) by Pfizer® (EMA, 
2012). 
Polymorphs of a drug can reveal information on the drug that were not known before. 
Therefore, this could expand the possibilities offered by many of the drug candidates 
(Zanolla et al., 2018a, Raza, 2014). This approach could also lower the costs 
associated with developing novel drugs. This is particularly important in drug discovery 
in the settings of neglected tropical diseases, which are, by definition, underfunded 
(Keiser, 2010). 
I tested a polymorph derivative of praziquantel, in which the structure of the API is kept 
the same as in the commercial praziquantel. This, according to the literature, can have 
many different advantages over the standard drug formulation. Moreover, the drug 
had already been pre-tested in our lab in vitro and in vivo in a small trial and we 
observed interesting results, which suggested proceeding to further testing with this 
drug. I therefore extensively tested the praziquantel polymorph in vitro and in vivo in 
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order to compare its activity and its pharmacokinetics to the ones of the standard 
commercial praziquantel (Chapter IV). 
1.5. Electrical impedance spectroscopy (EIS) 
Electrical impedance defines a measure to quantify the resistance offered by a circuit 
when an alternating current (AC) is applied. In the international system, Electrical 
Impedance (EI) is measured in Ohm (Ω). However, it is often symbolised as Z and it 
may be represented by writing its magnitude and phase in the form |Z|∠θ.  
EIS has been used in many biological applications already, such as a micro- flow 
cytometry devices that can evaluate the differentiation of cells by their size (Cheung 
et al., 2005). In another application, Gomez et al. showed a device based on EIS to 
evaluate the viability status of bacteria, in which products of the bacterial 
metabolism modified conductivity of the medium (Gomez et al., 2001). In another 
study, an EIS-based platform allowed continuous analysis of the growth rate of cell 
colonies in real time (Chawla et al., 2018).
The electrical impedance can be represented on a Cartesian plain. The 
impedance can give information on the magnitude and phase of the passing AC 
current. The impedance measurement is dependent on the frequency of the AC. 
Therefore, to analyse the behaviour of Z and the phase (angle of the Z function), 
one single frequency at the time can be used, or as well multiple frequencies. 
Figure 5: Schematic representation of the electrical impedance spectroscopy signal 
a b 
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in (a), where the output of the voltage is changing after the recording of a 
single movement of an NTS. (b) Schematic representation of the electric fluid 
between two co-planar electrodes, as used in the platform described in Chapter II. 
EIS can be used to analyse the dielectric properties of elements in a circuit, since Z 
can provide information on the magnitude and the phase of the resistance. 
Therefore, a biological cell as well as a biological organism can be considered as a 
dielectric element (Pethig, 1985). EIS calculates the impedance of a sample by 
applying an AC current through a range of frequencies and measuring the resulting 
voltage. Hence, a complex and element-specific spectrum of readings can be 
acquired from each biological element (Chawla et al., 2018). For these reasons, 
impedance based spectroscopy is a very interesting technique that provides not only 
information on the dimension of the biological entity analysed, but also on its 
dielectric properties and resistivity. EIS is a non-destructive technique that is being 
used in many different fields such as cell viability and/or differentiation 
measurements (d'Entremont et al., 2002) or abasic DNA detection (Heinrich et 
al., 2018). It is used also in agronomy to evaluate the presence of fertile seeds from 
ones that are not (Zhang et al., 2011). We decided to implement an electrical 
impedance based platform that allows the measurement of NTS motility for 
drug screening (Chapter II). The parasites' motility is one of the most important 
parameters to be assessed in parasite scoring (Lombardo et al., 2019). To measure 
NTS motility, a pair of coplanar electrodes can be used for measuring 
conductivity variations of the medium caused by parasite movements 
between the electrodes. To measure the signal fluctuations caused by the NTS, 
an AC voltage is applied on one of the two co-planar electrodes, and the current 
flowing through the sensing volume is then acquired at the other 
electrode and converted to voltage through a transimpedance amplifier. The 
magnitude and the frequency of the voltage give indications on the intensity 
and frequency of the NTS movements, respectively. Therefore, this method can 
be applied for the evaluation of the NTS viability, by analysis of the motility, for 
example to assess a compound activity (Chapter II).
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1.6. Liver microtissues 
Drug metabolism in vivo and pharmacokinetic prediction are among the greatest 
incognita to overcome once a novel lead compound reaches the animal testing phase. 
Therefore, choosing the correct in vitro and in vivo model for more accurate drug 
prediction is crucial (Wang et al., 2015, Pampaloni and Stelzer, 2009). Liver 
microtissues represent a novel cell-culture technology that is surging and its usage 
could be highly beneficial for toxicity testing and metabolic testing of novel 
compounds, since liver microtissues possess expression of the whole P450
cytochrome family (CYPs) comparable to in vivo (Kim et al., 2015, Chiba et al., 
2009). This in vitro model offers many advantages over conventional standard cell 
cultures (Wagner et al., 2013, Bale et al., 2016, Messner et al., 2013, Pampaloni and 
Stelzer, 2009). It has been shown, in fact, that the structural cell organisations 
present in the human liver are also present in the tridimensional liver microtissue-
based cell cultures, in both monocultures and in multi-cellular-cultures (with 
endothelial cells (ELC) and Kupffer cells) (Figure 6) (Bell et al., 2018, Messner et al., 
2013). These cells, especially hepatic primary cells, are variable (since they are 
taken from donor livers) and therefore they might better reflect the natural human 
genetic variability and proteome than standard cell line cultures (Simon et al.,
2018, Messner et al., 2013, Pampaloni and Stelzer, 2009).  
In a study from Olson et al. (Olson et al., 2000) it has been demonstrated that 43 % 
of toxic effects in humans were correctly predicted by tests in rodents, whereas 
this percentage increased to 63 % when liver primary microtissue models were 
used (Olson et al., 2000, Proctor et al., 2017). Another practical advantage is that 
those liver microtissues can be kept in vitro for 4-5 weeks, without risk of de-
differentiation (Simon et al., 2018, Ramaiahgari et al., 2017); many studies are 
reporting stable expression of the key proteins for the liver functionality (Leite et al., 
2012, Yokoyama et al., 2018). 
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Figure 6 Image of a human liver microtissue plate. The plate is scanned during quality 
control by Insphero®. Each well contains a liver microtissue of 250-350 µm diameter. 
Liver microtissues represent the human in vivo situation more closely compared to the 
standard animal model (most often rodents, and primates in the latest pre-clinical 
phases of drug development) and standard cell cultures (Proctor et al., 2017). In 
addition, liver microtissues are easy to handle and some “body-on-a-chip” prototypes 
for drug testing are being evaluated for drug screening and drug toxicity in more detail 
(Foster et al., 2019).  
Each batch of multidonor human liver microtissues is obtained by pooling ten different 
livers from deceased donors (accidents, cardiovascular complications). Five donors 
are female and five donors are male. The livers are mashed and pooled together. 
Some cellular components, such as the immune cells i.e. Kupffer cells, are 
removed from the homogenate. Afterwards the cells are cryopreserved. 
Eventually, cellular seeds are distributed in special U-bottom wells where the liver 
cells aggregate in tridimensional spherical microtissues by gravity and cell 
polarisation (Kim et al., 2015, Jiang et al., 2019, Kermanizadeh et al., 2019).The 
quality control ensures homogeneity of the batch, and tests are performed to 
evaluate overall viability of the batch, dimension of the aggregates and the 
23
expression of key enzymes such as P450 cytochromes (Figure 6).  
Given all the advantages of the liver microtissues over the standard cell cultures, we 
validated this platform as a tool in antischistosomal drug screening, as explained 
in Chapter III of this work.  
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1.7. Aim and objectives of the thesis 
The aim of this thesis was to study ways to overcome some of the limitations present 
in the Schistosoma spp. drug-screening pipeline, such as the low throughput and the 
subjectivity of the drug screening. We published a collection of protocols to uniform 
the drug screening procedure in Schistosoma mansoni with the aim to lessen the 
fragmentation between research groups involved in the search for novel 
antischistosomal drugs. Together with the D-BSSE of the ETH in Basel, more 
specifically with the Bio Engineering Laboratory led by Professor Dr. Andreas 
Hierlemann, I worked on the development of a novel device that could overcome some 
of the drawbacks linked to the laborious and subjective gold standard phenotypic drug 
screening procedure on Schistosoma spp.. This collaboration was essential for the 
development of a novel platform based on electrical impedance (EIS) for real-time 
measurement of NTS viability through motility readout. We developed a drug 
screening procedure based on primary human microtissues to extend the standard 
drug screenings on NTS to prodrugs and other compounds, assess the compound's 
cytotoxicity and to evaluate the effect of the liver CYPs on the compound’s activity in 
vitro on NTS. Finally, in collaboration with the University of Trieste I also evaluated a 
novel formulation of a polymorph of the racemic praziquantel in vivo and in vitro. To 
summarize, our aim was to 
I. Make drug screening more uniform across different labs by providing a
collection of procedures to detail our in-house drug screening in Schistosoma
mansoni (Chapter I).
II. Improve the current drug screening procedure and overcome its previously
identified limitations by developing novel drug screening systems: an EIS-
based drug screening platform (Chapter II) and an approach incorporating
human liver microtissues in the screening process (Chapter III).
III. Explore ways to improve the drawbacks of praziquantel and contribute to the
currently empty drug pipeline by demonstrating the possibilities offered by a
polymorph formulation (Chapter IV).
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Jennifer Keiser1,2*
Drug discovery for schistosomiasis is still limited to a handful of academic laboratories worldwide, with only a few novel
antischistosomal lead compounds being actively researched. Despite recent international mobilization against the disease to
stimulate and promote antischistosomal drug discovery, setting up a drug-screening flow with schistosome parasites remains
challenging. Whereas numerous different protocols to obtain and cultivate schistosomes have been published, those
describing the drug-screening process are scarce, and none gather together parasite cultivation and early drug discovery
procedures. To help overcome this hurdle, we provide here a set of integrated methods either adapted from already-published
protocols or based on our long-term experience in schistosomiasis research. Specifically, we detail the establishment and
maintenance of the complex and several-week-long Schistosoma mansoni life cycle in a laboratory setting, as well as the
means of retrieving and culturing the parasites at their relevant life stages. The in vitro and in vivo assays that are performed
along the drug-screening cascade are also described. In these assays, which can be performed within 5 d, the effect of a drug
is determined by phenotypic assessment of the parasites’ viability and morphology, for which stage-specific scoring scales are
proposed. Finally, the modalities for testing and evaluating a compound in vivo, constituting a procedure lasting up to
10 weeks, are presented in order to go from in vitro hit identification to the selection of early lead candidates.
Introduction
In May 2012, the World Health Organization (WHO) put forth an ambitious goal to eliminate schis-
tosomiasis, a debilitating parasitic disease caused by trematodes of the Schistosoma genus, as a public
health problem by 2020 (WHO, https://www.who.int/neglected_diseases/9789241564540/en/). To fulfill
this mandate, treatment coverage using the only drug available, praziquantel (PZQ), would need to
expand from 35 to 75% of school-aged children in at-risk areas (WHO, https://www.who.int/neglected_
diseases/news/WHO_urges_increased_access_to_praziquantel/en/). Yet, because of concerns about drug
resistance, along with the drug’s other drawbacks, the scientific community has recognized an urgent
need for the development of new treatments1,2. Despite the pressing need, however, no new drug
candidates are currently close to reaching market. As one of the neglected tropical diseases, the drug
discovery pipeline for schistosomiasis is, by extension, underfunded3. Nonetheless, drug discovery efforts
have been extensive in the academic community4–7. Moreover, recent product-development partner-
ships, such as the Drugs for Neglected Diseases initiative (DNDi) and the Medicines for Malaria Venture
(MMV), have been productive in securing compound libraries to be tested against a broad range of
infectious diseases, including schistosomiasis, which has resulted in an array of hit compounds for the
disease8–10. Hence, this is a key moment to expand antischistosomal drug discovery efforts.
This protocol aims to support these efforts by providing the necessary basics for establishing a
screening cascade. Specifically, it details the procedures used at the Swiss Tropical and Public Health
Institute (Swiss TPH) to establish the complex S. mansoni life cycle in the laboratory, obtain the relevant
life-stage parasites, integrate them into an in vitro and in vivo drug-screening cascade, and lay out
best-practice phenotypic assay evaluation procedures. As fewer than 30 institutions worldwide host an
in-house S. mansoni life cycle11, different culturing conditions and various screening techniques are being
successfully used. The fact that we focus here on the protocols currently used at the Swiss TPH should
therefore neither overshadow nor discredit alternative methods, which we discuss when applicable.
1Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland. 2University of Basel, Basel,
Switzerland. 3These authors contributed equally: Flavio C. Lombardo, Valérian Pasche. *e-mail: jennifer.keiser@swisstph.ch



















Development of the protocol
Methods for breeding and maintaining Biomphalaria glabrata snails and schistosomes in laboratories
have been established since the 1950s12,13. The procedure described here to maintain an S. mansoni
life cycle is based on these original methods, with several modifications over time11–16, as this life
cycle has been running for more than 50 years at the Swiss TPH.
Since the 1970s, different techniques for mechanical cercarial transformation have been descri-
bed17–19. In this protocol, we propose a transformation method adapted from Milligan and Jolly20
(see video therein) and Colley and Wikel17, which consists of a series of washing steps and repeated
passage between two connected syringes.
Despite recent advances in automated or quantitative methods for drug screening on the different
S. mansoni stages, there is no broadly accepted consensus on automated assays. Therefore, drug
sensitivity assays based on phenotypic evaluation of adult worms have formed the basis of standard
operating procedures recommended by the UNICEF/UNDP/World Bank/WHO Special Program for
Research and Training in Tropical Diseases (TDR) since 200711,21. However, when screening large
libraries of chemical compounds, huge quantities of parasites are required. A medium-throughput
phenotypic screening procedure based on schistosomula assessment was proposed by Abdulla et al.22.
This approach was later applied by Mansour and Bickle23, and modified to be suitable for screening
large libraries of compounds. Assessing the viability of the parasite after drug exposure is essential to
determining the effect of a drug candidate11. For this reason, we adapted the phenotypic scoring scale
described by Ramirez et al.21 and Abdulla et al.22 for the assessment of newly transformed schisto-
somula (NTS) in vitro11,24.
Overview of the procedure
The first part of the procedure (Steps 1–38) details how to set up and maintain the S. mansoni life
cycle (Fig. 1a), which comprises setting up a B. glabrata snail life cycle (Steps 1–10), obtaining
S. mansoni eggs from the infected hamsters (Steps 11–16), hatching the miracidia from the eggs and
infecting the snails (Steps 17–28), inducing cercarial shedding from the snails (Steps 29–34), and
infecting mice or hamsters with S. mansoni cercariae (Steps 35–38). Once the life cycle is established,
it is possible to conduct the in vitro and in vivo screening.
The drug-screening process (depicted in Fig. 1b) often starts with a pre-screen of the compound










































Fig. 1 | Overview of the protocol. a, The S. mansoni life cycle (Steps 1–38) requires that eggs obtained from an
infected rodent be exposed to water to hatch as miracidia (Steps 11–28), which infect Biomphalaria glabrata snails.
After a few weeks of asexual reproduction, S. mansoni cercariae emerge after snails are exposed to light (Steps
29–34). A cercarial suspension can then be collected to infect a mouse or hamster (Steps 35–38). The life stages
used in the drug-screening cascade are indicated in blue boxes in the figure. For other Schistosoma species, please
refer to Supplementary Table 1. b, The antischistosomal screening cascade starts with a pre-screen of compounds on
NTS at 10 µM (can be adjusted) (Steps 51–55). Active compounds are tested on adult-stage worms (Steps 72–78)
in vitro, and the most active from this screen are further tested in mice harboring S. mansoni chronic infection (Steps
79–82). The activity of the compounds that show worm burden reduction >80% can be further characterized on
mice bearing juvenile worms.
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protocol therefore begins with the production of larval-stage parasites, hereafter referred to as NTS
(Steps 39–50). The drug assay setup, as well as the drug assay evaluation procedure, is then
detailed (Steps 51–55). Only the compounds that are found to be active on NTS are tested on the
primary target of interest, the adult-stage worms (Steps 72–78). In the last part of the protocol, the
methods for testing and evaluating the activity of lead candidates in a mouse model are presented
(Steps 79–86).
Alternative methods
Establishment and maintenance of a schistosome life cycle
The methods for establishing a schistosome life cycle vary slightly, depending on the Schistosoma
species and lab conventions. At Swiss TPH, we generally use a Liberian S. mansoni strain, B. glabrata
(Egyptian) for snail infection, coupled with an S. mansoni—hamster or S. mansoni—mouse infection
model, as described in the Procedure. Variations to the protocols required for S. haematobium and
S. japonicum are described in Supplementary Table 1, in addition to various mouse strain options.
We also cite the optimal snail size for infection with miracidia (4–6 mm), development period until
cercarial shedding (5–6 weeks) and length of exposure to light to induce cercarial shedding (3–4 h)
that we have found to be effective in our drug discovery work7,9,25,26. However, this could vary from
lab to lab for a number of reasons, such as the Schistosoma or snail strains chosen. We therefore
recommend that readers experiment and determine their own optimal conditions.
In our experience, the RJHan:AURA hamster (Janvier Labs) is optimal for life cycle maintenance
because of its ability to harbor many parasites for a sufficient period of time. However, the alternative
rodent hosts listed in Supplementary Table 1 are also suitable.
Research groups that do not want to undertake the task of establishing a life cycle can make use of
the NIH National Institute of Allergy and Infectious Diseases (NIAID) Schistosomiasis Resource
Center, which maintains a variety of schistosome–snail and schistosome–rodent infections, available
freely to any research team that requests them (http://www.afbr-bri.com/schistosomiasis/).
Cercarial transformation
The time requirement for the cercarial transformation using two connected syringes followed by a
saline rinse is, in our experience, much shorter than those for other procedures based on pipetting or
vortexing16,18 to trigger separation of the cercarial head from the tail, or using a Percoll gradient16,27
to rinse the tails.
In vitro drug testing
This procedure allows a certain flexibility and some modifications to it may be required to meet the
reader’s needs. For example, Basch medium can be used instead of M199 medium for larval-stage
assays11. Also, the drug concentration range (10–100 µM) and the duration of each assay will depend
on the type of drug being tested. Whereas a screen at 10 µM might be suitable for synthetic
compounds, a test concentration of ≥100 µM might be more suitable to test sublethal effects of
natural product derivatives28.
Although phenotypic screenings based on microscopy as a readout are beneficial for researchers
working in low-resource facilities, they are laborious and undeniably subjective11. Intensive research
has been conducted to overcome these limitations, and various automated readout alternatives have
been proposed. These include notably S. mansoni NTS drug assays using luminescent29 or fluorescent
markers30,31, label-free microcalorimetry32 or other methods based on electrical recordings33,34. In
parallel, the development of computer-assisted image analysis is expected to improve the readout of
phenotypic assays22,35,36.
In vivo studies
We commonly use NMRI outbred mice for in vivo experiments, as they are more amenable to testing
in larger numbers, easy to handle and can maintain an S. mansoni infection for a long period. As
stated, we have listed alternative mouse models in Supplementary Table 1. It has been noted that drug
efficacy can vary depending on the mouse strain used, and the reason for this variation is not clear37,38.
It is also debatable whether inbred versus outbred mice are preferred38. Inbred mice would reduce
experimental variability, but the results may be less reproducible across other breeds and species.
For infection of mice, the concentration of cercariae per injection we use (100 cercariae per
mouse), as well as the 7-week infection period, has been optimized for our NMRI mouse strain.
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If researchers desire to use other strains, they might need to adjust these parameters. Instead of
subcutaneous injection with the cercarial suspension, mice can alternatively be infected by dipping
the tail or the shaved abdomen directly into a Petri dish with a cercarial suspension or by percu-
taneous exposure12,16,39. Whereas these techniques allow the development of a natural infection, the
parasite load cannot be fully controlled. In addition, the fact that these infection methods require
animals to be anesthetized or restrained might be an issue in regard to ethical requirements. On that
last concern, the paddling method proposed by Dettmann et al.40 might provide an alternative, as it
allows mouse infection without prior shaving.
In studies with schistosomes, portal perfusion is often used to flush out the adult worms. This
technique has been well described15,16,41. However, in this protocol, we collect the worms from the
mesenteric veins manually. It has the advantage that it is a fairly straightforward method to adopt for
labs that are completely new to the process. It also ensures that all worms have been collected. In
addition, one can visualize the localization of the worms after drug treatment. For example, the
worms can lose their adherence from the mesenteric veins and be shifted to the liver (liver shunt).
This could indicate partial activity of a drug25. On the other hand, the method we describe has the
main disadvantage of being more time consuming as compared to the portal perfusion methods41.
Applications
Several parts of this protocol are not restricted to antischistosomal drug discovery and can be useful
to research teams working in other fields and with other parasites. The methods for establishing and
maintaining a Biomphalaria snail cycle in a controlled environment can be used by malacologists, for
example, in behavioral or ecological studies42,43. Schistosomes and their intermediate hosts are model
organisms often used in the field of evolutionary biology and host–parasite interactions44,45. Similarly,
NTS can be useful not only for the analysis of schistosome development but also for a range of
biological studies, including genomic and transcriptomic analysis46–48. Nonetheless, the reader should
note that NTS are not completely identical to the schistosomula present in the host after natural
infection. However, only minor differences in morphology, antigenic profile and gene expression have
been identified between NTS and ‘natural’ schistosomula46,49,50. Also, at the host–parasite interface,
studies investigating hosts’ immunity toward helminths—notably characterized by a shift from Th1 to
Th2 immune responses—can use S. mansoni−mouse infection models51. Such immunological studies
are also very relevant for developing a potential vaccine, which could prevent continuous reinfections
with the parasite52.
Advantages and limitations
The drug-screening process for Schistosoma spp. comes with a few challenges that may hinder
research groups (especially in low-resource settings) from establishing their own screening flow. First,
as target-based screening for schistosomiasis is still under development53, antischistosomal drug
discovery relies essentially on whole-organism drug sensitivity assays. Although more efficient at
producing successful first-in-class compounds54, whole-organism screening necessitates regular
access to parasites that can neither reproduce nor be maintained in vitro for very long11. Therefore, a
life cycle with both the intermediate and the definitive hosts—snails (e.g., Biomphalaria spp. for
S. mansoni) and rodents (hamsters or mice), respectively—must be established and maintained.
Moreover, only a limited number of adult-stage schistosomes (the most relevant parasite life stage for
drug screening) can be collected from rodents, and only several weeks after infection. This is not an
issue when only a handful of compounds are to be tested, but it poses an ethical and resource
bottleneck when screening large compound libraries. This limitation is partly addressed by first
screening compounds on NTS. The cercarial transformation method used to produce them and
which is presented hereafter is reliable, fast and simple to execute.
Second, as there is no consensus on an acceptable automated reading system, the gold standard
method of determining the antischistosomal activity of a drug is still direct observation using an
optical microscope, which is simple and low-tech but subjective and laborious23. The post-drug
exposure assessment of the parasites in vitro is therefore particularly important for the selection of
lead candidates. Nonetheless, drug-screening results can vary greatly from lab to lab; a recent study
showed that when two independent laboratories tested the same set of compounds, <30% of their hits
overlapped25. This may be in great part due to differences in evaluation outcomes. In this protocol, we
aim to minimize this by providing a graphic guide to parasite viability scoring.
PROTOCOL NATURE PROTOCOLS
464 NATURE PROTOCOLS | VOL 14 | FEBRUARY 2019 |461–481 |www.nature.com/nprot
38
Third, the lead selection process described here is rather simple, and it is based on activity
thresholds. However, additional tests can be performed to increase the chances of successful
in vitro–in vivo translation, such as metabolic or enzymatic assays23.
Experimental design
Note on animal experimentation
Many parts of this procedure include work on laboratory rodents. Compulsory certifications in
animal experimentation are required in many countries, and we also recommend prior practical
training. Untrained personnel may improperly inject the material, causing harm to the animal or
themselves. We also encourage the reader to comply with the 3Rs principles for in vivo experimental
design and statistical analysis, as well as to adhere to the ARRIVE guidelines for reporting animal
research55. National laws and institutional regulatory board guidelines must be followed.
Establishment and maintenance of a schistosome life cycle
This part of the protocol comprises four essential steps, namely establishing a B. glabrata snail cycle
(Steps 1–10), hatching miracidia for infecting snails (Steps 11–28), shedding and collecting of the
cercariae (Steps 29–34), and infecting the rodent host with the collected cercariae (Steps 35–38). For
the snail cycle, simple aquarium systems are used, with ecological water, ambient temperature and
light cycle. Snails are kept until they start to produce eggs. Half of them are moved to a new tank
containing flat, square polystyrene pieces on which they lay eggs. The eggs are then collected and
placed in breeding tanks (Steps 1–10). The other half of the snails are collected for infection with
S. mansoni (Steps 21–28). To infect the snails, the schistosome eggs are recovered from a saline
solution of blended liver of an infected hamster that has been previously filtered (Steps 11–17)
(Fig. 2a). The eggs are then placed in warm water in a covered side-arm flask (Fig. 2b) where the side
arm is exposed to lamp light (Steps 18–23). After the hatched miracidia swim to the side arm, the
suspension is collected and placed in well plates together with snails of appropriate size (4–6 mm) to
infect them (Steps 24–28). After 5–6 weeks, the infected snails normally start to shed cercariae. The
cercariae are collected by placing the snails under a neon lamp for a couple of hours (Steps 29 and 30)
(Fig. 3 (i)). The cercariae are shed optimally for 2–4 weeks. Snail shedding of cercariae is highest in
the first 2 weeks after initial shedding. After that, the persistence of the infection is highly variable,
ranging anywhere from 4 weeks to 3 months. The collected cercarial suspension is then used to infect
hamsters by subcutaneous injection (Steps 35–38). After the 7 weeks required for establishing a
patent infection, the infected livers can be used to continue the cycle (Steps 11–28).
Cercarial transformation and adult worm collection
Mechanical stress is used to transform cercariae into NTS. The cercarial suspension (Fig. 3 (ii–iv)) is
pushed between two interconnected syringes, followed by a cold rinse to separate heads from tails
a b
Fig. 2 | Equipment required for collecting eggs and hatching the miracidia. a, Four stainless-steel sieves
(45–425 µm) (Step 15). b, 0.5-L side-arm flask (Step 18).
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(Steps 39–50) (Fig. 4). An overnight incubation in culture medium is required to complete the
transformation. To obtain adult worms for drug screening, laboratory rodents (hamsters or mice) are




Fig. 3 | Collection of S. mansoni cercariae for transformation to NTS. (i) Snails are first exposed to light (Step 30).
(ii) The snails are removed (Step 32), and the pond water containing the cercaria shed by the snails is collected
(Step 33). (iii) The cercarial suspension is allowed to sediment at RT and is then poured through a 100-µm filter (yellow)





Fig. 4 | Transformation of cercariae to NTS. a, One syringe is filled with cercarial suspension (Step 43). b, The
syringes are connected (inset) and the contents are pushed back and forth vigorously, three to four times (Step 43).
c, Most (>90%) of the heads should be separated from the tails. This can be directly visualized under the microscope
(Step 43). After several washing steps, the NTS are counted and the suspension is adjusted to the desired concentration
(Step 49); tails (1) can be distinguished from the NTS (2). Scale bar, ~100 µm. d, Counting the NTS (Step 50).
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euthanized, the mesenteries are excised and the adult worms are directly collected from the rodent
mesenteric veins using flat-tip tweezers and a dissecting microscope (Steps 67–71) (Fig. 5). The
collected worms are incubated with culture medium and can be used for ~2 weeks after the dissection.
In vitro drug testing
When screening large compound libraries, initial efficacy tests on NTS are helpful in selecting
candidate compounds of interest. We first describe a pre-screen assay at a mono-concentration to
assess the antischistosomal activity of a compound (Steps 51–55). The parasite viability is evaluated
over 3 d post compound exposure and compared to the negative control wells containing the highest
concentration of the solvent, dimethyl sulfoxide (DMSO) (Steps 51–55). Hits are further tested to
determine their 50% inhibitory concentration (IC50). We use a benchmark of IC50 < 10 µM to select
compounds to test on adult worms, as drug concentrations higher than this are rarely found in vivo
with realistic dose levels (Steps 56–62). Hits are then tested on adult worms (Steps 72–78) to select
compounds with which to pursue in vivo testing (Steps 79–86).
In vivo studies
Drug candidates are tested in laboratory mice harboring an S. mansoni infection. Different rodent
strains can be used (Supplementary Table 1). We infect 3- to 4-week-old female NMRI mice with







Fig. 5 | S. mansoni adult worm recovery. a, The intestines are excised by cutting at the distal part of the rectum (1)
and the esophagus (2). The operator must hold the portal vein firmly closed, while excising the liver, to avoid blood
spill resulting in the loss of adult worms (3). b, The liver is excised and placed between two transparent plastic layers
and pressed vigorously. A grid is drawn on the plastic foil to facilitate worm localization (Step 69). c, The intestines
are excised and placed under a dissection microscope. d, Zoomed-in view at ×1.8 magnification. The adult worms
present in the mesenteric veins and indicated by the white arrows in c and d are then collected (Step 70). Scale bars,
~1 cm. For all our experiments involving laboratory animals, we were granted ethical and experimental approval from
both the Canton Basel-Stadt and the Swiss federal veterinary authorities (license no. 2070). A certification for
animal experimentation was required for all the operators involved.
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administered 7 to a maximum of 8 weeks post infection, the time it takes for adults to develop in the
mouse model (Steps 79–82).
To test the activity of a drug candidate on juvenile worms, the mice should instead be treated
3 weeks post infection. In addition, drugs can be tested for their protective efficacy by administering
the drug before the infection (i.e., day −2 up to day 0) or for efficacy against migrating schistoso-
mula56. In both cases, the value used to assess the activity of a drug is the worm burden reduction
(WBR). It is determined by comparing the number of live worms found in the treated mice to the
numbers of live worms in the control group (Steps 83–86).
Controls
The negative controls for the in vitro procedure are parasites incubated in appropriate medium with
the drug solvent only, in general 0.1% (vol/vol) DMSO. For positive-control wells, the experimenter
can use auranofin or mefloquine for the NTS assays (Step 54) or praziquantel for the adult worm
assays (Step 77). The control mice for in vivo experiments are either untreated or administered with
the drug vehicle only (Step 82).
Materials
Biological materials
! CAUTION National and institutional guidelines on animal experimentation must be followed. Refer to
the ‘Experimental design’ section. For all our experiments involving laboratory animals, we were granted
ethical and experimental approval from both the Canton of Basel-Stadt and the Swiss federal veterinary
authorities (license no. 2070). A certification in animal experimentation was required for all the
operators involved.
● B. glabrata snails (these can be initially obtained from, e.g., the NIAID Schistosomiasis Resource
Center, https://www.niaid.nih.gov/research/schistosomiasis-resource-center)
● Hamster or mouse infected with S. mansoni worms (these can be initially ordered from the NIAID
Schistosomiasis Resource Center, https://www.niaid.nih.gov/research/schistosomiasis-resource-center)
● RJHan:AURA male hamsters (3 weeks old, e.g., Janvier Labs, cat. no. HAMST-M)
● NMRI female mice (3 weeks old, e.g., Charles River, cat. no. 605NMRI)
Reagents
● ‘Pond water’ (filtered dechlorinated tap water)
● Fresh lettuce and spinach leaves
● 70% (vol/vol) Ethanol (EtOH; Merck, Switzerland, cat. no. 1.00983.6025) in water
● Milli-Q water (Merck, e.g., Milli-Q Advantage A10 Water Purification System, cat. no. Z00Q0V0WW)
● NaCl (Merck, cat. no. 1.06404.1000)
● Hank’s Balanced Salt Solution (1× HBSS; Gibco, cat. no. 24020117)
● Penicillin–streptomycin (pen–strep; 10,000 U/mL; Sigma-Aldrich, cat. no. P4333-100ML)
● Medium 199 (Gibco, cat. no. 22340-020)
● Fetal calf serum (FCS; Bioconcept, cat. no. 2-01F30-1)
● Kanamycin (Fluka, cat. no. 60615)
● Penicillin G (Sigma, cat. no. P3032-10MU)
● 5-Fluorocytosine (Sigma, cat. no. F7129)
● Chloramphenicol (Fluka, cat. no. 23275)
● dH2O
● Dimethyl sulfoxide (DMSO; Sigma-Aldrich, cat. no. 276855-2L)
● RPMI 1640 (Gibco, cat. no. 51800-043)
● Tween 80 (Fluka, cat. no. 23908273)
● Absolute ethanol (Merck, cat. no. 1.00983.6025)
Equipment
● Personal protective equipment: nitrile gloves, lab coat, sleeve protection, long gloves, facial shield and
laboratory goggles
● 5-gallon standard fish tank or a simple, transparent rectangular plastic bin
● Simple fish tank mesh lid (should completely cover the fish tank opening)
● Simple fish tank air pump
● Flat polystyrene (in square pieces of 8–9 cm)
PROTOCOL NATURE PROTOCOLS
468 NATURE PROTOCOLS | VOL 14 | FEBRUARY 2019 |461–481 |www.nature.com/nprot
42
● CO2 chamber for euthanizing rodents
● Dissection board
● Pins for dissection
● Scissors
● Forceps
● Hamster polycarbonate type 4 cages (Tecniplast, cat. no. 1354G)
● Mouse polycarbonate type 3 cages (Tecniplast, cat no. 1290D)
● Four stainless-steel sieves with pore sizes of 425, 180, 106 and 45 µm (Fig. 2a; VWR,
cat. nos. VWRI510-0586, VWRI510-0576, VWRI510-0570 and VWRI510-0560)
● Laboratory immersion blender with variable speed (variable-speed laboratory blender; Waring,
cat. no. Z272183)
● Pressure garden sprayer with brass lance and brass nozzle pump (5 L)
● 1-L side-arm flask (e.g., Sigma-Aldrich, cat. no. Z290459-1EA; alternatively, fit an Erlenmeyer filter
flask with a custom-made L-shaped adapter (Fig. 2b))
● Water bath (Julabo VC)
● A fitted cardboard or wooden box to cover the side-arm flask (or aluminum foil)
● Transparent plastic foil (Semadeni, cat. no. 2457)
● Incandescent bulb (40 W; Osram)
● Dissecting microscope (Optika, model no. Lab 20)
● Eppendorf pipettes (P20, P200 and P1000; Eppendorf)
● Pyrex glass beakers (10, 30 and 1,000 mL; Corning, cat. nos. CLS100010, CLS100030 and CLS10001L)
● 24-, 48- and 96-well plates (Sarstedt, cat. nos. 83.3922, 83.3923 and 83.3924)
● Light source for cercaria shedding: neon lamp (36 W, 4,000 K, 3,350 lumens, G13; Osram,
cat. no. 4050300517872)
● Tweezers (flat tip, no teeth; Fisherbrand, cat. no. 16100127)
● Hypodermic 25-gauge syringe needle (0.5 × 16 mm, sterile; Braun Medical, cat. no. 4657853)
● Filter for sterilization (0.2 µm, Filtropur S 0.2; Sarstedt, cat. no. 83.1826.001)
● Conical graduated cylinder (Dynalon, cat. no. 1211Y42)
● Stericup (0.22 µm, 500 mL; Corning, cat. no. 431097-COR)
● Nylon filters (100 µm, nylon, VWR, cat. no. 732-2759)
● 15- and 50-mL Test tubes (Sarstedt, Germany, cat. nos. 62.547.004 and 62.554.002)
● Serological pipettes (5, 10 and 25 mL; Sarstedt, Germany, cat. nos. 86.1253.001, 86.1254.025 and
86.1685.001)
● Syringes with Luer-Lok tips (10 mL; BD, cat. no. BD 309695)
● Luer-Lok connector (Discofix; B. Braun, cat. no. 40951111)
● Petri dish, 94 × 16 mm (Greiner, cat. no. 633102)
● Upright bright-field microscope with 4, 10 and 20× lenses (Primovert)
● Pyrex borosilicate glass Petri dishes (55-mm diameter; Fisher Scientific, cat. no. 12013333)
● Oral gavage needle (straight; Carl Roth, cat. no. HPY8.1)
● Pasteur pipette (Pastette; Alpha Laboratories, cat. no. LW4111)
● 1-mL Sterile plastic syringes (B. Braun, cat. no. 9161406V)
● Waterproof markers (Stabilo, cat. no. 842/41)
● Mouse identification marker: picric acid solution (1.3% (vol/vol) in H2O; Sigma-Aldrich,
cat. no. P6744-1GA)
Reagent setup
S. mansoni egg rinsing solution
S. mansoni egg rinsing solution is 4 °C physiological saline solution (0.9 or 1.2% NaCl in Milli-Q H2O
at 4 °C). Prepare fresh solution before each experiment.
Hank’s Balanced Salt Solution
Hank’s Balanced Salt Solution (HBSS 1×) should be supplemented with 1% (vol/vol) pen–strep. It can
be stored at 4 °C for up to 4 weeks.
NTS culture medium
M199 medium should be supplemented with 5% (vol/vol) FCS, 1% (vol/vol) pen–strep and 1% (vol/vol)
antibacterial/antifungal mix (see preparation below) with 45% (vol/vol) kanamycin, 27% (vol/vol) penicillin
G, 23% (vol/vol) 5-fluorocytosine and 5% (vol/vol) chloramphenicol. It can be stored at 4 °C for 2–4 weeks.
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Antibacterial/antifungal mix for 10-mL solution
Antibacterial/antifungal mix should be prepared as shown below. It can be stored at −20 °C for up to
3–6 months57.
● Weigh 10 mg of chloramphenicol and dissolve it in 143 µL of 70% (vol/vol) EtOH.
● Weigh 50 mg of 5-fluorocytosine and dissolve it in 9,857 µL of dH2O in a 15-mL tube.
● Weigh 100 mg of kanamycin.
● Weigh 60 mg of penicillin G.
● Mix all ingredients together in a 15-mL tube.
● Sterilize by 0.2-µm filtration.
● Prepare aliquots of the solution for convenience.
Adult worm culture medium
RPMI 1640 medium supplemented with 5% (vol/vol) FCS and 1% (vol/vol) pen–strep. It can be
stored at 4 °C for 2–4 weeks.
Drug solution for oral administration
Drug solution for oral administration is 70:30 Tween 80/absolute ethanol solution dissolved in
Milli-Q H2O (10% (vol/vol)). Prepare fresh solution before each experiment.
Procedure
Establishing and maintaining a snail cycle ● Timing 30 min
1 Fill the aquarium tank three-quarters full with pond water warmed to 26–28 °C.
! CAUTION Water quality is important: charcoal-filtered water must be used in the case that the
water quality is untested. Water must always be dechlorinated. As it will be frequently used, we
recommend setting up a large reservoir of pond water: simply fill a large tub with tap water and add
a simple air pump.
2 Insert the air pump and turn it on such that bubbles form and float to the top to prevent water
fouling.
c CRITICAL STEP Never allow the water to become stagnant. Check the air flow in the tanks
periodically.
3 Place between 200 and 300 snails of different sizes in the tank and add a few leaves of lettuce and/or
spinach.
4 Cover the tank with a weighted mesh lid and place the aquarium under neon lamps.
5 Set and maintain the room temperature (RT) at 26–28 °C.
6 Maintain a 12-h day and night light cycle by, for example, automatically setting lights to turn on at
6 AM and turn off at 6 PM.
7 Feed the snails once daily with fresh lettuce and spinach, and clean the tanks weekly.
c CRITICAL STEP The fresh vegetables should not remain longer than 1 d in the tank, as they will
start to rot. Feed only as much as the snails consume. Store the food in a wine cooler refrigerator, as
this works best for lettuce and spinach.
8 At the time of snail infection, select snails that have reached the adult stage (size ≥4–6 mm) and
transfer these to a new tank, filled with 26 –28 °C pond water. Those snails will be infected with
S. mansoni miracidia (Steps 11–28). This new tank is referred to as the ‘infection tank’. Take the
remaining snails and place them into a second new tank filled with 26–28 °C pond water. This tank,
known as the ‘breeding tank’, will be used to produce offspring (Steps 1–10).
! CAUTION This step should be performed once for each batch of snails. Therefore, in the breeding
tank(s), snails of different sizes will be present. Each tank should have no more than 200–300 snails.
9 Put an 8- to 9-cm2 flat piece of polystyrene into each breeding tank(s) with the smooth side upside
down, so the snails can lay their eggs on the surface. Move the polystyrene pieces with the eggs to a
new tank filled with pond water, for breeding the snails.
! CAUTION Snails might lay eggs on the walls of the tank. Collect these eggs and add them to the breeding
tank(s). Alternatively, siliconized surface materials can be used to prevent the eggs from attaching.
? TROUBLESHOOTING
10 Set up the new tanks as described in Steps 1 and 2, and maintain them as described in Steps 4–7.
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Hatching miracidia and infecting snails ● Timing 30 min to collect eggs plus overnight
release of eggs; 2.5 h to hatch and infect; maintain tank for 5–6 weeks
! CAUTION National and institutional guidelines on animal experimentation must be followed. Refer to
the ‘Experimental design’ section. For all our experiments involving laboratory animals, we were granted
ethical and experimental approval from both the Canton Basel-Stadt and Swiss federal veterinary
authorities (license no. 2070). A certification in animal experimentation was required for all the
operators involved.
11 Euthanize two infected hamsters by CO2 inhalation (see the ‘Materials’ section, or infected mice can
be used, from Step 38).
! CAUTION The number of hamsters for S. mansoni egg isolation depends on the investigator’s
needs. The hamsters can be kept between 2 and 12 months post infection at maximum.
12 After checking for the absence of vital signs and reflexes, dissect each hamster upward from the
lower abdomen to expose the liver (Fig. 5a).
13 Excise the liver and place it into cold (4 °C) physiological saline overnight (see ‘Materials’ for saline
preperation). This will create small tissue cracks in the liver, which will increase the release of
S. mansoni eggs.
14 The next day, blend the cracked livers with cold (4 °C) saline solution, using a variable-speed
blender progressively from 0 to ~9,000g for 10 s. Repeat this step three times.
c CRITICAL STEP The blending must ensure that the liver is very well homogenized, so that the
maximum number of S. mansoni eggs are released. However, it must not be too rough, or the eggs
will be destroyed in the blending process.
? TROUBLESHOOTING
15 Pour the liver homogenate sequentially through four sieves (Fig. 2a) in the following order of pore
size: 425, 180, 106 and 45 µm. Rinse all the sieves with the cold (4 °C) saline solution using the
pump sprayer, until the smallest filter is reached.
c CRITICAL STEP If the saline solution becomes warm (25–28 °C), the miracidia could hatch;
therefore, it is important to keep the solution cold (at 4 °C) during the filtering process.
? TROUBLESHOOTING
16 Collect the unfiltered fractions from the 425- and 180-µm sieves into a 1,000-mL beaker by rinsing
them with the 4 °C saline solution using the pump sprayer; then blend and sieve the unfiltered
fractions by repeating Steps 14 and 15 three times.
17 The eggs will have been collected on the 45-µm sieve, as they do not pass through this sieve. Rinse
the eggs from the 45-µm sieves into a 1,000-mL beaker by using 50–100 mL of cold (4 °C) saline
solution, using the pump sprayer.
18 For hatching, pour the egg suspension into the side-arm flask (Fig. 2b). Add dechlorinated tap
water (28 °C) until it reaches and fills the side arm of the flask.
19 Place the side-arm flask into a 30 °C water bath and place an incandescent lamp above. Wait until
you see by eye the first hatched miracidia (10–20 min).
? TROUBLESHOOTING
20 Cover the entire side-arm flask with a carton box (or aluminum foil), except for the side arm.
21 Expose the side arm of the flask to the light. The miracidia will concentrate in the side arm,
attracted by the light, and will swim up to the surface.
22 Collect the entire volume of miracidial suspension from the side arm with a P1000 pipette and place
it in a 30-mL beaker. Check for the presence of miracidia under a bright-field microscope.
23 Determine the concentration of miracidia by sampling 5 × 10-µL drops of the miracidial
suspension, placing them in a Petri dish and counting the number of miracidia in each drop.
c CRITICAL STEP Miracidia tend to sediment, so shake the solution before each sampling to ensure
a homogeneous distribution.
24 Fill each well of a 48-well plate halfway with pond water.
25 Transfer each snail from the infection tank (saved for infection in Step 8) and place one snail per
well of the plate prepared in Step 24.
! CAUTION Use flat-tip tweezers carefully to avoid damaging the snails.
c CRITICAL STEP Selecting snails that are smaller or larger in diameter than 4–6 mm will result in
an unsuccessful or mild infection, and, on average, early mortality of small snails.
26 Add a volume of the miracidial suspension that would correspond to six to eight miracidia per well.
27 Place the 48-well plate under a 40-W incandescent bulb and leave it for 2–3 h at RT. In our
experience, this ensures a proper infection of the snails by the miracidia.
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28 Place the infected snails into a new tank, referred as the ‘working tank’, set up as described in
Steps 1 and 2, and maintain as described in Steps 4–7.
Shedding and collecting of the cercariae ● Timing 30–60 min
c CRITICAL A record of each infection should be kept, with infection rate (number of snails infected
per batch) and the intensity of infection (average number of cercariae shedding per snail).
29 After 5–6 weeks post infection, the snails from the working tank (Step 28) should be ready to shed
cercariae. Fill each well of a 24-well plate with 1 mL of pond water.
! CAUTION Cercariae can infect humans via direct skin contact. Wear protective clothing that
includes a lab coat, nitrile gloves and laboratory goggles. Note: simple hospital latex gloves are
potentially insufficient for protection.
30 Place one snail into each well (carefully using flat-tip tweezers). Put the lid on the plate and leave it
under a neon lamp for 3–4 h (Fig. 3 (i)).
! CAUTION As the procedure is a source of stress for the snails, we recommend that it not be
repeated more than twice a week. Alternatively, if several snail batches are available, we recommend
using them in rotation.
c CRITICAL STEP Cercarial shedding from the snail follows a circadian rhythm, so it is essential
that the snails be placed under light in the morning and retrieved 3–4 h later in the afternoon. In
our laboratory, the snails are placed under the light before 9 AM, but each lab should track the
cercarial shedding pattern once the cycle is established.
31 Retrieve the plate and examine for cercariae, using a bright-field microscope with a ×10 or ×20
magnification.
? TROUBLESHOOTING
32 Place all the infected snails back into the working tank (Step 28) until the next cercarial shedding.
! CAUTION Steps 29–34 can be repeated six to eight times with the same snails. Snails that are not
shedding cercariae after 8 weeks should be killed by placing them into soapy water. Do not use a
batch of infected snails more than twice a week (better only once). The snails should have time to
recover; otherwise the parasite yield could decrease.
c CRITICAL STEP Only uninfected snails lay eggs, but do not keep the snails that are not shedding
cercariae for breeding, as this would decrease the overall genetic susceptibility of the breeding pool
to S. mansoni infection.
33 Use a Pasteur pipette to collect the cercariae from the 24-well plate into a 150-mL conical-bottom
beaker at RT before pouring the cercarial suspension through a 100-µm filter into 50-mL tube(s). At
this point, the cercarial solution is either immediately adjusted for animal infection and injected
(Steps 35–38) or is transformed into NTS (Steps 39–50).
34 Count the cercarial concentration by sampling 5 × 10 µL drops of the suspension on a Petri dish.
Use a bright-field microscope to count and average the number of cercariae for 10 µL.
Infecting rodents ● Timing 30 min–2 h, depending on the number of rodents
! CAUTION National and institutional guidelines on animal experimentation must be followed. Refer to
the ‘Experimental design’ section. For all our experiments involving laboratory animals, we were granted
ethical and experimental approval from both the Canton Basel-Stadt and Swiss federal veterinary
authorities (license no. 2070). A certification in animal experimentation was required for all the
operators involved.
35 Adjust the cercarial concentration to 100 cercariae/100 µL by either adding the appropriate volume
of pond water to dilute the suspension from Step 33, or by centrifuging it (211g, 3 min, RT) and
removing the appropriate volume of supernatant to concentrate the suspension.
36 Aspirate 100 µL of the cercarial suspension with the 1-mL syringe, ensuring there are no air bubbles
in the aspirate. Make sure to stir the suspension before aspirating.
37 Inject the suspension subcutaneously into the mouse/hamster neck. The number of mice/hamsters
to infect depends on the cercarial yield and/or the investigator’s needs.
! CAUTION In the case that a higher number of S. mansoni adult worms is required, we recommend
infecting some of the mice with 200 cercariae instead of 100, or infecting hamsters with a dose of up
to 800 cercariae. Although this will increase the yield of adult worms, we do not recommend using
the highly infected mice for drug testing, as they will probably not be able to withstand the testing
period.
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38 After infection, house the animals at 25 °C with a 12-h day/night cycle with free access to rodent
diet and water in enriched cages. At 7 weeks post infection, the adult parasite infection is
established and the egg production is initiated. For perpetuating the life cycle, return to Step 11. For
adult worm collection, refer to Steps 67–71.
? TROUBLESHOOTING
Transformation of cercariae to NTS ● Timing 3–4 h
39 Place the suspension from Step 33 on ice for 30 min to immobilize the cercariae (Fig. 3 (iv)).
40 Centrifuge the tube for 3 min at 211g at RT.
41 Use a Pasteur pipette to remove the supernatant and discard it.
42 Resuspend the pellet in 7 mL of ice-cold HBSS supplemented with 1% (vol/vol) pen–strep.
Alternatively, supplemented M199 medium at 37 °C can be used.
43 Fill a 10-mL syringe with the 7-mL cercarial suspension obtained in Step 42 and connect it to
the Luer-Lok (Fig. 4a,b (inset). Connect another empty syringe to the opposite side of the
Luer-Lok. Push the liquid back and forth three to four times vigorously (Fig. 4b). The
transformation yield can immediately be viewed under the bright-field microscope. The tails must
have been separated from the heads for at least 90% of the parasites (Fig. 4c). If this is not the case,
repeat this step three to four times more and check for any improvement under the bright-field
microscope.
! CAUTION Test the syringe-Luer-Lok connection by passing some water or HBSS before you
proceed. An incorrect connection can result in a splattering of infectious cercarial suspension.
Personal protection, including a face shield, must be worn in case of spills. Wearing two pairs of
gloves, with a long-sleeved pair over the top is advisable.
44 Pour the suspension into 15-mL tubes. Place them on ice and in the dark for 7 min to allow the
sedimentation of the heads.
45 Remove the supernatant (and therefore the tails), by slowly pipetting, and discard. Avoid disturbing
the sedimented heads (hereafter referred to as NTS).
? TROUBLESHOOTING
46 Resuspend the NTS in 4 °C HBSS supplemented with 1% (vol/vol) pen–strep to wash them.
47 Repeat Steps 44–46 three times to eliminate the remaining tails. Observe the successful separation
of the tails from the heads under a bright-field microscope (Fig. 4c).
c CRITICAL STEP It is imperative to reduce the number of tails and untransformed cercariae as
much as possible, as they can harm the NTS with their rapid whipping movements.
48 Remove the wash solution by pipetting and resuspend the sediment in 5–10 mL of supplemented
M199 by inverting the tube or gently pipetting up and down.
! CAUTION Do not vortex, as additional mechanical stress could damage the parasites and
negatively influence their overall viability.
49 Count the NTS by sampling 5 × 10-µL drops from the NTS suspension. Pipette each drop into a
Petri dish (Fig. 4d) and observe under a bright-field microscope.
c CRITICAL STEP To obtain a homogeneous NTS suspension, mix it gently by inverting the tube
before each sampling.
50 Adjust the suspension to the appropriate NTS concentration. To increase the concentration of NTS,
place the tubes in a vertical position for 5 min to allow them to sediment. The proper volume of
medium can then be removed by gently pipetting away the supernatant. For decreasing the
concentration, simply top up with an appropriate volume of supplemented M199 medium.
c CRITICAL STEP We recommend that the NTS be suspended in an appropriate volume of
medium for a maximum concentration of 2,000 NTS/mL.
j PAUSE POINT Before being used in drug assays, the NTS should be left overnight in the
incubator (37 °C, 5% CO2) for 12 to a maximum of 24 h. This allows the parasites to complete
the necessary biochemical and metabolic changes to emulate the larval stage of the parasite in the
definitive host46.
Drug-screening assay with NTS ● Timing 2–3 h
c CRITICAL Because not 100% of the cercariae will be transformed, it is important to wear laboratory
goggles and use proper biosafety level 2 (BSL 2) equipment.
51 Dilute the initial 10 mM drug stock solution (in DMSO) to a 100 µM solution in supplemented
M199 medium.
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52 Add 175 µL of supplemented M199 medium per well of a 96-well plate.
53 Add 25 µL of the 100 µM drug solution to each well, then 50 µL of the 2,000 NTS/mL suspension
(from Step 50) for a final drug concentration of 10 µM and a final count of ~100 NTS per well. Each
drug should be tested in duplicates or triplicates.
54 Repeat Steps 52 and 53 for the control wells, using the solvent (DMSO) instead of the drug. One can
also include a positive control such as auranofin or mefloquine, but this is not required for assays
based on visual scoring as assessment.
! CAUTION Praziquantel is not a good positive control for NTS in vitro assays because it is not very
active on the larval stages of the parasite.
c CRITICAL STEP If the drugs are dissolved in DMSO, the final assay concentrations of DMSO
should never exceed >1.5% (vol/vol), as this can decrease the parasites’ viability.
55 Place the plate in the incubator (37 °C, 5% CO2). Score the NTS viability every 24 h for up to 72 h
to evaluate the drug effect compared to the controls. The evaluation procedure is described below
(Steps 56–66).
? TROUBLESHOOTING
Determination of compound IC50 values ● Timing 2–3 h
! CAUTION The desired drug concentration range varies from assay to assay. Here, we provide a sample
protocol that is used in our lab as a guiding example. The procedure below is for a starting concentration
of 10 µM and a dilution factor of 1:2.
56 To determine the IC50 values of any drug, first prepare in a 96-well plate a drug dilution series that
is ten times higher than the desired final assay concentration. Thereafter, the whole assay is diluted
10× in another 96-well plate, where the NTS are added. To prepare this pre-dilution plate, fill row A
of a 96-well plate with 180 µL of supplemented M199 medium and add 20 µL of a 1 mM drug
working solution to reach a concentration of 100 µM (one drug per well).
57 To rows B to G, add 100 µL of supplemented M199 medium. Pipette 100 µL from row A to
row B for a 1:2 dilution and mix well. Continue by pipetting from row B to row C, and so on. Reject
the last 100 µL from row G. This results in concentrations of 100, 50, 25, 12.5, 6.25, 3.13 and
1.56 µM.
58 In row H, prepare DMSO controls by adding 20 µL of 10% (vol/vol) DMSO in 180 µL of
supplemented M199 medium for a final concentration of 1% (vol/vol) DMSO in the well.
59 In another 96-well plate (test plate), add 175 µL of supplemented M199 medium to all wells.
Assign three columns of the plate to each drug dilution (in order to have three replicates for
each drug).
60 Transfer 25 µL of column 1 from the pre-dilution plate to columns 1, 2 and 3 of the new plate.
Repeat for each drug (e.g., column 2 of the pre-dilution plate to columns 4, 5 and 6 of the new plate,
and so on).
61 Add 50 µL of NTS suspension (Step 50) to each well of the new plate. The result is a drug dilution
assay with concentrations of 10, 5, 2.5, 1.25, 0.63, 0.31 and 0.16 µM and control wells with 0.1%
(vol/vol) DMSO.
62 Incubate at 37 °C and 5% CO2 and evaluate at 24, 48 and 72 h post drug incubation (Steps 63–66).
? TROUBLESHOOTING
Assessment of the parasites in vitro ● Timing 2 h
63 Evaluate each well, using a bright-field microscope (×4 or ×10 magnification), and assign a score to
each well that reflects the phenotype of the majority of the parasites. Score the control wells first. In
Figs. 6 and 7, we present the viability score scale and sample phenotypes for NTS and adult worms,
respectively. The motility is the most important parameter to take into account when assigning a
score. Living parasites move smoothly. An abnormally decreased or enhanced motility, a loss of
plasticity, saccades or wobbles would lead to a lower score. The second important aspect to consider
is the morphology and the integrity of the tegument. Impaired parasites may lose their original
shape by shrinkage or swelling. Blebs on the tegument or a darkened pigmentation can also appear
(Figs. 6 and 7, and Supplementary Videos 1–12).
! CAUTION Do not keep the plates outside the incubator for longer than 15 min. The NTS
movement decreases when the medium cools; this might bias the scores.
c CRITICAL STEP Control wells should have a minimum score of 2 to ensure that the NTS were
sufficiently viable for the assay. If not, the assay should be rejected and repeated.
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64 Report all the data in a spreadsheet and calculate the effect score of each drug by normalizing the
drug scores to the control well scores, using the following formula: average (Test) is the average
score of all test wells containing the drug and Average (Control) is the average score of the
control wells.






Fig. 6 | NTS phenotypes corresponding to each viability score. 3 =motile, no changes to morphology or transparency;
2 = reduced motility and/or some damage to tegument noted, as well as reduced transparency and granularity;
1= severe reduction of motility and/or damage to tegument observed, with high opacity and high granularity; 0= dead.
The images of the NTS in the left column were taken with a ×20 magnification. The images in the right column were
obtained using a ×10 magnification (Step 63). Scale bars, ~100 µm. See also Supplementary Videos 9–12.
d e f
a b c
Fig. 7 | Adult worm phenotypes. a–c, The viability scores of 3 =motile, no changes to morphology, transparency and
intact tegument, active ventral and oral sucker (see also Supplementary Videos 7 and 8) and (d–f) 0 = dead, the
worms appear darkened and motility of the ventral and oral sucker is absent (see also Supplementary Videos 1 and
2). Additional characteristics can also help to assign a score (see also Supplementary Videos 3–6 for examples of
scores 1 and 2). For instance, the ventral sucker of impaired worms (score <2) is often detached from the bottom of
the well, whereas the presence of eggs can be used as a sign of good viability of the worm (score >2). The images
were taken with ×4 (a,d), ×10 (b,e) or ×20 (c,f) lenses (Step 63). Scale bars, 1 mm (b,c,e,f); 2.5 mm (a,d).
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65 With a single concentration assay (Steps 51–55), determine the threshold effect for what you
will consider to be a hit. Usually, this threshold reflects either total mortality of the parasite
(100% effect) or substantially reduced parasite viability (e.g., 75% effect).
66 For dose–response assays (Steps 56–62), plot the effect scores against the drug concentrations to
generate a dose–response curve in order to determine the IC50 value. There are many tools for this;
an easy and freely available tool is CompuSyn (http://www.combosyn.com/).
S. mansoni adult worm recovery ● Timing 15–30 min per mouse
! CAUTION National and institutional guidelines on animal experimentation must be followed. Refer to
the ‘Experimental design’ section. For all our experiments involving laboratory animals, we were granted
ethical and experimental approval from both the Canton Basel-Stadt and Swiss federal veterinary
authorities (license no. 2070). A certification in animal experimentation was required for all the
operators involved.
67 Euthanize the infected mice from Steps 34 to 38 with CO2 for 5 min (see ‘Materials’ section).
68 After checking for the absence of vital signs and reflexes, dissect the mice by cutting from the lower
abdomen up to the sternum to expose the intestines and liver (Fig. 5a).
69 Resect the liver, then excise the intestines and place them into a Petri dish. At this point, the liver
can also be removed. Manually, press the liver between two pieces of transparent plastic foil in
order to obtain a thin layer of tissue so that the worms can be visualized, counted and sexed under a
dissecting microscope. A pair is counted as two worms. Draw a grid on the plastic foil with a
marker to facilitate the localization of the worms (Fig. 5b). The live worms can be collected with
flat-tip tweezers and placed in 37 °C supplemented RPMI 1640 medium. For in vitro assays, refer to
Steps 72–78.
c CRITICAL STEP The portal vein must be located and pinched firmly with tweezers in order
to prevent the worms from spilling out, because S. mansoni are mostly located in the portal vein
(Fig. 5a).
? TROUBLESHOOTING
70 Place the intestines under the dissection microscope and, using flat-tip tweezers, gently open the
veins and pick out the worms (Fig. 5c,d). Place the recovered worms in supplemented RPMI 1640
medium. Count and sex the worms as in Step 69. Transfer them to a new Petri dish filled with
supplemented RPMI 1640 medium and incubate them at 37 °C, 5% CO2.
c CRITICAL STEP It is important to avoid damaging the worms with the flat-tip tweezers during
collection. Do not tug the worms.
j PAUSE POINT Worms can be kept in an incubator for up to 10 d if the medium is replaced
regularly (every 3 d). To allow sufficient nutrient supply, a maximum of 15 worms should be placed
in a single Petri dish.
? TROUBLESHOOTING
71 Use the worms recovered from Steps 69 to 70 for in vitro assays (Steps 72–78). The worm counts
can be used to determine the WBR (Steps 83–86).
In vitro assay of S. mansoni adult worms ● Timing 40–60 min
72 From a 10 mM drug stock solution in 100% (vol/vol) DMSO, prepare a 1 mM working solution in
supplemented RPMI 1640 medium. We recommend the use of a 10 μM drug concentration as a
starting concentration (unless natural crude extracts are being screened). Higher concentrations are
unlikely to be achieved in vivo.
73 In each well of a 24-well plate, pipette 15 μL of the 1 mM drug solution, and add 1,485 μL of
supplemented RPMI 1640 medium. Each compound should be tested in duplicate or triplicate
when possible.
c CRITICAL STEP To ensure that the worms remain clearly viable throughout the assay, the volume
to add to the well should not be <1.5 mL.
74 Prepare a 10% (vol/vol) DMSO (or any other solvent) solution in supplemented RPMI 1640
medium and transfer 15 μL of it to the control wells to have a final concentration of 0.1% (vol/vol)
of the solvent. Praziquantel can be used for positive control wells in this assay; follow Steps 72
and 73.
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75 Carefully, place two pairs or three random worms of both sexes per well, using flat-tip tweezers.
c CRITICAL STEP To avoid contaminations, clean the flat-tip tweezers by dipping them first into a
solution of 70% (vol/vol) ethanol–water and then into supplemented RPMI 1640 as frequently as
possible.
76 Check the assay to ensure that each well has the correct number of worms. Place the assay in the
incubator (37 °C, 5% CO2).
77 Score each of the worms individually. Record both the sex and the phenotypic score every 24 h for
up to 72 h (Steps 63–66 and Fig. 7).
78 Compounds that are active can then be further tested in a drug dose–response assay to determine
their IC50 value. The same assay setup is used (Steps 72–78) with a 1:2 or 1:3 serial drug dilution,
and at least three drug concentrations.
In vivo drug administration ● Timing >4 h
! CAUTION National and institutional guidelines on animal experimentation must be followed. Refer to
the ‘Experimental design’ section. For all our experiments involving laboratory animals, we were granted
ethical and experimental approval from both the Canton Basel-Stadt and Swiss federal veterinary
authorities (license no. 2070). A certification in animal experimentation was required for all the
operators involved.
79 Prepare the drug solution for oral administration in Tween 80/EtOH solution (or any other
vehicle). Intraperitoneal or intravenous administration can also be considered. The drug dosage
depends on the researcher’s needs, and it should be adapted accordingly.
c CRITICAL STEP Make sure that the drug is well dissolved; otherwise, you risk administering
different concentrations to each mouse.
? TROUBLESHOOTING
80 Weigh each infected mouse from Step 38 individually.
! CAUTION The mice must be individually identifiable and marked before drug administration
using any standard identification (ID) method. We recommend noninvasive and painless methods
such as skin or fur marking in order to comply the 3Rs principles58. We use picric acid solution
(a yellow synthetic marker) on the mouse’s back for labeling.
81 Calculate the drug volume to administer to each mouse using the following formula:
Volume administration ¼ ðtarget dose ðmg=kgÞ ´mousemass ðkgÞÞ=drug concentration ðmg=mLÞ:
82 Prepare the administration volume in a 1-mL syringe. Administer the drug to the infected mouse.
The control mice for the experiment can be administered with the vehicle only or left untreated.
c CRITICAL STEP Do not administer >100 µL for every 10 g of weight, keeping in mind that it is
better to work with small volumes. It is important to administer each drug to several mice. The
number of mice used depends on the experimental design59.
? TROUBLESHOOTING
Data recovery for in vivo results ● Timing >2–3 h
83 After a maximum of 21 d after drug administration, euthanize the mice as in Steps 67–71.
84 Dissect the mice and recover the liver and the intestines as described previously (Steps 67–70). The
granuloma distribution and the hepatosplenomegaly provide important information on the
magnitude of the infection of each mouse.
85 Evaluate the presence of live adult worms in the pressed liver and in the mesenteric veins of test and
control mice (Steps 69–70). Sex, count and include them in the WBR evaluation formula (Step 86).
86 Calculate the WBR using the following equation:
WBRð%Þ ¼ 100% ð100%=WB Control ´WB treatmentsÞ;
which compares the average number of live worms in the treated mice to the live worms found in
the mouse control group.
? TROUBLESHOOTING
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Troubleshooting
Troubleshooting advice can be found in Table 1.
Timing
Steps 1–10, establishing and maintaining a snail cycle—initial setup: 30 min
Steps 11–28, hatching miracidia and infecting snails: 30 min to collect eggs plus overnight release of
eggs; 2.5 h to hatch and infect; maintain tank for 5–6 weeks
Steps 29–34, shedding and collection of cercariae: 30–60 min
Steps 35–38, infecting rodents: 30 min–2 h, depending on the number of rodents
Steps 39–50, transformation of cercariae to NTS: 3–4 h
Steps 51–55, drug-screening assay with NTS: 2–3 h
Steps 56–62, determination of IC50: 2–3 h
Table 1 | Troubleshooting table
Step Problem Possible reason Solution
9 No/poor snail egg deposition • Poor water quality
• Poor water tank airflow
• Poor-quality snail food
• Stagnant water
•Use filtered water
• Check air flow
•Use fresh leaves (we suggest spinach)
• Check water quality
1–10 Snails die • Poor water quality
•Not enough food
• Too many snails in the same tank
•Use filtered water
•Avoid allowing food to rot in the tanks and
change it daily
• Subdivide the snail population into separate
tanks, keeping the population between 200
and 300 snails
14, 15 Damaged S. mansoni eggs • Too-aggressive blending of the liver(s) • Reduce the time and/or speed of each
blending step
19 No miracidia hatching • Too-aggressive blending of the liver(s)
•Water temperature not correct
• Reduce the time and/or speed of each
blending step
• Ensure water temperature is 30 °C
• Increase the exposure time by 10–15 min
31 No/poor cercarial shedding • Snails are not permissive
• Snails are too old
• Circadian cycle is not adequate
• Too many cercariae collections
•Make a freshly infected batch of snails
•After 6–8 weeks, infected snails should be
replaced
• Consider starting the light cercarial
induction earlier in the morning
• Increase the collection time span to ensure
one cercarial shedding per week
38 Mice die after infection with
S. mansoni
• Too many cercariae were injected •Adjust the cercariae concentration to 100
cercariae/100 µL and inject smaller volumes
45 The NTS pellet is taken away or
disturbed
• Pipetting error • Repeat the washing step (Steps 46 and 47)
55 Dead NTS in the assay control
wells
•Overly aggressive transformation
• Too many NTS in medium kept overnight
• Incorrect medium used
• Reduce the number of syringe passages
(three or four instead of four to six)
• Control the medium formulation and
concentration
62 No changes in NTS viability after
testing a known active drug
(positive control)
• Suboptimal concentration used, low
solubility of the compound and/or low
activity on NTS (e.g., praziquantel)
• Increase the drug concentration and/or
improve solubility (e.g., by changing the
solvent)
69, 70 Dead adult worms recovered from
untreated mice
•Worms were recovered too late
•Worms were damaged during collection
• Collect the worms at an earlier time point
•Avoid pressure with tweezers during worm
collection
79, 86 Erratic worm burden in vivo •Multiple operators perform the mouse
infection
• Biological variation
• Consider using a single operator for
infections
• Include a randomization step
82 Mice die a few days after drug
treatment
• Too many cercariae
• The drug dose was too high
• The compound is toxic
•Adjust cercariae concentration for mouse
infection
• Lower the administered dose
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Steps 63–66, assessment of parasites in vitro: 2 h
Steps 67–71, S. mansoni adult worm recovery: 15–30 min per mouse
Steps 72–78, in vitro assay of S. mansoni adult worms: 40–60 min
Steps 79–82, in vivo drug administration: >4 h
Steps 83–86, data recovery for in vivo results: >2–3 h
Anticipated results
This protocol describes the establishment of an S. mansoni life cycle, which is the basis for conducting
in vitro and in vivo drug sensitivity assays. Once a schistosome life cycle has been established in the
laboratory, cercariae should be shed by the snails into the water on a regular basis for 5–8 weeks.
There is, however, no typical volume of cercarial yield, as this depends on the number of snails, their
infection level and the age of the snail infection. In our experience, a cercarial suspension with a
minimum range of 250–1,000 cercariae per milliliter is required for performing an effective trans-
formation. Practically, a satisfactory cercarial yield can be visualized under a bright-field microscope,
directly in the wells containing the shedding snails, before starting the transformation. Although
some cercariae can be very motile, not all are active. The transformation should therefore be
attempted even in the absence of fully active cercariae.
The described phenotypic drug assays can be used for testing compounds and libraries in a low-
throughput manner, as described in previous studies7,9,10,25. These assays allow determination of
dose–response relationship or IC50 values essential to identifying hits and selecting early lead drug
candidates to be tested in vivo. The worm burden obtained from infected mice or hamsters is variable,
but in our experience, 10–50 adult worms can be recovered 7 weeks post infection with 100 cercariae
(as described in Steps 76 and 77). Some examples of in vivo results for antischistosomal drug
discovery can be found in our previous studies7,9,10,25. Although anemia and loss of weight are often
observed in infected mice, they can survive for a maximum of 5 weeks post treatment without
presenting major symptoms or behavioral changes. As a consequence of egg deposition, infected
animals usually present an enlarged granulomatous liver and spleen (hepatosplenomegaly, Fig. 5a).
Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary.
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1. Introduction
Efficient and reliable screening methods 
are an essential tool for the discovery of 
novel drug candidates. The demand for 
improving the identification of prom-
ising compounds is particularly high in 
the field of neglected tropical diseases 
(NTDs), where funding and commercial 
investments are typically low.[1,2] Among 
the frequently occurring NTDs, schisto-
somiasis is a tropical disease caused by 
worms of the genus Schistosoma, which 
infect over 200 million people worldwide, 
predominantly children living in poor 
rural areas of Sub-Saharan Africa.[3,4] If left 
untreated, the infection slowly develops 
into a debilitating chronic disease, which 
leads to fibrosis of the liver, intestines 
and/or bladder, anemia, urogenital can-
cers and, eventually, death.[4] Despite the 
high prevalence of schistosomiasis, the 
current anthelmintic drug discovery pipe-
line is alarmingly unproductive.[5] For over 
40 years, praziquantel has been the treat-
ment of choice for schistosomiasis and 
has been widely used as chemotherapeutic 
agent in mass drug-administration campaigns.[3] Hundreds 
of millions of treatments are administered to children and 
populations at risk each year,[6] raising a significant potential 
public-health threat due to the emergence of praziquantel drug 
resistance.[5,7,8] In addition, reported cases of reduced efficacy 
of praziquantel have been associated with multiple rounds 
of mass drug administration, highlighting the need for new 
antischistosomal drugs.[9]
Compound libraries of pharmaceutical and academic organi-
zations offer a potential source for identification of candidate 
therapeutics. However, the large number of drugs that need to 
be tested requires the use of medium- or high-throughput assays 
to implement an efficient and cost-effective screening.[10,11] In 
addition to drug efficacy, information on pharmacodynamics 
would allow to select lead candidates. High activity, fast action, 
and low toxicity represent key parameters for the selection of 
promising leads during the in vitro screening process.[10,12,13] 
Despite these requirements, the current gold standard for 
antischistosomal drug screening is based on worm phenotypic 
evaluation using operator-based microscopy, which is limited 
in throughput, labor-intensive, and subjective. Therefore, the 
Schistosomiasis is an acute and chronic disease caused by tropical parasitic 
worms of the genus Schistosoma, which parasitizes annually over 200 million 
people worldwide. Screening of antischistosomal compounds is hampered 
by the low throughput and potential subjectivity of the visual evaluation of 
the parasite phenotypes, which affects the current drug assays. Here, an 
impedance-based platform, capable of assessing the viability of Schistosoma 
mansoni schistosomula exposed to drugs, is presented. This automated and 
parallelized platform enables unbiased and continuous measurements of 
dose–response relationships for more than 48 h. The platform performance is 
established by exposure of schistosomula to three test compounds, prazi-
quantel, oxethazaine, and mefloquine, which are known to affect the larvae 
phenotypes. The system is thereafter used to investigate the response of 
schistosomula to methiothepine, an antipsychotic compound, which causes 
complex drug-induced effects. Continuous monitoring of the parasites reveals 
transient behavioral phenotypes and allows for extracting temporal charac-
teristics of dose–response curves, which are essential for selecting drugs that 
feature high activity and fast kinetics of action. These measurements demon-
strate that impedance-based detection provides a wealth of information for 
the in vitro characterization of candidate antischistosomals and, represents a 
promising tool for the identification of new lead compounds.
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development of advanced screening methods for the identifica-
tion of new promising lead compounds is of high importance 
and priority.
In the last years, the more abundant Schistosoma mansoni 
larval-stage worms, or newly transformed schistosomula (NTS), 
have been used for the preselection of lead compounds prior 
to testing in adult parasites and to overcome the limitations 
related to the handling of adult worms for large-scale screen-
ings.[14,15] The advent of NTS-based screenings has set the 
stage for the development of automated and higher-throughput 
systems, and several screening methods have been explored. 
Microcalorimetry was found to be a useful tool to thoroughly 
analyze drug effects on adult and larval stage helminths in real-
time, however it requires a large number of NTS per sample (at 
least 400).[16,17] An alternate approach based on an image-based 
automated microscopy system was described as a label-free 
method to evaluate helminth viability based on morphology 
and motility.[18,19] Nonetheless, it has not been adopted for sys-
tematic dose-response assays and real-time monitoring, as the 
high computational burden and the low level of parallelization 
limit its use for routine analysis. The impedance-based xCelli-
gence system, which detects parasite viability in a 96-well plate 
format, has been applied to adult-stage S. mansoni but not to 
the highly abundant NTS.[20] In summary, no drug screening 
system, which can automatically measure NTS viability and 
continuously assess dose-response effects, is currently available.
To address these current limitations, a first version of an in 
vitro impedance-based microfluidic assay for drug screening on 
NTS has been developed.[21] Electrical impedance spectroscopy 
(EIS) is a noninvasive and label-free technique for investigating 
the dielectric properties of a sample and its potential variations 
within a specific frequency range.[22,23] We previously demon-
strated that the confinement of NTS in small sensing regions 
and the use of electrodes featuring dimensions comparable to 
those of the parasite larvae enable to assess NTS motility by 
means of EIS, and that this motility characterization may be 
a good indicator of NTS viability in drug screening applica-
tions.[21] However, the rather complex microfluidic structures 
ultimately limited the analysis throughput, the measurements 
still required considerable sample handling by an operator, and 
the system did not allow for long-term culturing and real-time 
detection of drug-induced effects.
In this paper, we present a parallelized impedance-based 
platform to continuously assess dose-response effects of drugs 
on NTS. The electrical-impedance microwell (EIM) platform 
includes 32 analysis units to allow for simultaneous execution 
of several measurement replicates and to increase throughput. 
To achieve high sensitivity of the detection method without 
physical confinement of the parasites in channels of sub-mil-
limeter dimensions, we used sensing electrodes with dimen-
sions comparable to the NTS size, which resulted in a sensing 
volume of ≈25 nL or ≈100 µm height, given the well dimen-
sions. This configuration enabled the use of a large medium 
reservoir over the sensing region to achieve long-term culturing 
of the parasites without affecting the detection characteristics 
of the system with respect to NTS motility. In addition, the 
chip design features simple loading of the parasites, which are 
driven into the nanoliter sensing volume by sedimentation. To 
validate our platform, we first measured the NTS response to 
three antischistosomal compounds, oxethazaine, praziquantel, 
and mefloquine, which have already been shown to cause dif-
ferent phenotypical behaviors in vitro, that is, they reduce 
parasite motility, stimulate hyperactivity or induce both effects, 
respectively.[24–28] As a case study, we then analyzed the activity 
of an antipsychotic drug, methiothepine, which belongs to the 
emerging class of tricyclic compounds and serotonin modu-
lators, which have been investigated as potential therapeutic 
agents against schistosomiasis.[24,29] The obtained results 
indicate that the EIM platform can provide continuous dose-
dependent viability and activity patterns of NTS on-chip and can 
be a suitable component for antischistosomal drug screening.
2. Results
2.1. EIM Platform Function and Operation
The overall concept of the EIM platform is illustrated in 
Figure  1. To provide continuous impedance-based recordings 
of parasite motility in parallel to optical inspection, the anal-
ysis unit was fabricated from two transparent components: a 
PDMS (polydimethylsiloxane) microwell and a glass slide pat-
terned with platinum electrodes. Each culture unit was loaded 
with 60  µL of NTS suspension (≈10–15 NTS per 60  µL) by 
using a pipette (Figure  1A-II). The NTS rapidly (≈1  min) set-
tled to the bottom of the microwell (chamber) on the patterned 
glass substrate. Each microwell was equipped with a pair of 
coplanar electrodes for detecting NTS motility by measuring 
conductivity variations that were caused by parasite move-
ments between the electrodes. To measure the signal fluctua-
tions upon NTS activity and movements, an AC voltage was 
applied to the left co-planar electrode, and the current flowing 
through the sensing volume was then measured at the right 
electrode and converted to voltage through a trans-impedance 
amplifier (Figure 1A-III). Motile and non-motile parasites were 
evaluated separately in the device to detect differences in the 
voltage signal during 1-min acquisition. Because of the parasite 
movements, the high-pass-filtered signal output of motile NTS 
exhibits clear fluctuations around zero (Figure  1A-IV), while 
non-motile NTS do not cause signal variations, and the trace 
only shows the readout background noise (in the µV range, 
Figure S1, Supporting Information).
To assign a motility value as a function of signal fluctua-
tions in a time window of 60 s, we computed the signal power 
in a bandwidth of 1–3 Hz. Figure 1B shows an example of the 
separation between the normalized signal power generated by 
motile and non-motile NTS, evaluated every 15 min during 
1 h. The signal power measured with alive and motile para-
sites (−13.1 ± 1.1 dBµ, ≈0.05 a.u.) was, therefore, constantly two 
orders of magnitude higher than the signal power obtained 
from the non-motile counterpart (−34.7 ± 0.6 dBµ, in the range 
of 0.0005 a.u.), which evidences the robust recognition and dif-
ferentiation of worm motility by using our platform.
The motility of the parasites was also qualitatively evaluated 
by visual inspection under an inverted microscope, as the chip 
was optically transparent and openings were included in the 
chip holder. The sequence of bright-field images clearly shows 
the contraction/extension movements of the alive NTS in 
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between the electrode pair, while non-motile NTS do not move 
or change position (Figure  1C). The microscopy observations 
correlated with the impedance-based recordings and confirmed 
that the impedance signal fluctuations arose from the parasite 
movements.
2.2. Higher-Throughput EIM Platform Design
The higher-throughput EIM platform was designed to achieve 
parallelized and automated monitoring of the motility of NTS 
exposed to different test conditions. The platform included 
three components (Figure 2A): 1) A custom-made printed cir-
cuit board (PCB) for signal routing; 2) four analysis chips; 3) a 
device holder to accommodate the chips and provide connec-
tions between the PCB and the electrode pads on the chips. 
All these parts were designed according to a 96-well-standard 
format to ensure compatibility with standard lab equipment 
and automated imaging and analysis tools. The PCB enabled 
the multiplexing of the analog input/output signals of the 
impedance spectroscopy unit to any of the 32 parasite cham-
bers. The PCB featured two analog multiplexers to separately 
switch the 32 input and output electrodes, spring-contact con-
nectors for interfacing with the fluidic chips, a mini-HDMI 
plug to connect to the controller board outside of the incu-
bator, and two analog SMA connectors to the input/output 
ports of the impedance spectroscope. The chips were inserted 
in a 3D-printed device holder with four insertion sites. Each 
chip included a top PDMS layer, containing the microfluidic 
structures that defined the 8 analysis units (microwell) and a 
bottom glass slide patterned with 16 co-planar platinum elec-
trodes. To prevent absorption of small hydrophobic molecules 
Figure 1. Detection of NTS parasite motility by the EIM platform. A) The analysis unit of the EIM platform consists of an inverted-pyramid-shape PDMS 
part, aligned with a pair of platinum electrodes I). After loading and sedimentation of the schistosomula in the inverted-pyramid-shape PDMS well II), 
the impedance-based motility measurement of NTS was carried out III). Signal fluctuations, caused by impedance variations between the electrodes 
owing to larvae movements, were acquired using a 500 kHz sinusoidal excitation. The graph shows an example of 60 s of signal recordings for both, 
motile and non-motile parasites IV). The signal was filtered using a 0.2 Hz high-pass filter to remove the signal baseline. B) The power of the signals 
acquired from motile and non-motile NTS parasites was calculated in a bandwidth of 1–3 Hz during a time window of 1 min and measured every 
15 min. The dotted line indicates the mean value of the signal power for motile (blue) and non-motile (red) NTS. The shaded areas show ±3 standard 
deviations. The power unit refers to 10−6 a.u. C) Bright-field microscopy images of motile and non-motile NTS parasites in the analysis units. The yellow 
arrows indicate parasites that contract and elongate between frames.
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from the solution into the PDMS during the drug assays, all 
chips were coated with a parylene-C layer (Figures S2 and S3, 
Supporting Information).[30] Moreover, the microwells were 
arranged at 9  mm pitch to allow for loading of the parasites 
and of the medium by means of a standard multichannel 
pipette to simplify platform operation. Each analysis unit was 
shaped as an inverted pyramid to bring the parasites down to 
the micro-sensing area (450 × 450 µm2) through sedimentation 
and to provide enough medium volume (60 µL) for multi-day 
experiments. Despite the considerable liquid volume over the 
sensing area, the electrode dimensions limited the sensing 
volume to the first 100 µm in height, which corresponds to the 
approximate size of the NTS (≈50 × 100 µm2) (Figure S4, Sup-
porting Information). The overall sensing volume (≈25 nL) was 
defined to enable testing with ≈10–15 NTS per condition, which 
represents an ≈tenfold reduction in sample consumption with 
respect to standard visual evaluation methods.[12]
The automated multiplexing in the platform allowed to 
simultaneously record from up to 32 analysis units. From 
an electrical point of view, each sample can be described as 
a variable impedance Zs, representing the NTS suspension 
between the electrodes, in series with two double-layer capaci-
tances, Cdl, which form at the interface between the electrodes 
and the medium (Figure  2B). The variations of Zs over time 
were caused by the movement of the NTS in between the elec-
trodes, while the Zs average value depended on the solution 
conductivity and on the number of parasites between the elec-
trodes. A multiplexing and switching architecture was used to 
route the output of the lock-in amplifier to each of the 32 para-
site chamber units. Correspondingly, a de-multiplexing stage 
was used to route the output signals of each chamber to the 
input of the trans-impedance amplifier (TIA). The frequency of 
the sinusoidal carrier signal (500  kHz) was selected to enable 
fast multiplexing and to minimize the signal attenuation in the 
EIM platform (≈−32 dBV, Figure S5, Supporting Information). 
The switching interval and the selection of the electrode pairs 
were defined by a custom-made Python script, which interfaced 
to a microcontroller (MCU, on the controller board) that con-
trolled the de/multiplexers on the PCB. To achieve continuous 
and quasi-parallel impedance measurements of the NTS in the 
32 chambers, we performed short recordings (1  ms) at each 
electrode pair and fast switching (1.5 µs) between all the units 
in a round-robin fashion, which resulted in an effective sam-
pling frequency of ≈32 Hz per chamber unit.
2.3. Monitoring of Parasite Motility Under Drug Treatment
To validate the ability of the EIM platform to detect NTS motility 
and to discriminate between different schistosomula movement 
characteristics, we measured the signal fluctuations caused by 
the parasites following incubation with two compounds, known 
to affect schistosomula phenotypes. We selected oxethazaine, a 
fast-acting in vitro compound that reduces parasite motility,[24] 
and praziquantel, which, although mostly effective against 
adult parasites, is known to have an excitatory effect on NTS in 
vitro.[26] The parasites were exposed to different concentrations 
of these test compounds, and we tested our impedance-based 
motility readout. As controls, we measured also the motility 
of NTS under standard medium conditions and in medium 
containing the drug vehicle (DMSO). The parasite larvae were 
first loaded in the chips under standard medium condition 
using a multichannel pipette. We then performed impedance 
measurements of all the chambers during 1 h to evaluate the 
motility of the untreated parasites and to confirm their initial 
viability (Figure  3A). After baseline acquisition, the different 
drug concentrations were added to the chamber units and NTS 
motility was recorded over time. This procedure enabled us to 
normalize the power of the signal fluctuations to the power of 
the first 1-h window for each condition and to extract a motility 
index. This normalization also allowed for comparing measure-
ments from chambers with different numbers of parasites, as 
the absolute signal power depends on the number of loaded 
parasites.
Our platform allowed to differentiate the inhibitory 
and excitatory effects, induced by the two test compounds 
(Figure  3B). After addition of oxethazaine (t = 0 h) at all con-
centrations tested, the NTS exhibited a considerable decrease in 
motility, compared to the vehicle control condition, during 48 h 
Figure 2. Design of the EIM platform. A) The EIM platform can accom-
modate up to four chip units, which were placed on a custom-made PCB. 
A single chip (highlighted with dashed red line) hosted eight PDMS anal-
ysis units that were plasma-bonded to a glass substrate featuring plat-
inum electrodes. The PDMS cavity featured an inverted-pyramid shape 
to promote sedimentation of the parasites to the sensing volume over 
the coplanar electrodes. B) The electrical equivalent circuit of the experi-
mental setup, which included a lock-in amplifier for generating the AC 
stimulation signal (Vin), a custom-made PCB for routing the AC signal to 
the selected analysis unit, and a trans-impedance amplifier (TIA) for cur-
rent-to-voltage conversion. The voltage signal was sampled by the lock-
in amplifier and recorded. A controller board featuring a microcontroller 
(MCU) was used for synchronizing the switching between the analysis 
units and the lock-in amplifier.
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of continuous measurements. The reduction of NTS motility 
showed a drug-dose dependence: the motility index for 6 µm 
oxethazaine reached zero (i.e., no motility) in 12 h, whereas the 
3 µm condition required about 24 h to achieve the same effect. 
The highest drug concentration, 12  µm, inhibited the larvae 
movement within the first 15 min upon addition of the com-
pound. Contrarily, praziquantel showed a drastic increase in 
NTS motility, which is in line with the phenotypical evaluations 
of drug effects reported in literature.[25,26] Higher motility index 
values (≈1.5) were obtained for 1.5 and 3 µm of praziquantel. 
After reaching a peak of the motility index, all the drug–dose 
curves exhibited a gradual decrease in motility and approached 
the vehicle-control behavior in about 18 h. Moreover, the 
effect of both drugs was also confirmed in a 96 well-plate by 
the standard visual method (Movies S1 and S2, Supporting 
Information).
By focusing on the first 2 h of the motility detection for both 
compounds, we evaluated the sensitivity of the platform in dis-
criminating motility changes caused by different drug concen-
trations (Figure  3C). To observe drug-induced rapid variations 
Oxethazaine exposure over 48 h














































t -1 h t 0 h t
Motility detection of untreated 
parasites







0 2 4 6 8 10 12 14 16 18
Time [min]
DMSO 0.5% 1.5 ˜M 3 ˜M 6 ˜M 12 ˜M 

























DMSO 0.5% 0.75 ˜M 1.5 ˜M 3 ˜M 6 ˜M 
Time [h]Drug Loading
DMSO 0.5% 1.5 ˜M 3 ˜M 6 ˜M 12 ˜M 
Time [min]
























Praziquantel exposure over 2 hOxethazaine exposure over 2 h 
Figure 3. Measurements of drug-induced NTS parasite motility via impedance-based recording. A) The flow diagram shows the main steps for per-
forming an impedance-based drug assay. First, 30 µL of NTS solutions were loaded into all analysis-unit chambers. After 1 h of impedance-based 
motility detection, the measurement was stopped and additional 30 µL of drug solution were dispensed into each chamber. Afterward, the impedance 
detection was restarted and recordings of drug-induced motility variations continued until the end of the assay. B) The graphs show the variations in 
the motility index of the vehicle-control sample (exposed to 0.5% v/v DMSO) and of NTS exposed to four different concentrations of oxenthazaine (left) 
and praziquantel (right). For clarity, one point per hour is displayed, and each point indicates the mean value of the motility index determined from 
three analysis units. Five trend lines were superimposed to the points to guide the eye for the different tested conditions. C) The motility graphs of the 
first 2 h of recording for both, oxenthazaine and praziquantel. Each point represents the mean value of the motility index simultaneously measured 
with three analysis units, while the error bars represent the standard error of the mean.
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of NTS behavior, the motility index was computed for 1-min 
windows every 15 min during the entire recording. We achieved 
a robust discrimination of the effects induced by 3, 6, and 
12 µm of oxethazaine after 75  min compared to the 0.5% v/v 
DMSO and 1.5  µm oxethazaine conditions. For praziquantel, 
we observed a significant increase in motility after 30 min for 
all tested concentrations in comparison to the vehicle-control 
condition.
2.4. Long-Term Dose-Response Analysis
To evaluate the performance of our platform in continuously 
assessing NTS viability and generating real-time dose–response 
curves, we exposed the parasite larvae for 48 h to six serially 
diluted concentrations (1.5, 3, 6, 12, 25, 50  µm) of two com-
pounds, oxethazaine and mefloquine, which are known for 
their antischistosomal activity in vitro.[24,28] The impedance-
based parasite viability was calculated by normalizing the 
motility index of each drug condition to the motility index of 
the vehicle control at each time point along two days of drug 
exposure.
By measuring parasite viability exposed to oxethazaine via 
the EIM platform, no signal fluctuations were detected for the 
NTS incubated with the highest drug concentrations (12, 25, 
and 50 µm) after 30 min, indicating that the NTS were dead 
(Figure 4A). For the same time point, the viability upon dosage 
of 6 µm was already reduced to ≈0.5, which indicates that a sig-
nificant fraction of the NTS population has deceased or lost its 
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Figure 4. Temporal evolution of the dose–response curves determined through continuous long-term monitoring of NTS viability by impedance-based 
detection. A) The graphs show the impedance-based estimations of the NTS viability at four selected time points as a function of drug concentration. 
The NTS was exposed to six different concentrations (1.5, 3, 6, 12, 25, and 50 µm) of oxethazaine (left) and mefloquine (right) during 48 h. Each circle 
represents the mean value of the viabilities of three replicates, and the error bars represent the standard error of the mean. The four sigmoid fits, used to 
calculate the IC50, values are superimposed to the viability measurements. B) The temporal evolution of the IC50 values for oxethazaine and mefloquine 
as determined by using impedance-based detection. The IC50 values obtained through standard visual scoring at 24 and 48 h are shown for comparison 
(marked in red). The circles represent the values obtained through the sigmoidal fits, while the error bars show the 95% confidence intervals.
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a viability above 0.5 (0.54 ±  0.05), which further decreased to 
≈0.2 (0.2 ± 0.19) at 48 h of incubation with the drug. By testing
the activity of mefloquine on the NTS, we obtained dose–
response curves along time that evidenced a lower potency
compared to oxethazaine. After 3 h, only the parasites exposed
to 50 µm were dead, whereas those exposed to 25 µm showed a
viability slightly below 0.5 (0.39 ± 0.21). Toward the end of the
drug assay (39 h), only the parasites exposed to 6 µm displayed
a viability of 0.37 ± 0.19, which further decreased to 0.15 ± 0.08
at 48 h. Parasites exposed to drug concentrations lower than
6 µm were viable and showed a high level of motility during the
entire assay.
We used the viability calculations to extract IC50 values of 
oxethazaine and mefloquine (Figure  4B). IC50 corresponds to 
the drug concentration at which the larvae were compromised 
in their activity and moving 50% less. Sigmoid fits (shown in 
Figure  4A) were used to calculate the IC50 values over time. 
The IC50 values obtained from the impedance-based viability 
measurements showed that oxethazaine featured an IC50 of 
6.1  ±  0.76  µm at 30 min incubation. The IC50 value rapidly 
decreased and reached 2.02 ± 0.16 µm after 12 h of drug expo-
sure. Between 24 and 48 h, the IC50 did not change significantly 
anymore (1.51 ±  0.21 µm and 1.45 ±  0.34 µm, respectively). In 
the case of mefloquine, the impedance-based estimations evi-
denced an IC50 of 24 ±  1.42 µm after 3 h of exposure, which 
decreased linearly to 8.51 ± 1.07 µm during 24 h of incubation. 
Finally, the IC50 calculated at 48 h using the EIM platform was 
5.05 ± 0.21 µm.
The parasite viability was also evaluated using the standard 
visual scoring method at 24 and 48 h in a 96-well plate to 
validate the IC50 estimations obtained with the EIM platform 
(Movies S1–S3, Supporting Information). The IC50 concentra-
tions of oxethazaine obtained from the visual evaluation were 
1.39  ±  0.06  µm after 24 h and 1.23  ±  0.04  µm after 48 h. In 
the case of mefloquine, the IC50 estimations from the visual 
method were 2.28 ± 0.22 µm at 24 h, and 2.03 ± 0.16 µm at 48 h. 
The visual-score-based evaluations were in good accordance 
and within the same order of magnitude as the results obtained 
with the impedance-based method (Figure S6, Supporting 
Information).
2.5. Characterization of Methiothepine Effect on NTS
As a case study, we challenged our system by investigating 
the effect of methiothepine on schistosomula. Methiothepine 
is a tricyclic antipsychotic compound whose behavior on NTS 
has not been fully characterized in vitro.[24] Tricyclic antipsy-
chotic compounds bind to the serotonin transporter (SERT) 
of helminths and have been studied for their antischistosomal 
effects.[31] It has been previously shown that SERT antagonists 
can cause either persistent or transient hyperactivity of hel-
minths and, eventually, can affect parasite viability.[32] To explore 
the temporal evolution of the dose-response effect, we meas-
ured the motility index and the viability of NTS exposed to six 
different methiothepine concentrations (1.5, 3, 6, 12, 25, 50 µm) 
for 48 h. We observed an excitatory effect lasting ≈24 h that was 
induced by the drug at sub-lethal concentrations (<25  µm at 
24 h; Figure  5A), which is in line with previous observations 
of NTS exposed to other members of the tryclic-compound 
family.[31,32] Live imaging of parasites in the chamber unit con-
firmed the hyperactivity of NTS that were incubated with sub-
lethal methiothepine concentrations (Figure 5B).
After 4 h of incubation, only the 50 µm-condition caused a 
drastic decrease in NTS viability (0.2 ± 0.09; Figure 5C). A com-
parably high level of NTS viability was maintained over 30 h for 
lower doses, while, for longer exposure times, methiothepine 
showed a slow-acting and dose-dependent killing behavior. At 
the end of the assay, after 48 h of incubation with the drug, all 
concentrations higher than 1.5 µm exhibited a viability below 
0.5. The extraction of the IC50 over time also showed the slow 
efficacy of methiothepine in killing the NTS (Figure  5D). To 
inhibit the parasite viability by 50% during the first 24 h, a con-
centration of more than 26.81 ± 0.94 µm of methiothepine was 
required. The IC50 calculated after 48 h using the EIM platform 
was 2.45 ±  0.9 µm. The IC50 values extracted by the standard 
visual evaluation amounted to 10.88  ±  2.05  µm at 24 h and 
2.22 ±  0.31 µm at 48 h. Differences in IC50 values obtained at 
24 h by the two methods were expected, as the hyperactivity of 
the NTS introduces additional difficulties to visually score the 
parasite status for the operator (Movie S4, Supporting Informa-
tion). Nevertheless, the IC50 values obtained at 48 h with the 
two different methods are in good accordance.
3. Discussion
Advancing the development of automated and medium- or high-
throughput approaches for antischistosomal drug screening is 
of fundamental importance for the identification of new com-
pound candidates. In this work, we introduced a novel platform 
with integrated electrodes for the automated detection of schis-
tosomula viability by means of an impedance-based method. In 
particular, we showed how this label-free technique offers an 
unbiased method to quantitatively score parasite viability, and 
that the impedance method enables long-term and continuous 
assessment of drug efficacy.
The EIM platform allows for robust and simple screening of 
the viability of NTS that have been exposed to different drug 
concentrations, and it requires minimal operator interference. 
The use of micron-size electrodes and the small detection vol-
umes reduces the number of NTS that are needed for analysis 
≈tenfold in comparison to the current standard visual evalua-
tion method,[12] and up to 30-fold in comparison to lumines-
cence- and fluorescence-based assays reported in literature.[33,34]
The arrangement of the pyramid-shape wells facilitates the
loading of the parasite samples with standard multichannel
pipettes and ensures the positioning of the parasites on top of
the electrodes for over 48 h. In addition, the 96-well format of
the platform enables compatibility with standard lab automa-
tion tools, such as automated liquid handlers, which further
improves automation and increases the throughput.
The impedance-based readout allows to overcome major 
limitations associated with the currently used visual evalua-
tion method, which include limited throughput, potential 
subjectivity, and bias in the operator's scoring.[14,35] In a pre-
vious proof-of-principle study, we showed the possibility to 
use impedance measurements of NTS motility as proxy for 
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parasite viability.[21] However, the previous system did not 
allow for long-term culturing of NTS and could only provide 
end-point evaluation of the larvae viability. Furthermore, the 
complex fluidic structure that was used to confine the larvae 
in the sensing area and to increase the signal-to-noise ratio 
of the measurements strongly limited the analysis throughput 
to four recordings in parallel. Here, we were able to preserve 
the previously demonstrated high sensitivity of the imped-
ance-based characterization by confining the larvae to a small 
detection volume in an easy-to-operate open fluidic structure. 
This solution enabled to simplify the platform operation and 
increase the analysis throughput to up to 32 recordings in 
parallel. We also determined the Z′-factor, which indicates 
the quality of an assay based on the difference of mean values 
of positive and negative controls in reference to the corre-
sponding standard deviations.[36,37] The developed system 
showed a Z′-factor of 0.63 (calculated from 32 ×  4 measure-
ments of pre-treated motile and dead parasites of the imped-
ance-based assays, powermotile  = −12.8  ±  1.9 dBμ and pow-
erdead = −34.5 ± 0.8 dBμ), which highlights the potential of the 
platform as a robust and higher throughput antischistosomal 
screening method according to NIH guidelines.[36] The novel 
design also enabled the long-term culturing of the parasite 
larvae to realize a real-time evaluation of drug activity, which 
is important for providing insights into drug kinetics and for 
selecting fast-acting compounds.[38] High and fast drug activity 
Figure 5. Characterization of NTS parasite motility and viability during long-term exposure to methiothepine. A) The motility values of the NTS, 
exposed to four different concentrations of methiothepine, are shown and compared to the motility indices of the vehicle-control sample (NTS exposed 
to 0.5% v/v DMSO). Each point represents the mean value of the motility indices of three replicates. Trend lines were superimposed to the points 
to guide the eye for the different tested conditions. B) Time-lapse images of NTS showed qualitative movement differences between NTS exposed to 
6 µm methiothepine and to 0.5% v/v DMSO. The yellow arrows indicate parasites that moved between the different frames. C) The impedance-based 
viability measurements of NTS at four selected time points are plotted as a function of the drug concentration. The NTS was incubated with six different 
concentrations of methiothepine (1.5, 3, 6, 12, 25, and 50 µm) during 48 h. Each circle represents the mean viability value of three replicates, and the 
error bars represent the standard error of the mean. The sigmoid fit was used to calculate the IC50 value at each time point. D) IC50 values, calculated 
from the impedance-based detection of NTS viability, are compared with IC50 values obtained by standard visual scoring at 24 and 48 h (marked in 
red). The circles represent the values determined from the sigmoid fits, while the error bars show the 95% confidence intervals.
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along with low toxicity are relevant criteria to select promising 
antischistosomal lead compounds.[24]
The constant decrease of motility in the control samples 
during long-term in vitro culture, a common behavior of NTS 
also observed in standard assays, may introduce artifacts in the 
evaluation of compound efficacy in multi-day drug-exposure 
experiments using motility-based parasite evaluation. There-
fore, medium exchanges may be considered to extend the via-
bility time of the NTS in the platform for long-term assays.
We first validated the EIM platform by recording variations 
in NTS motility upon dosage of three active drugs triggering 
antischistosomal effects (Figure S7, Supporting Information). 
By analyzing the effect of praziquantel on NTS motility, we 
were able to reproduce the in vitro excitatory action of the drug 
on parasites, which lasted for over 18 hours. This hypermotility 
is caused by the activity of praziquantel as calcium channel ago-
nist, which increases the calcium concentration in the schisto-
somula body within minutes of exposure and causes intense 
and sustained muscular contraction of the parasites.[26,39] In 
contrast, the exposure of NTS to oxethazaine caused a fast-
acting inhibitory effect on their motility.[24] Motility reduction 
is most likely caused by the high affinity of the drug to the 
sodium channels of the NTS, which has been shown to have 
an in vitro inhibitory effect on the schistosomula smooth mus-
cles by blocking the action of serotonin.[27] Via our impedance-
based detection, we were able to confirm the fast action and the 
high efficacy of the drug in vitro, which showed an IC50 value 
of 3.48 µm already after 1 h of incubation. To investigate com-
plex antischistosomal drug response, we studied the effect of 
mefloquine on NTS with the EIM platform. This antimalarial 
compound is known to induce hyperactivity and to affect NTS 
viability in vitro, which may be attributed to its potential role as 
an inhibitor of glycolysis and interference with schistosomula 
metabolic activity.[40] Our impedance-based IC50 estimations 
confirmed the reported lethal effect of mefloquine on NTS 
showing values below 10 µm after 20 h of drug exposure.[21] Dif-
ferences in IC50 values, obtained with impedance-based and 
visual methods were expected for mefloquine at 24 h, as the 
morphology of the NTS was highly affected at high drug con-
centrations, and it was difficult to detect subtle movements of 
the larvae by eye, which, however, remained detectable using 
the impedance system.[21,28]
After validating the ability of our method in detecting 
changes of NTS motility caused by drugs with known in vitro 
effects, we used the EIM platform to analyze the response of 
the schistosomula to methiothepine. The complex dose- and 
time-dependent response of the NTS to the compound under-
lines the importance of continuous monitoring of parasites 
when investigating the efficacy of new drugs. Methiothepine 
is an antipsychotic drug of the tricyclic group, which acts 
as an inhibitor of both the serotonin receptor and the SERT, 
depending on the dose.[24,29] A transient increase in schistoso-
mula motility was detected for sub-lethal drug concentrations 
(<12 µm of methiothepine for the first 24 h of incubation). This 
result corroborates the effects observed for two classical SERT 
inhibitors, fluoxetine and clomipramine, which were shown to 
induce strongly hyperactive phenotypes.[41] Recently, incuba-
tion of NTS with paroxetine, another S. mansoni SERT inhib-
itor, in the 1–10 µm concentration range was reported to have a 
similar hypermotility effect during the first 24 h of incubation, 
while the motility then decreased for longer exposure times.[32] 
Our measurements demonstrate that methiothepine has a 
similar effect on NTS for an analogous concentration range, 
as the schistosomula showed decreased motility after 24 h. 
Higher concentrations of methiothepine (>12 µm) resulted in 
a rapid loss of motility and a consequent reduction in larvae 
viability,[42] which confirmed earlier findings[24] and was similar 
to what has been previously reported for high concentrations of 
paroxetine.[32]
In summary, we developed a parallelized and automatable 
drug-screening platform, which continuously provides dose-
dependent viability scores of NTS. The drug-dose responses of 
the parasites to four different antischistosomal compounds that 
were obtained through impedance detection show good agree-
ment with those obtained from standard visual scoring of NTS 
motility. This agreement evidences that the impedance-based 
approach constitutes a reliable alternative method to identify 
novel drug candidates in vitro. The current platform layout ena-
bles the operator to use up to 4 chips, which include 32 anal-
ysis units in parallel, with a single instrument. The electrical 
detection method allows for further parallelization to achieve 
increased throughput with minimal experimental-setup modifi-
cations. The chip design, implemented in PDMS, can be easily 
realized with standard plastic materials to avoid issues related 
to compound ad/absorption in PDMS, and fabrication pro-
cesses for mass production, such as injection molding, can be 
used. Finally, the EIM platform can be readily adapted to other 
relevant motile schistosome stages, such as cercariae, juvenile 
and adult parasites, or to different parasite species by simple 
modification of the sensing-area design, which will contribute 
to improve anthelmintic drug-screening applications.
4. Experimental Section
Culture Medium and Drugs: M199 medium was obtained from
Gibco (cat. no. 22340-020, Thermo Fisher Scientific, Waltham, USA). 
Penicillin/streptomycin 10′000 U mL−1 (pen/strep, cat. no. P4333-
100ML, Sigma-Aldrich, Buchs, Switzerland) and inactivated fetal calf 
serum (iFCS, cat. no. 2-01F30-I, Bioconcept AG, Allschwil, Switzerland) 
were purchased from Bioconcept AG. All media were sterilized by 
filtration using a 0.22  µm filter bottle (cat. no. 431097-COR, Vitaris 
AG, Baar, Switzerland). Oxethazaine (cat. no. O5380-5G, Sigma-Aldrich, 
Buchs, Switzerland), praziquantel (cat. no. P4668-5G, Sigma-Aldrich, 
Buchs, Switzerland), mefloquine (cat. no. M2319-100MG, Sigma-Aldrich, 
Buchs, Switzerland), and methiothepine (cat. no. M149-100MG, Sigma-
Aldrich, Buchs, Switzerland) were all purchased as racemic powders 
from Merck (Sigma-Aldrich).
Parasite Culture and Transformation: S. mansoni culturing and NTS 
transformation were performed according to protocols previously 
described in literature.[12,43] In brief, S. mansoni -infected Biomphalaria 
glabrata snails were placed singularly in 24-well plates and exposed 
to a neon lamp (36 W, 4000 K, 3350 lumens), for 3–4 h, to induce the 
shedding of cercariae. The supernatant was collected and filtered to 
remove impurities in the solution. The mechanical transformation of 
the cercariae into NTS was performed by physically removing the tail 
by constricted passage through a Luer-Lok tip in between two 12  mL 
syringes. The NTS was resuspended in M199 medium supplemented 
with 5% v/v iFCS, 1% pen/strep, and 1% antifungal mix.
In Vitro Antischistosomal Drug Assay: The drug assay in the EIM 
platform was performed by first dispensing 30 µL of NTS solution with 
1 NTS 2  µL−1. After 1 h recording of the NTS-induced fluctuations as 
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baseline activity, 30  µL of drug solution (1.5–50  µm in NTS medium) 
were added, yielding a total volume of 60 µL in each analysis unit. Final 
drug concentrations ranged between 0.75 and 25 µm in a 2× dilution 
series. In each assay, 0.5% v/v DMSO (vehicle control) and blank 
M199 medium controls were included. All conditions were measured in 
quadruplicates. NTS viability under each test condition was measured 
every 15 min for 48 h in the EIM platform. A viability score ranging from 
0 to 1 (0 = non motile and dead parasite, 1 = motile and alive parasite) 
was assigned to each test condition and per time point, according to 
the relative motility of the parasites with respect to the vehicle control 
motility (see Data Analysis for more information).
In parallel, identical drug concentrations were set up in a 96-well 
plate (cat. no. 83.3924, Sarstedt, Nümbrecht, Germany) to perform 
the same experiment by using the standard visual scoring method to 
compare the results obtained via standard viability detection with the 
impedance-based characterization. 50  µL of 2 NTS 1  µL−1 suspension 
were dispensed in each well, and subsequently 50  µL of drug-
concentration solutions were added to reach a final drug concentration 
ranging from 0.75 to 25 µm. Each condition was prepared in duplicates 
or triplicates. A trained operator evaluated the viability of the NTS in 
the different drug solutions assigning a score from 0 to 3 on a quarter-
of-a-point scale. In this scale, 0 represents NTS with complete loss of 
motility, while 3 represents NTS with good motility, good overall viability, 
and healthy behavior.[12] Visual scoring was carried out after 24 and 48 h 
of drug incubation.
Each drug test was performed in a separate experiment.
Chip Fabrication: The analysis chip consisted of two parts: a 
polydimethylsiloxane (PDMS) layer containing the microfluidic 
structures and a glass slide with a patterned metal layer. The PDMS layer 
was cast from a 3D-printed master mold (fabricated in Accura SL 5530, 
Protolabs, Feldkirchen, Germany) by using soft lithography. The silicone 
and curing agent (Sylgard 184, Dow Corning Corp., Midland, USA) were 
mixed at a 10:1 w/w ratio, degassed, and poured onto the master mold. 
After curing or 2 h at 85 °C, the PDMS layer was peeled off the master 
mold and cut into individual chips.
The 200-nm-thick platinum electrodes were deposited on a 6-in., 
500-µm-thick borosilicate glass wafer via a lift-off process. Briefly, the
wafer was spin-coated with lift-off resist (LOR3B, Microchem Corp., 
Newton, USA), followed by a positive photoresist (S1813, Rohm-Haas, 
Schwalbach, Germany), and patterned using photolithography. After Pt 
deposition, the lift-off of the metal was carried out by using Mr-Rem-400 
remover (micro resist technology GmbH, Berlin, Germany). Finally, the 
glass wafer was diced into individual glass slides (20 mm × 62 mm).
Each PDMS chip and patterned glass slide were aligned using a 
custom-made alignment tool and irreversibly bonded together after 
surface treatment using oxygen plasma (Harrick Plasma PDC-002, 
Harrick Plasma, Ithaca, USA).
Parylene Coating of PDMS Chip: To prevent drug absorption by 
PDMS during long-term compound incubation (48 h), we coated the 
chip surface with parylene-C polymer.[30,44] All microfluidic chips were 
coated using a parylene coating system (Parylene P6, Diener Electronic 
GmbH, Ebhausen, Germany). The devices were placed in the center of 
the rotating trays in the deposition chamber. 10  g of parylene-C dimer 
powder (parylene, Diener Electronic GmbH, Ebhausen, Germany) were 
placed into the evaporator. The system was evacuated to 0.012 mbar 
before the deposition was initiated. The powder was evaporated in a 
temperature range of up to 170 °C, cleaved in the pyrolysis tube at 720 °C, 
and deposited onto the samples at 80 °C and 0.03 mbar over the course 
of 4.2 h (Figure S2A, Supporting Information). After the evaporation of 
the parylene powder, the deposition chamber was cooled down to 41 °C 
and the devices were then removed from the coating system.
The thickness of the deposited parylene-C layer was evaluated by 
using a 3D optical surface profiler (Zygo Corporation, Middlefield, 
USA) on a microscope slide (Menzel-Gläser, Thermo Scientific, 
Dreieich, Germany), placed in the chamber with the devices (Figure 
S2B, Supporting Information). For this purpose, the parylene layer was 
cut, one part was pealed from the glass slide, and the thickness was 
measured along the cut.
Rhodamine Absorption Evaluation: To compare the dye absorption 
in parylene-coated PDMS and bare PDMS chips, 30 µL of rhodamine 
B (83689, Sigma-Aldrich, Buchs, Switzerland) solution (0.1  mm in DI 
water) were loaded into each well chamber. Fluorescence images inside 
the chambers were captured before the loading of the dye, at 5 min, 1 
and 2 h after sample loading using an inverted microscope (Nikon Ti-E, 
Nikon, Egg, Switzerland). During the measurements, the chips were 
kept in the dark to prevent photobleaching and at 37 °C, 5% CO2 using 
a stage-top incubator. The microscope was controlled using Youscope 
software, and offline image analysis was performed using ImageJ (Figure 
S3, Supporting Information).
EIM Platform Assembly: The chips were placed between a custom-
made printed-circuit board (PCB) and a chip holder (Figure S8, 
Supporting Information). The PCB was designed in Altium Designer 17.0 
and ordered from PCBWay (Hangzhou, China). Electrical connections 
between the PCB and the analysis chips were obtained by contacting the 
electrode pads from above using spring-loaded pins (0956-0-15-20-75-
14-11-0, Mill-Max Mfg. Corp., Oyster Bay, USA). The PCB featured four
window-like openings (15 mm × 58 mm) to allow for visual access to the
chips without disassembling the platform.
The chip holder was 3D-printed by means of stereolithography 
(Protolabs, Feldkirchen, Germany) in ABS-like material (Accura Xtreme 
White 200, Protolabs, Feldkirchen, Germany). The printing material was 
selected as to withstand the high-humidity conditions in the incubator 
and the high force levels required for reliable chip connection. The chip 
holder also featured four openings to allow for visual examination of the 
parasites using a standard inverted microscope.
Neodymium block magnets (Q-10-03-02-HN, Supermagnete, Uster, 
Switzerland) were used to align and keep the chip holder and PCB in 
position, and to provide the force necessary for pressing the spring-
loaded pins onto the electrode pads on the chips for stable electrical 
connection. The magnets were attached to the chip holder and the PCB 
with a 2-component white epoxy adhesive (EA 9492, Henkel, Düsseldorf, 
Germany). Finally, the platform was covered with an omniTray lid 
(Nunc OmniTray Single-Well Plate, Thermo Fisher Scientific, Reinach, 
Switzerland) to prevent medium evaporation from the culture units.
Impedance Measurement: Impedance measurements were 
performed using a HF2-LI impedance spectroscope (Zurich 
Instruments AG, Zurich, Switzerland). The analysis chips were 
contacted via a custom-made PCB to route the connections from 
the impedance spectroscope to the integrated electrodes. An AC 
voltage with an amplitude of 100 mV and a frequency of 500 kHz was 
applied between the selected pair of coplanar electrodes. The current 
flowing through the system was then converted to voltage through a 
trans-impedance amplifier (HF2TA, Zurich Instruments AG, Zurich, 
Switzerland) with a 1-kΩ feedback resistor and sampled by the HF2-LI 
with a sampling frequency of 14 kHz. The acquired signal was filtered 
with a 2.2-kHz low-pass filter in the impedance spectroscope. The 
amplitude variation of the sampled current-to-voltage signal was then 
used for further analysis. A custom-made software, written in Python, 
was used to control the selection of the electrode pair and to control 
the signal acquisition.
Microscopy: During the recording of the impedance signals, the 
platform was placed on the stage of an automated microscope. 
Microscopic images were obtained using an inverted microscope (Nikon 
Ti-E, Nikon, Egg, Switzerland), placed in an environmental control 
box, which maintained a stable temperature of 37 °C, CO2 of 5%, and 
a relative humidity of ≈90%. Bright-field images were captured on the 
Nikon microscope using a Nikon Plan Fluor 10X objective (NA 0.3, WD 
16  mm). Automated imaging was performed for 20  s every hour from 
each analysis unit during the entire experiment. The live micrographs 
were recorded to compare the results of the gold-standard evaluation 
(visual scoring) with those obtained by the impedance-based readout. 
The microscope was controlled using Youscope software, and offline 
image analysis was performed using ImageJ.
For standard visual assessment, the parasites were incubated in 
culture medium with the test compounds in a 96-well plate in duplicates/
triplicates for 48 h. Every 24 h, the drug effects on the parasites were 
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assessed by visual scoring with a light microscope using a magnification 
of 4–10×.
Computational Modeling: A finite-element-method (FEM) model 
was used to verify the current-density distribution in the microwell 
(Figure S4A, Supporting Information). The current passing through the 
electrodes in the measurement chamber was calculated by integrating 
the current density over the middle orthogonal cross section area of 
the microwell in Comsol Multiphysics 5.4 (COMSOL AB, Stockholm, 
Sweden). To evaluate the current density across the entire depth of the 
microwell, the current was derived over the microwell height (Figure 
S4B, Supporting Information).
Data Analysis: The voltage-converted current signals were processed 
and analyzed in MATLAB (The MathWorks Inc., Natick, USA). The 
recorded signals were filtered using a 0.2-Hz high-pass filter to remove 
slow signal variation due to solution evaporation. Each analysis unit 
may exhibit different baseline values due to differences in solution 
conductivity caused, for example, by different drug compounds or drug 
concentrations, or by subtle variations in the alignment of the electrodes 
with the microwell base. To reduce the influence of such effects, the 
high-pass-filtered traces were normalized with respect to the mean 
baseline signal of the respective unit. To quantify the signal fluctuations 
induced by the parasites, the power of the filtered and normalized signal 
was computed in a 1–3  Hz bandwidth. This approach minimizes the 
effect of readout noise, which is present at higher frequencies, while it 
preserves the signal power that is related to the movement of the NTS 
between the electrodes. To confirm that the sample was correctly loaded 
in the microwell, the signal power was first measured during 1 h prior to 
addition of the drug compound. Only analysis units, the signal power 
of which ranged between (−18.5, −7.1) dBμ (± 3 standard deviations of 
the average NTS motile value, −12.8 ±  1.9 dBμ), were further analyzed. 
The runtime calculated power of the measured fluctuations in each 
unit was normalized to its initial power magnitude (t-1hr) in order to 
compare measurements with different numbers of NTS in the sensing 
compartments and to extract motility index parameters. To evaluate 
NTS viability, the motility index of every condition was normalized 
to the motility index of the vehicle control. This procedure followed 
the normalization performed in the standard drug assay using visual 
scoring and it helped to remove NTS phenotype variations caused by 
the vehicle.[21] In addition, a viability value of 1 was assigned to all the 
microwells in which the NTS showed a motility equal or higher than that 
in the vehicle control microwells.
The viability scores obtained from visual evaluation were averaged 
across replicates and normalized to the vehicle-control viability score.
The half-maximum inhibitory concentration (IC50) values of the tested 
drugs were determined for both visual-inspection-based and impedance-
based viability scores by applying a nonlinear least-squares analysis. A 
two-parameter sigmoid function with a constant hill slope was fitted 
to the viability scoring data. A single average slope was first computed 
across all experimental time points for each drug and then applied to 
the fit for the estimation of the IC50 during the continuous long-term 
measurements.
The Z′-factor of the impedance-based assays was computed to 
determine the suitability of the EIM platform for high-throughput 
screening applications.[36,37] The Z′-factor is defined as
σ σ
µ µ





3 3  
where µ+ and µ− indicate the mean signal power of alive (motile and 
pre-treated) and dead (non-motile) schistosomula and σ+ and σ− the 
corresponding standard deviations.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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ABSTRACT: Schistosomiasis is a major neglected tropical disease with more
than 200 million infections annually. Despite only one drug, praziquantel, being
available, the drug pipeline against schistosomiasis is empty, and drug screening
tools have limitations. We evaluated the potential of human liver microtissues
(hLiMTs) in antischistosomal drug discovery. Because hLiMTs express all
human P450 enzymes, they are an excellent tool to evaluate compounds’
bioinactivation, bioactivation, and toxicity. To validate the metabolic
conversion capacity of hLiMTs, we first quantified (R)- and (S)-praziquantel
and the main metabolite trans-OH-praziquantel following incubation with
0.032−50 μM (0.01−15.62 μg/mL) praziquantel for up to 72 h by a validated
LC-MS/MS method. We cocultured hLiMTs with newly transformed
schistosomula (NTS) and evaluated the antischistosomal activity and
cytotoxicity of three prodrugs terfenadine, tamoxifen citrate, and flutamide.
HLiMTs converted 300−350 ng (R)-praziquantel within 24 h into trans-OH-
praziquantel. We observed changes in the IC50 values for terfenadine, flutamide, and tamoxifen citrate in comparison to the standard
NTS assay in vitro. Cytotoxicity was observed at high concentrations of flutamide and tamoxifen citrate. An in vitro platform
containing hLiMTs could serve as an advanced drug screening tool for Schistosoma mansoni, providing information on reduced or
increased activity and toxicity.
KEYWORDS: Schistosoma mansoni, primary human liver microtissue, praziquantel, drug screening
Schistosomiasis causes a tremendous public health burden,affecting annually more than 200 million people world-
wide.1,2 The parasites mainly responsible for the disease are
Schistosoma haematobium, S. japonicum, and S. mansoni.2,3
More than 90% of the cases occur in sub-Saharan Africa.3 Only
one drug, praziquantel, has been available for decades to treat
schistosomiasis.4,5 Oxamniquine had been commonly used
against S. mansoni for about 40 years, but after massive use,
especially in South America, resistant strains were frequently
detected, leading to the abandonment of oxamniquine as
treatment option.6 Therefore, novel drug candidates to fill to
the empty drug pipeline are urgently needed in case of
emergence of praziquantel resistant strains.1
Currently, the research for antischistosomal compounds has
limitations. The drug screening procedure is mainly based on
phenotypic screenings, which are performed by microscopy-
based visual scoring of the fitness of parasites by trained
operators. This procedure is laborious, subjective, and slow.7
However, the effect of a compound can be observed on the
parasite directly rather than on an isolated component, which
captures complex biological mechanisms. Moreover, this
system can be relatively easily modified and sophisticated.
The human primary liver microtissues (hLiMTs) are a
rather novel technology,8 which has been explored in
toxicology studies for evaluation of drug-induced liver injuries
(DILIs),9,10 because hLiMTs might indicate toxicity that
otherwise might be overlooked in animal studies.11 It has been
shown that about 60% of drug-induced toxic effects could be
predicted using microtissue-based liver systems, whereas
standard rodent-based drug testing showed only roughly 40%
of those toxic effects in comparative studies.10,12
Moreover, the three-dimensional structure of the micro-
tissues triggers and enhances some physiological mechanisms
that would not be reproduced in two-dimensional cell cultures,
such as activity of the cytochrome P450 enzymes (CYP450)
and cell polarization.10,12,13 Microtissue models offer a
microenvironment that better represents in vivo conditions
with respect to cell shape, adhesion, behavior, topology, and
morphology.10,14 One important advantage offered by this 3D
cell-culture technology is the possibility to coculture different
cell types that can self-assemble and mimic tissue/organ
organization.10 Because these primary human hepatocytes
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(PHH) are harvested directly from human donors, they feature
high expression levels of CYPP450 enzymes such as P450-4A3
and P450-2E9, which are comparable to the in vivo situation.10
In this study, we tested hLiMTs as a component of a
phenotypic drug screening assay for schistosomiasis. We first
established the system by incubating hLiMTs with newly
transformed schistosomula (NTS). We next assessed the
activity and metabolic conversion of the hLiMTs with the
antischistosomal drug praziquantel, known to be quickly
metabolized with P450 cytochromes into trans-4-hydrodoxy-
praziquantel by LC-MS/MS-based quantification. In a case
study, we evaluated the effects of different doses of the
prodrugs terfenadine, flutamide, and tamoxifen citrate (Figure
1) in the newly established system of an NTS and hLiMTs
coculture. The compounds were selected for their known first
pass liver metabolism and/or for their hepatoxicity. We
measured ATP content of hLiMTs as proxy to test eventual
drug cytotoxicity because ATP is a valid marker to measure cell
viability. This new system could serve as an advanced
Figure 1. Structures of drugs tested in this study: (a) praziquantel, (b) tamoxifen, (c) flutamide, and (d) terfenadine.
Figure 2. (R)-Praziquantel, (S)-praziquantel, and trans-OH-praziquantel quantified by LC-MS/MS following exposure of hLiMTs to praziquantel
for a period of 3 days for (a) 2 μM praziquantel, (b) 10 μM praziquantel, (c) 25 μM praziquantel, and (d) 50 μM praziquantel. Error bars represent
the standard deviation of three independent experiments. (e) ATP content of hLiMTs after 24, 48, and 72 h of incubation with praziquantel
(without NTS); as reference, untreated separate parallel controls were used. The standard deviation is indicated as error bars from triplicate
experiments.
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article
https://dx.doi.org/10.1021/acsinfecdis.0c00614
ACS Infect. Dis. XXXX, XXX, XXX−XXX
B
71
preclinical tool to identify safe and active antischistosomal
compounds.
■ RESULTS
Validation of the hLiMTs-Based Drug Screening with
Praziquantel. To compare the liver microtissue-based system
to the standard in vitro assay on NTS, we used praziquantel as
a test drug, and in the first step assessed a potential toxicity.
We exposed the cocultures of NTS and hLiMTs to different
concentrations of praziquantel. To confirm that praziquantel
was not detrimental to the hLiMTs, we studied the toxicity of
praziquantel on the hLiMTs over a period of 72 h by
measuring intracellular ATP content (Figure 2). The data
suggest that the ATP content is stable (ranging from 74 to
135%) regardless of praziquantel concentration and evaluation
time point for a period of 3 days.
LC-MS/MS Method Partial Validation. To reliably verify
the robustness of the LC-MS/MS quantification method, we
performed a partial interday validation, which was analyzed by
comparing three separate and independent validation tests that
were run on separate days. In every run, at least 75% of the
calibration line samples were within a precision of ±15%
(±20% for the LLOQ) to the nominal concentrations. The
fitted linear regression values R2 were >0.995 for every set. The
accuracy was between 85 and 115% and 80−120% for the
LLOQ. At least 67% of the QC samples were within a
precision of ±15% and ±20% for the LLOQ. The accuracy was
calculated to lie between 85 and 115% (LLOQ: 80−120%).
We analyzed the coefficient of variation of the QC replicates in
each set, and it was found to be below 7% intra-assay between
separate sets (Table S1).
Evaluation of Accuracy, Precision, and Matrix Effect.
We considered the samples below the LLOQ 10 ng/mL as 0,
as indicated by the FDA guidelines.15 Each set was within
±15% and ±20% for the LLOQ. The interassay accuracy was
between 94 and 103%, with the highest variation of 9.2%
observed at the high QC (2000 ng/mL) for (S)-praziquantel.
The interday precision was between 3 and 7% for the LLOQ
values and 5% for the ULOQ. The matrix effects were between
91 and 107% overall (Table S1). The highest matrix effect
value was determined for the ULOQ QC (2000 ng/mL) for
(R)-praziquantel and an intersample deviation of 5%. The
matrix effect lowest value (91% for (S)-praziquantel) was
calculated for the low LLOQ QC (10 ng/mL). In the low QC,
we observed a standard deviation of 12% for (R)-, 10% for (S)-
praziquantel, and 3% for trans-OH-praziquantel. The total
recovery values were between 103 and 105% for (R)-
praziquantel (lowest to highest concentration) and 89−104%
for (S)-praziquantel. The total recovery of trans-OH-
praziquantel was between 92 and 98%. Results are summarized
in Table S 1.
Praziquantel and trans-OH-Praziquantel Quantifica-
tion by LC-MS/MS. To evaluate the functionality of the
metabolism of the hLiMTs, we sampled the supernatant from
microtissues exposed to praziquantel every 24 h by LC-MS/
MS, quantifying (R)-,(S)-, and the metabolite trans-OH-
praziquantel. trans-OH-praziquantel was detected after 24 h,
increasing from 323 ng/mL at 24 h to 828 ng/mL at 72 h
when the microtissues were exposed to the highest
concentration tested, 50 μM praziquantel (Figure 2). A similar
trend was observed for the lower concentrations tested. In
praziquantel control samples (no microtissues, incubation for
72 h at 37 °C) praziquantel was found to be stable (no trans-
OH-praziquantel present) (Table S2).
Activity Evaluation of Tamoxifen Citrate, Flutamide,
And Terfenadine. We evaluated the IC50 values of tamoxifen
citrate, flutamide, and terfenadine in the hLiMTs assay and in
the standard drug assay (Table 1). The evaluation was
performed by visual screening as described elsewhere.7
Tamoxifen citrate-treated-NTS showed over the course of 72
h a gradual decrease in movements and at 72 h a darkening of
the tegument in both hLiMTs’ coculture and standard drug
screening; however, the changes were more accentuated in the
standard NTS drug assay. Terfenadine-treated NTS revealed a
darkening and reduction of movements, which was highly
pronounced in the standard assay, while less visible in with the
hLiMT assay. In the case of flutamide in the standard NTS
assay, changes of motility and morphology became evident
mostly at 72 h, while NTS coincubated with hLiMTs showed a
reduction of movements after 24 h that gradually increased at
48 and 72 h.
A significant difference in IC50 values was observed when
comparing the two systems after 48 and 72 h for terfenadine
(1.6 μM in hLiMTs versus 0.8 μM in the standard drug assay
and 0.8 μM in hLiMTs versus 0.4 μM in the standard drug
assay), tamoxifen citrate (6.5 μM in hLiMTs versus 1.8 μM in
the standard drug assay and 3.5 μM in hLiMTs versus 0.5 μM
in the standard drug assay), and at 72 h for flutamide (16.2 μM
in hLiMTs versus 0.1 μM in the standard drug assay). Drug
effect curves for each drug are shown in Figure S1. The mean
drug activity of praziquantel and the three drugs on NTS
recorded at different concentrations and time points is
presented in Table S3.
ATP Quantification Following Incubation with Test
Drugs. We evaluated the cell viability measuring ATP content
of the hLiMTs after 72 h coincubation with the three test
drugs. Tamoxifen citrate reduced the hepatocyte viability to 0
at 25 μM, while the other concentrations yielded a viability
above 100%. ATP content following flutamide incubation
ranged from 71 to 113%, while terfenadine incubation yielded
a cell viability based on ATP content of over 100% at all
concentrations tested, as shown in Figure 3.
■ DISCUSSION
In this study, we evaluated for the first time a primary human
liver microtissue-based (hLiMTs) assay for drug screening on
S. mansoni NTS.
Table 1. IC50 Values Calculated for Praziquantel and Three
Test Drugs on NTS Using an Assay Containing hLiMTs




compound 24 h 48 h 72 h 24 h 48 h 72 h
praziquantel 1.9 1.8 3.1 1.4 2.5 2.5
flutamide 5.1* 16.0 16.2 >50 25.1 0.1
tamoxifen citrate 4.7* 6.5* 3.5* 3.2 1.8 0.5
terfenadine 1.5 1.6* 0.8* 1.7 0.8 0.4
aIC50 calculated from experiment triplicates every 24 h for 72 h. The
values marked with * show a statistical significance in comparison
with the same time point without liver microtissues with p-values
<0.05 tested by a two-way ANOVA.
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Recently, hLiMTs have been receiving increased attention as
a valuable, highly sensitive tool in drug discovery. Compared to
traditional approaches, hLiMTs achieve higher sensitivity to
predict metabolism or toxicity.10 For example, in a recent
study, S9 liver fractions showed decreased CYP450s enzyme
activity in comparison to human primary hepatocytes flat cell
cultures.16 Moreover, compared to the flat cells cultures,
hLiMTs were also shown to be more sensitive to overall drug-
induced cytotoxicity.17
We observed significant differences in the activity of the
prodrugs in the microtissue assay versus our standard NTS
assay. This finding corroborates the capability of hLiMTs in
processing and metabolizing drugs, as demonstrated in the
validation part of our study for praziquantel, which is
metabolized at a rate of about 300−350 ng/day per single
microtissue, and hence, metabolism can bioactivate com-
pounds as well as reducing the activity of others.
In more detail, terfenadine is an antihistaminic drug, which
was found to be active on S. mansoni NTS and adult worms in
a previous study.18 We observed an increase of the IC50 value
after coculturing the drug with hLiMTs at 48 and 72 h, which
is likely due to conversion of the parent drug into fexofenadin,
which is inactive against S. mansoni in vitro and in vivo.19,20
Similarly, tamoxifen citrate, a chemotherapeutic, showed
significantly higher IC50 in the presence of hLiMTs. The IC50
value in the NTS standard assay we obtained in this study is
very similar to the one reported by Cowan et al.21 Tamoxifen
citrate is a prodrug and when it undergoes liver processing
especially by CYP3A4 and CYP2C9, two metabolites,
afimoxifene and endoxifen are formed, both selective estrogen
receptor modulators. Our finding is supported by the study of
Oliveira et al., where the authors found only 54% activity
against adult S. mansoni after administration of tamoxifen or
tamoxifen citrate per os or intraperitoneally in a murine-based
study.22 In the case of flutamide, we also observed a
considerable difference in the IC50 values after coculturing
NTS for 72 h with and without hLiMTs (16.2 μM versus 0.1
μM). Flutamide, a nonsteroidal selective androgen receptor
antagonist, is an established prodrug used against prostate
cancer,23 which was reported to show low activity against S.
mansoni in vitro and in vivo.24 The compound was mainly
chosen for its known hepatotoxicity.23 Indeed, at the highest
concentration tested, a decrease in cell viability was detected in
the hLiMTs system.
Although we demonstrated that praziquantel is metabolized
by hLiMTs when tested against NTS, the IC50 values were very
similar between standard in vitro testing and after coincubation
with liver microtissues. This could be due to the fact that
praziquantel is active but not lethal, even at very low
concentrations on NTS,25 and slight differences on viability
and phenotype might be hard to detect using a visual scoring
method,26 in particular when both the parent drug and
metabolites are present in the same wells. Another possibility
of the unchanged potency of praziquantel on NTS could be the
disproportional reduction of fraction metabolized with
increasing concentration of praziquantel as shown in Figure
2. In addition, there was a high uncertainty in the IC50 values
for praziquantel due to the difficulty in scoring the parasites
because of their increased motility and the darkened
phenotype of the tegument.
A limitation of our study is that we did not quantify the
metabolism of tamoxifen, terfenadine, and flutamide, which
would provide additional information on the behavior of the
compounds over time. Moreover, the liver microtissues in this
study were used as single experimental units, but it might be
possible to use multiple microtissues per well to increase the
metabolic output. However, if microtissues are pooled
together, they could merge and increase in size, which can
be detrimental for both viability and drug intake during
testing.27 Furthermore, microtissues are costly, and the
implementation at a larger scale can result in high costs.
Hence, it is debatable whether a sophistication of a phenotypic
stage is required already at this early stage of antischistosomal
drug discovery. Lastly, additional studies underlining the
advantages of the hLiMTs in comparison with 2d primary
hepatocytes cultures for the discovery of novel antischistoso-
mal compounds are necessary to evaluate the method’s full
potential.
■ CONCLUSION
Our liver-based screening assay represents the first study
integrating hLiMTs in the drug screening process for
schistosomiasis. The data indicate that the hLiMTs are useful
for detecting changes in the activity of test drugs on NTS due
to drug metabolism as well as toxicity in a single test system.
More studies need to be conducted to confirm these findings
with other drugs. An improved coculturing screening system
might advance the research in helminth drug discovery by
lessening the number of inactive compounds tested in vivo, in
compliance with the 3R guidelines. Such a system can also
better predict compounds’ cytotoxicity.
■ METHODS
Newly Transformed Schistosomula (NTS). Schistosoma
mansoni cercariae of a Liberian strain were harvested from
light-exposed infected Biomphalaria glabrata snails. Once the
Figure 3. Viability of the liver microtissue is shown by ATP
quantification after 72 h coincubation with hLiMTs and NTS for (a)
tamoxifen citrate, (b) flutamide, and (c) terfenadine. The error bars
indicate the standard deviation of triplicate experiments.
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cercariae were shed, they were mechanically transformed into
NTS as described elsewhere.7 They were then cultured at 37
°C, 5% CO2 in M199 medium (Gibco, USA, cat. no. 22340-
020), enriched with 5% v/v iFCS (Bioconcept AG, Switzer-
land, cat. no. 2-01F30-I), 1% v/v penicillin/streptomycin
10 000 U/mL (Sigma-Aldrich, Switzerland, cat. no. P4333-100
ML), 1% v/v antifungal and antibacterial cocktail, as described
elsewhere.7 All media were filter-sterilized prior usage by using
a 0.22 μm filter bottle (Corning Stericup 500 mL, Vitaris AG,
Switzerland, cat. no. 431097-COR).
Primary Human Liver Microtissue (hLiMT) System
Handling. The multidonor (10) hLiMTs were purchased
from Insphero AG (Schlieren, Switzerland). The handling was
performed according to the manufacturer’s guidelines. Briefly,
upon arrival, the sealed Insphero Akura 96 Microtissue
Delivery Plate was first centrifuged at 250g for 1 min and
immediately removed from the inner sealing, followed by
medium exchange with Insphero AF medium, prewarmed at 37
°C.
Compounds. All drug stock concentrations (10 mM) were
freshly prepared in DMSO (Merck, Zug, Switzerland, cat. no.
276855-2L) before the experiments and kept at −20 °C.
Praziquantel as racemic powder (cat. no. P4668-5G),
terfenadine (cat. no. T9652-5G), flutamide (cat. no. F9397-
1G) and tamoxifen citrate (cat. no. 579000-100MG) were
purchased from Sigma-Aldrich (Buchs, Switzerland). Prazi-
quantel was chosen for its fast first pass liver metabolism, while
terfenadine, flutamide, and tamoxifen citrate were chosen
because they are known prodrugs,3,20,28 and flutamide reveals
hepatotoxic effects.23
Coincubation of NTS Directly with hLiMTs. NTS were
resuspended in Insphero Tox medium at a concentration of 1
NTS/1 μL. For each test condition, a volume of 10 μL of NTS
solution was loaded directly into the Insphero Akura 96
Microtissue Delivery Plate. In parallel, NTS were tested by
applying the same drug conditions using the standard drug
assay procedure (without microtissues), as described else-
where.7 For praziquantel and tamoxifen citrate, we tested a
drug concentration range between 3.13 and 25 μM; for
terfenadine, we used a drug concentration range between 0.78
and 6.25 μM, and for flutamide, the concentrations ranged
from 6.25 to 50 μM. These concentration ranges were
preselected by testing the drug compounds on the NTS
alone and by evaluating the IC50 value. A volume of 45 μL of
each of the drug concentrations was added to 10 μL of NTS-
suspension and resuspended in Insphero Tox medium at 1
NTS/μL. Finally, each well was filled with 25 μL of Insphero
Tox medium, to a final volume of 80 μL. The parasites were
incubated at 37 °C, 5% CO2 and evaluated under the
microscope every 24 h for a period of 3 days.
ATP Assay for Viability Evaluation of hLiMT after
Drug Exposure. The viability of the hLiMTs alone after
praziquantel exposure was evaluated at 24, 48, and 72 h by an
ATP assay (Promega AG, Du bendorf, Switzerland, cat. no
G9681). In a separate experiment, NTS coincubated with
hLiMTs at 37 °C, 5% CO2 were evaluated at 72 h post
coincubation with praziquantel. The other compounds tested
were evaluated at 72 h post drug exposure. The ATP
quantification was performed by removing the medium and
rinsing each well 3 times with 100 μL of sterile PBS to remove
the medium and NTS. Later, 40 μL of Celltiter Glo 3D
reagent, prediluted 1:1 v/v with sterile PBS, was dispensed into
the Akura 96 microtissue plate. The solution was mixed up and
down to ensure a homogeneous lysis of the microtissues and
left for 30 min in the dark at room temperature within a
thermomixer at 350 rpm (Themomixer C, Eppendorf,
Hamburg, Germany). The solutions from the microtissue
plates were collected and dispensed into 96 half-volume well
plates (Corning, Root, Switzerland, cat. no. CLS4580-10EA).
Each half-volume plate was then read with the Dynex MLX
Luminometer (Dynex Technologies, Inc., Denkendorf, Ger-
many) set for bioluminescence data acquisition. As standard
for the assay quantification, adenosine 5′-triphosphate
disodium salt hydrate (ATP) was used (Sigma-Aldrich,
Buchs, Switzerland, cat. no. A7699-1G). The standard was
diluted from 10 to 0.156 μM in duplicate. The ATP solutions
were freshly prepared in filtered-sterile Milli-Q water to a final
concentration of 100 μM before every experiment to avoid
ATP decay. We calculated the relative variations in the
microtissue cells’ viability by the ratio of the quantified ATP
under tested conditions and the quantified ATP under control
conditions (DMSO 0.5% and blanks) as described elsewhere.29
Preparation of the Standards for Liquid Chromatog-
raphy Tandem Spectroscopy (LC-MS/MS). Quality con-
trols (QCs) and calibration line (CL) samples were freshly
prepared before every experiment. One microliter of the
appropriate concentration was used as spiking solution by
mixing it with 19 μL of the 72-h blank conditioned Insphero
TOX medium. The spiking solution was prepared in 10% v/v
methanol and 90% v/v filtered Milli-Q water. The CL covered
the following drug concentrations of praziquantel and trans-
OH praziquantel: 0.01, 0.025, 0.05, 0.1, 0.25, 1.0, and 2.0 μg/
mL. The QCs were prepared by spiking the following drug
concentrations: 0.01, 0.1, 0.5, and 2.0 μg/mL of praziquantel
and of trans-OH praziquantel. Each of the three validation sets
contained the four QCs in six replicates plus a calibration line.
The QCs covered the lower limit of quantification (LLOQ),
low, middle, and high concentrations as recommended by the
Food and Drug Administration (FDA) guidelines for industry
for bioanalytical method validation.15
To prepare a praziquantel stock solution, praziquantel was
dissolved in 100% methanol (Merck, Zug, Switzerland, cat. no.
1.06035.2500) to a final concentration of 5 mg/mL. To
prepare the metabolite stock solution, trans-OH-praziquantel
was dissolved in methanol at 10 mg/mL. This solution was
used for preparing the QCs and CLs in the spiking solution.
The internal standard (ISTD) stock solution was prepared in
pure hyper-grade acetonitrile (Merck, Zug, Switzerland, cat.
no. 1142912500) at a concentration of 500 ng/mL of d11-
praziquantel (Toronto research, Canada, cat. no. cat. no.
P702107). The ISTD stock solution was stored at −20 °C to
avoid d11-praziquantel decay. The ISTD working solution was
prepared in 20% v/v Milli-Q water, 80% acetonitrile v/v and
contained d11-praziquantel at a final concentration of 400 ng/
mL. The ISTD working solution was used as extraction
solution for the samples.30
Validation of the LC-MS Method. A partial validation
was performed by running three complete validation sets on
three different days, as described elsewhere.30 We adapted the
quantification method from an already validated method for
praziquantel quantification from mouse plasma.30 The recovery
was evaluated as spiked-sample concentration, compared to the
nominal concentration in solution without matrix. FDA
guidelines recommend limits for the quantification of analytes
of high, middle, low concentration to be within ±15% of their
nominal spiked concentration, or ±20% for the LLOQ.15 The
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matrix effect was tested by comparing the normalized area
under the curve (AUC) of the extracted and spiked samples of
Tox Insphero medium to the AUC of spiked extraction
solvent.
LC-MS/MS Method and Instrumentation. All measure-
ments were performed using an Agilent 6460 Series triple
quadrupole LC−MS/MS. The apparatus was run by Mass
Hunter Workstation software suite (Agilent Technologies,
United States, version: B.06.00), as described elsewhere.30 The
HPLC system’s six-port switching valve was used to divert the
flow to the MS/MS from 3 to 9.5 min. To prevent carry-over
effect, we used a solution of 1:1 v/v filtered Milli-Q water and
2-propanol hypergrade (Merck, Zug, Switzerland, cat. no.
1027811000). This solution was used to wash the
autosampler’s needle after each injection. For every injection,
a sample volume of 5 μL was injected for the analysis. A
column-trapping system HALO C18, 4.6 × 5 mm, (Optimize
Technologies, United States) was used before eluting to the
main column for chiral separation, a Lux Cellulose-3 column
(cellulose tris(3-chloro-4-methylphenylcarbamate) phase), 150
× 4.6 mm, 3 μm (Phenomenex, United States, cat. no. 00F-
4456-B0).
Preparation of LC-MS/MS Samples. The samples were
extracted with 180 μL of ISTD working solution containing
400 ng/mL d11-praziquantel in 4:1 v/v acetonitrile/Milli-Q
water. After extraction, the samples were thermomixed at 20
°C for 30 min at 350 rpm (Eppendorf Themomixer C,
Hamburg, Germany). The samples were filtered directly into
96-deep-well plates (500 μL) (Eppendorf, Switzerland, cat. no.
0030501101) by centrifugation (10 min at 2250g and 22 °C)
of 2 μm PVDF membrane filter 96-well plates (Corning Life
Sciences, CA, United States, cat. no. CLS3508-50EA). The 500
μL 96-deep-well plates were sealed with plastic sealing mats
(Eppendorf, Germany, cat. no. 15319247) and immediately
run.
Data Analysis and Statistics. For the data analysis, we
used GraphPad Prism version 8. The half-maximal inhibitory
concentration (IC50) values were calculated by using a least-
squares-fit model using a three-parameter nonlinear regression.
The statistical model used to evaluate the statistical
significance of the IC50 comparisons was a two-way ANOVA
test with a confidence interval of 95%.
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A B S T R A C T
Schistosomiasis is a global disease of significant public health relevance. Only one racemic drug, praziquantel,
characterized by low bioavailability, low water solubility and extensive first pass metabolism, is currently
available. We studied a new praziquantel formulation (polymorph B), which is based on a racemic praziquantel
crystalline polymorph (TELCEU01). Its in vitro activity was tested on newly transformed schistosomula (NTS)
and adult Schistosoma mansoni. In vivo studies were conducted in mice harboring chronic S. mansoni infections.
Pharmacokinetic (PK) profiles of R- and S-praziquantel and R- and S- polymorph B following oral administration
with both formulations were generated by sampling mice at 30, 60, 240min and 24 h post-treatment, followed
by LC-MS/MS analysis. PK parameters were calculated using a non-compartmental analysis with a linear tra-
pezoidal model. In vitro, commercial praziquantel and the polymorph B performed similarly on both NTS
(IC50= 2.58 and 2.40 µg/mL at 72 h) and adults (IC50= 0.05 and 0.07 µg/mL at 72 h). Praziquantel showed
higher in vivo efficacy with an ED50 of 58.75 mg/kg compared to an ED50 of 122.61 mg/kg for the polymorph B.
The PK profiles of the two drugs exhibited differences: R-praziquantel showed an overall 40% higher area under
the plasma drug concentration–time curve (AUC0→24) (R-praziquantel = 3.42; R-polymorph B=2.05 h*µg/mL)
and an overall 30% lower apparent clearance (Cl/F) (R-praziquantel= 70.68 and R-polymorph B=97.63 (mg)/
(µg/mL)/h). Despite the lack of improved activity and PK properties of polymorph B against S. mansoni, here
presented; research on pharmaceutical polymorphism remains a valid and cost-effective option for the devel-
opment of new praziquantel formulations with enhanced properties such as increased solubility and/or dis-
solution.
1. Introduction
Schistosomiasis is a global disease, which predominantly affects
countries in Sub-Saharan Africa and some parts of Asia and South
America [1,2]. An estimated 779 million people are at risk of infection,
of which more than 50% are children [3]. More than 200 million people
are infected [3,4], with Schistosoma haematobium, S. mansoni and S.
japonicum being responsible for the bulk of infections [1]. There is no
vaccine available and the only drug marketed for treatment against
Schistosoma spp. infections is praziquantel. Alarmingly, the drug pipe-
line against schistosomiasis is empty. Praziquantel is commonly used in
mass drug administration (MDA), so-called preventive chemotherapy
[1,5]. For example, in 2016 alone, about 89 million doses of prazi-
quantel were distributed in Sub-Saharan Africa [6,7]. However, it is not
a perfect drug, primarily because of its low efficacy against juvenile
stages of Schistosoma spp., high inter-individual variability of effects
and poor compliance [8-11]. Praziquantel is a racemic compound,
composed by 50% of R-praziquantel and 50% of S-praziquantel. Of
these two enantiomers, R-praziquantel is the main active form. S-pra-
ziquantel shows less activity, while being responsible for the bitter taste
[12,13].
According to the biopharmaceutical classification system (BCS),
praziquantel belongs to the class II drug category, because of its high
permeability and low solubility (0.4 mg/mL) [14,15]. Praziquantel also
has a high first pass metabolism (1–3 h), which converts the active R-
praziquantel into inactive metabolites very rapidly [10,16]. To over-
come the low bioavailability, a crystalline polymorph of racemic pra-
ziquantel was prepared. The novel polymorph, polymorph B, as well as
commercial praziquantel, consists of a mixture of R- and S- en-
antiomers.
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For the preparation of the polymorph B, standard praziquantel was
milled by neat grinding in a vibrational mill [17]. During the milling
process in suitable conditions, in absence of solvents, the standard
praziquantel turns into a new polymorphic anhydrous crystalline form,
polymorph B [17], indexed as TELCEU01 in the Cambridge Structural
Database [18]. As widely known, a polymorphic variety has different
physical properties with respect to the standard crystal form, due to the
different crystalline lattice [19–22]. In this case, polymorph B, forming
a monotropic pair with commercial praziquantel crystal form, is char-
acterized by double water solubility, and doubled intrinsic dissolution
rate in comparison to the starting solid form [17]. In addition, it is a
promising product because it is physically stable at the solid state for at
least 1 year at ambient temperature [17]. Moreover, the polymorph B
showed promising results in preliminary in vitro and in vivo studies on
adult S. mansoni [17].
The aim of the present study was to thoroughly evaluate whether
polymorph B would offer benefits over standard praziquantel such as
increased efficacy and improved pharmacokinetic (PK) parameters. We
conducted an in-depth side by side comparison of praziquantel and the
polymorph B formulation (as aqueous suspensions). Both in vitro and in
vivo studies as well as a PK analysis of the praziquantel polymorph B
and standard praziquantel were performed. In vitro studies were con-
ducted on the larval and adult stages of S. mansoni. ED50 values were
determined in mice harboring a chronic S. mansoni infection. Finally,
we determined PK parameters of R- and S-praziquantel and R- and S-
polymorph B following treatment with both formulations in mice using
a validated liquid chromatography (LC) tandem mass spectrometry
(MS-MS) method (LC-MS/MS).
2. Materials and methods
2.1. Reagents
Ammonium formate (cat. no 70221-25G-F), formic acid (cat. no
5.33002.0050), ammonium acetate (cat. no. 73594-25G-F), methanol
(cat. no. 1.06035.2500), acetonitrile (cat. no. 1.00029.2500), and 2-
propanol (cat. no. 1.02781.1000) were MS grade. All MS reagents were
purchased from Sigma-Aldrich (Buchs, Switzerland). Dimethylsulfoxide
(DMSO) was the product of Sigma-Aldrich, Buchs, Switzerland, (cat. no.
276855-2L). Ultrapure water was filtered using a Millipore MilliQ water
purification system (Merck Millipore, MA, USA). Human blood was
supplied in lithium heparin-coated vacutainer tubes (Becton Dickinson
(BD), Allschwil, Switzerland, cat. no. 367962) by the local blood do-
nation center (Basel, Switzerland). Internal standard (ISTD) prazi-
quantel d11 was purchased from Toronto research (Toronto, Canada,
cat. no. P702097). Praziquantel as racemic powder was purchased from
Sigma Aldrich (Buchs, Switzerland, cat. no. P4668-5G).
Penicillin/Streptomycin 10′000 U/mL (Sigma-Aldrich, Buchs,
Switzerland, cat. no. P4333-100ML) and inactivated fetal calf serum
(iFCS, Bioconcept AG, Allschwil, cat. no. 2-01F30-I) were purchased
from Bioconcept AG (Allschwil, Switzerland). M199 medium and RPMI
1640 were obtained from Gibco (Waltham, USA cat. no. 22340-020).
All media were filter sterilized using a 0.22 µm filter bottle (Corning
Stericup 500mL, Vitaris AG, Allschwil, Switzerland, cat. no. 431097-
COR).
2.2. Praziquantel polymorph B
The preparation of the crystalline polymorph B was realized via a
neat grinding process of standard racemic praziquantel in a vibrational
mill as described elsewhere [17]. Briefly, this treatment resulted in the
high yield and low costs production of a racemic crystalline polymorph
B, physically stable for at least one year. The crystalline form of the
praziquantel underwent chemical analysis by HPLC, NMR and polari-
metry, confirming that the chemical entity of the praziquantel remained
the same. Further analysis reported different physical properties of the
polymorph B compared to standard praziquantel, such as increased
water solubility and lower melting point [17].
2.3. In vitro studies with newly transformed schistosomula (NTS)
Biomphalaria glabrata snails infected with a Liberian strain of S.
mansoni were placed under a neon light to allow cercarial shedding for
3–4 h. The cercarial suspension was then transformed using a technique
based on the mechanical transformation proposed by Milligan & Jolly
[23]. The obtained NTS were incubated at 37 °C with 5% CO2 over-
night. The NTS were resuspended at 2 NTS/µL in M199 medium sup-
plemented with 1% v/v penicillin/streptomycin, 5% v/v iFCS. The
proper volume of medium was added to each well of a 96-well-plate
and supplemented with the appropriate volume of drug. A volume of
50 µL of NTS solution (100 NTS) was dispensed into each well [24].
Both praziquantel formulations were first suspended in DMSO to a
working concentration of 10mg/mL. The drug aliquots were kept at
−20 °C until use. Polymorph B and praziquantel concentrations eval-
uated ranged from 100 to 0.78 µg/mL (320–2.50 µM). For the negative
controls (in triplicates), DMSO was used at a final volume of 1% v/v.
Each assay was evaluated every 24 h [25–27]. The parasites were given
a score between 0 and 3, depending on their viability. On this scale, 0
represents dead parasites and 3 indicates alive and undamaged para-
sites [28,29]. The scores are then used to compute the IC50 curves with
Compusyn® [24,30].
2.4. In vitro studies with adult S. mansoni
Schistosoma mansoni adult worms were recovered from female NMRI
mice 7 weeks post infection. Mice were dissected after CO2 euthanasia
and cervical dislocation. The intestines and the liver were excised and
analyzed with a dissection microscope. The adult worms were re-
covered from the organs by manual picking, using flat-tip tweezers.
Alive worms were recovered and incubated in a Petri dish in supple-
mented RPMI 1640 at 37 °C with 5% CO2, for up to 3 days. For the IC50
calculation, 2 worm pairs or 3 single worms were randomly chosen
from the Petri dishes. The worms were then placed in 24 well plates at a
final volume of 1.6mL in fully supplemented RPMI 1640. Duplicates or
triplicates, depending on the worm availability, were performed for
every condition. Negative control wells consisted of medium with 1%
v/v DMSO. The polymorph B and the standard praziquantel were tested
using a concentration range of 0.45–0.05 µg/mL (1.44–0.16 µM). The
drug effect was evaluated every 24 h by visual scoring with a light
microscope, as described above, using a magnification of 4-10X.
Similarly to the NTS, the adult S. mansoni were given a score from 0 to
3, depending on their viability. On this scale, 0 represents dead para-
sites and 3 indicates alive and undamaged individuals [24]. As for the
NTS procedure, the IC50 values were calculated using Compusyn® [30].
2.5. In-vivo studies
All animals were ordered from Charles-River (Sulzfeld, Germany).
Animal experiments were conducted in accordance with the local
cantonal veterinary guidelines, license number 2070. A total of 66
three-week-old female NMRI mice were used for this study. Upon ar-
rival, the animals were left for one week for acclimatization. The ani-
mals were housed at 25 °C in a controlled environment (temperature ~
25 °C; humidity ~ 70%; 12-hour light and 12-hour dark cycle) with free
access to water and rodent diet. The mice were infected subcutaneously
with 100 S. mansoni cercaria in the neck area. Seven weeks post-in-
fection, mice were treated with 400, 300, 200, 100, 50mg/kg of the
polymorph B or praziquantel. The oral suspensions were freshly pre-
pared in a vehicle, composed of 90% v/v tap water and 10% v/v
ethanol-Tween 80 (7% v/v Tween 80 and 3% v/v absolute ethanol).
The administered volume was calculated for each mouse weight, as
described elsewhere [27]. Each treatment arm had four mice, randomly
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chosen within the same infected batch. After treatment, the mice were
monitored daily, for the next 21 days, before undergoing CO2 eu-
thanasia. The mice were then dissected and their livers were excised.
Adult worms were picked, sexed and counted as described above. The
worm burden reduction (WBR) was calculated by comparing the
average number of recovered worms from each treatment arm to the
control arm. The detailed in vivo procedure is described elsewhere [24].
The following formula was used for the evaluation of the WBR [27],

















ED50 values were determined using the WBR and the doses using
CompuSyn.1
2.6. Blood micro sampling for establishing pharmacokinetic profiles in mice
The day of drug administration of the polymorph B or praziquantel,
plasma samples were collected from the infected mice by tail micro-
sampling using 75mm sodium hepatized microhaematocrit capillary
tubes (Paul Marienfeld, cat: TX79.1, Lauda-Königshofen, Germany) at
30, 60, 240min, and 24 h post-drug-administration. Volumes of 50 µL
of whole blood were collected into capillary tubes. Each capillary tube
was sealed on one side with one cm of wax by pressing them gently on a
wax plate (Paul Marienfeld, Lauda-Königshofen, Germany, cat. no.
2960409). The tubes were placed in a microcentrifuge (Sigma-
Zentrifugen, 1-16 special edition, Osterode am Harz, Germany) and
centrifuged for 5min at 5000 rpm at room temperature. The plasma
was pipetted into a previously labelled 1.5mL tube (Eppendorf,
Hamburg, Germany). Finally, the tubes were stored at −80 °C until
further analysis.
2.7. Preparation of the standards for LC-MS/MS
Quality controls (QCs) and calibration line (CL) samples were
freshly prepared before every experiment. 2 µL of blank mouse plasma
were mixed with 6 µL of blank human plasma. The blank mouse plasma
was obtained from the control mice by heart puncture. Blank human
plasma was obtained from the local blood donation centre (Basel,
Switzerland). The plasma mixture was spiked with 2 µL of the appro-
priate drug concentration. The spiking solution was prepared in 10% v/
v methanol and 90% v/v milliQ water. The CL covered the following
drug concentrations: 0.01, 0.025, 0.05, 0.1, 0.25, 1.0, 2.0, 4.0 µg/mL.
The QCs were prepared by adding the appropriate volume to obtain the
following drug concentrations: 0.01, 0.1, 0.5, 2.0 µg/mL. Each valida-
tion set contained the 4 quality control (QCs) concentrations in 6 re-
plicates each, plus a calibration line with 9 points. The QCs covered the
lower limit of quantification (LLOQ), low, middle and high concentra-
tions as recommended by the Food and Drug Administration (FDA)
guideline for industry for bioanalytical method validation [31]. Each
set was accepted within the partial validation criteria described below.
Praziquantel was dissolved in 100% methanol to a final concentration
of 5mg/mL. This solution was used for preparing the QCs and CLs. The
stock of internal standard (ISTD) was resuspended at a concentration of
1.25mg/mL in methanol. The ISTD working solution was prepared in
20% v/v milliQ water, 80% acetonitrile and 400 ng/mL d11-PZQ and it
was used as extraction solution for the samples. The spiking solution
used was in 10% methanol v/v and 90% milliQ water v/v.
2.8. Validation of the LC-MS method
The quantification of the praziquantel enantiomers in this study was
adapted from an already validated method for human plasma using a
lower sample volume and a slightly changed matrix [32]. The adapted
matrix for this study was a mixture of human and mice plasma at a ratio
3:1. A partial validation was performed by running 3 complete vali-
dation sets on three different days. Inter-day precision, accuracy, ma-
trix-effect and recovery were evaluated.
The accuracy was calculated as the percentage of the measured
concentration compared to the nominal spiked concentration. The
precision was calculated as the percentage of the standard deviation of
multiples compared to their average value. The recovery was evaluated
as the calculated spiked sample’s concentration, compared to the
nominal one in solution without matrix. We followed the US FDA-
guidelines [31]. The guidelines recommend limits for the quantification
of analytes of high, middle, low concentration to be within±15% of
their nominal spiked concentration, or± 20% for the LLOQ. The matrix
effect was tested by comparing the normalized area under the curve
(AUC) of the spiked plasma samples to the AUC of the extracted samples
of blank plasma, which were added to extraction solvent.
2.9. LC-MS/MS method LC-MS/MS instrumentation
All measurements were performed using an Agilent 6460 Series
triple quadrupole LC–MS/MS. Mass Hunter Workstation (Agilent
Technologies, CA, USA, version: B.06.00) was used to operate the in-
strument and for data analysis. The Agilent triple quadrupole 6460
instrument was coupled with an Agilent 1200 HPLC system. The MS
was equipped with an electrospray system (ESI). The HPLC system
(Agilent Technologies, CA, USA) consisted of four LC-20AD pumps, a
G1367E auto-sampler (Agilent Technologies, CA, USA) and a G1322A
degasser (Agilent Technologies, CA, USA). A column-trapping system
HALO C–18, 4.6× 5mm, (Optimize Technologies, OR, USA) was used
before eluting to the main chiral column, a Lux Cellulose-3 column
(cellulose tris(3-chloro-4-methylphenylcarbamate) phase),
150× 4.6mm, 3 μm (Phenomenex, CA, USA, cat. no. 00F-4456-B0) for
the analyte separation.
The elution gradient was defined as follows: 1–3min A 0–100%;
3–9.5min, B 0–100%; 9.5–10.5 min A 0–100%. The flow rate was
0.3 mL/min. The six-port switching valve was used to divert the flow
from the HPLC columns to the mass spectrometer during 0–3 and
9.5–10.5 min of each sample run.
The mobile phase A consisted of a solution of ammonium acetate
10mM in milliQ water with 0.015% v/v formic acid. The solution was
filtered and degassed using 500mL 0.22 µm filter bottles. The mobile
phase B was based on a mixture of ammonium formate 20mM in milliQ
water 20% v/v and acetonitrile 80% v/v.
The columns were kept at 20 °C. For every sample, 5 µL were in-
jected as sample volume. The product ions were tracked in multiple
reactions monitoring (MRM) at 204 and 203m/z for the ISTD and
praziquantel, respectively. The gas temperature was set to 400 °C, with
a flow rate of 12 L/min.
Carry-over was prevented by rinsing the auto-sampler syringe after
each injection with 50% v/v milliQ water and 50% v/v isopropanol.
2.10. Preparation of LC-MS/MS samples
The samples were extracted with 200 µL of extraction solution
containing 400 ng/mL d11-PZQ. After extraction, the samples were
thermomixed at 20 °C for 20min at 750 RPM (Eppendorf Themomixer
C, Hamburg, Germany). The samples were filtered directly into 96-
deep-well plates (500 µL) (Eppendorf, Switzerland, cat. no.
0030501101) by centrifugation (10min at 2250g and 22 °C) of 2 μm
PVDF membrane filter 96-well plates (Corning Life Sciences, CA, USA,
cat. no. CLS3508-50EA). The 96-deep-well plates were sealed with
plastic sealing mats (Eppendorf, Germany, cat. no. 15319247) and
stored, for a maximum of 24 h, at 4 °C.1 ®.




Precision was evaluated using the coefficient of variation (CV) be-
tween the replicates, and accuracy was calculated as the percentage
ratio of the measured concentration to the nominal concentration.
Calibration curves were normalized by the ISTD peak areas and fitted
by linear regression. The weighting factor for the linear regression (1/
x2) was selected to yield the lowest total error. In every set, a calibra-
tion line (CL) ranging from 0.01 to 4 µg/mL was included, with a re-
gression fitting coefficient R2 above 0.996. Additionally, 6 replicates of
QCs LLOQ, low, middle and high concentration were included in each
set.
2.12. ISR (incurred sample reanalysis)
10% of the mice plasma samples were randomly chosen for incurred
sample reanalysis (ISR). The criterion for ISR acceptance is that two-
thirds (67%) of the repeated sample results should be within 20% be-
tween the first and the second measurement. The percentage difference
of the results is determined with the following equation: ((Repeat –
Original) * 100/Mean).
2.13. Statistics and pharmacokinetic parameters
All the data were handled with R version 3.4 and R-studio V 1.1.453
[33]. Statistics were performed with R-studio. Kruskal-Wallis rank sum
test was used for the statistical analysis (Supplementary Fig. 1), non-
compartmental analysis (NCA) was used to calculate the area under the
curve 0-infinity (AUC0-∞), maximum concentration (Cmax), time to
maximum concentration (Tmax), half-life (t1/2), area under the curve
0–24 h (AUC0-24h) and the apparent oral clearance (Cl/F) for both the R-
and S- enantiomers of praziquantel and R- and S-enantiomers of poly-
morph B.
3. Results
3.1. In vitro results with S. mansoni newly transformed schistosomula
(NTS)
After 72 h, the calculated IC50 value for standard praziquantel on
NTS was 2.58 µg/mL (8.26 µM), while for the polymorph B it was
2.40 µg/mL (7.68 µM) (Table 1). Both formulations showed decreased
IC50 values over time, from 16.45 µg/mL (52.66 µM) (24 h) to 2.40 µg/
mL (7.68 µM) (72 h) for the polymorph B and from 12.64 (24 h) to 2.58
(72 h) µg/mL (39.69 to 8.26 µM) for standard praziquantel (Table 1).
3.2. In vitro results with S. mansoni adults
The IC50 values determined after 24 h were 0.14 µg/mL (0.45 µM)
for standard praziquantel and 0.23 µg/mL (0.74 µM) for the polymorph
B. After 72 h, similar IC50 values of 0.07 µg/mL (0.22 µM) for the
polymorph B and 0.05 µg/mL (0.16 µM) for the standard praziquantel
were calculated (Table 2).
3.3. In vivo results
There was no significant difference between the number of female
and male adult worms recovered from infected mice treated with pra-
ziquantel or the polymorph B for any of the treatment groups. However,
both the polymorph B and standard praziquantel reduced the overall
worm burden significantly (p value< 0.05) compared to the control
mice (Table 3, Supplementary Fig. 1). The highest WBR was achieved at
300mg/kg for both treatment arms (polymorph B=89%; prazi-
quantel= 87%). The lowest WBR was observed at 50mg/kg dose for
both standard praziquantel and the polymorph B (33.3% and 12.5%
mg/kg, respectively) (Table 3). The 50% effective dose (ED50) was
determined as 58.75 and 122.61mg/kg for standard praziquantel and
the polymorph B, respectively.
3.4. LC-MS/MS partial validation and incurred samples reanalysis (ISR)
At least 75% of the CL were within a precision of ± 15%
(LLOQ):± 20%) and an accuracy between 85% and 115% (LLOQ:
80–120%). In every set, a minimum 75% of the CL samples showed
linearity with a fitted linear regression R2 value of above 0.996. At least
four quality controls (QCs) (or 67%) were within precision of± 15%
(LLOQ:±20%) and an accuracy between 85% and 115% (LLOQ:
80–120%).
During the partial validation process, the complete sets with QCs
and CLs were run on different days (inter-day validation) and analysed.
The coefficient of variation between the QC replicates was below 7%.
Fig. 1. Plasma concentration profiles of the standard R-praziquantel (a) and of
R-polymorph B (b), Concentration time profile of the standard R-praziquantel
(a) and of R-polymorph B (b) after quantification by LC-MS/MS. The error lines
represent the standard deviation of the samples.
Table 1
IC50 values in vitro on S. mansoni newly transformed schistosomula (NTS).
IC50 (µg/mL) 24 h SD 48 h SD 72 h SD
Polymorph B 16.45 4.88 4.45 2.96 2.40 0.50
Praziquantel 12.64 2.33 4.48 3.5 2.58 0.36
Data obtained as average of three independent experiments. SD= standard
deviation.
Table 2
IC50 values in vitro on adult S. mansoni worms.
IC50 (µg/mL) 24 h SD 48 h SD 72 h SD
Polymorph B 0.23 0.20 0.08 0.11 0.07 0.05
Praziquantel 0.14 0.16 0.06 0.09 0.05 0.06
Data obtained as average of three independent experiments. SD= standard
deviation.
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The observed matrix effect values were between 93% and 114% for R-
praziquantel (lowest to highest concentration) and 97% to 104% for S-
praziquantel. The total recovery values were between 87% and 97% for
R-praziquantel (lowest to highest concentration). A total recovery of
87% to 91% was observed for S-praziquantel (lowest to highest con-
centration). The 10% of ISR (17 samples) randomly chosen were within
the±20 variation, as recommended by the FDA guidelines.
3.5. Accuracy, precision, and matrix effect
During the analysis about 2.5% of the samples exceeded the upper
limit of quantification (ULOQ) (4 µg/mL). These samples were diluted
three times in the extraction solution without ISTD and re-run within
the same run. The samples below the LLOQ (0.01 µg/mL) were con-
sidered as 0, as recommended by the Food and Drug Administration
(FDA) guidelines [31].
The inter-day accuracy of the analytical method was measured in
every individual set as described above. Each set was within± 15%
and±20% for the LLOQ. The highest deviation was observed on the
LLOQ in all three sets. The inter-assay accuracy was between 96% and
112%, with the highest variation of 12% observed at LLOQ. The inter-
day precision was between 2% and 12% for the LLOQ values.
The matrix effect is summarized in Supplementary Table 1. The
matrix effect of R praziquantel was 93.4% with a standard deviation of
10% for lower concentrations; at higher concentrations (2.5 µg/mL) the
matrix effect was 113.6%, with a standard deviation of 1.6%. The R-
praziquantel recovery was between 87% and 97% (low to high con-
centrations), with a maximum standard deviation of 10% at low con-
centrations. For S-praziquantel, the total recovery was 86.6% with a
standard deviation of 16.7% for lower concentrations, while at high
concentrations it was 104.3% with a standard deviation of 2.4%.
3.6. Pharmacokinetic parameters
Pharmacokinetic parameters for R and S-praziquantel and the R and
S-polymorph B are summarized in Table 4. Median Tmax values between
0.5 and 0.75 h were determined for both the R-, S-polymorph B and R-,
S-praziquantel. The median values of Cmax ranged between 0.67 and
2.73 µg/mL (2.14 to 8.74 µM) for R-praziquantel and between 0.18 and
1.56 µg/mL (0.58 to 5 µM) for R-polymorph B at 50–400mg/kg. The
Cmax values for the S-polymorph B and S-praziquantel show a similar
trend. The median values for the t1/2 for R-praziquantel were between
2.64 and 5.93 h and between 4.02 and 10.56 h for the R-polymorph B.
At the 100mg/kg dose R-praziquantel showed a 4 times lower t1/2 than
the R-polymorph B, while the other doses showed similar t1/2 profiles
for the two formulations (Table 4). The median values for the AUC0→24h
ranged between 1.25 and 6.28 h*µg/mL for R-praziquantel, with the
maximum value observed at the 400mg/kg dose and the lowest value
at the 100mg/kg dose. The AUC0→24h for the R-polymorph B reached
the maximum level at 300mg/kg (3.1 h*µg/mL) and the minimum at
50mg/kg (0.3 h*µg/mL). The values for the S- polymorph B and S-
praziquantel were lower. The apparent clearance for the R-polymorph B
and R-praziquantel median values were between 22.25 and 123.94 and
between 53.08 and 134.7 (mg)/(µg/mL)/h, indicating a ~30% varia-
tion in the overall profiles of the two formulations (Table 4). No re-
lationship was observed between WBR and AUC0→24h or Cmax.
(Supplementary Fig. 2).
4. Discussion
For over 30 years, praziquantel has been the only available drug
against schistosomiasis together with oxamniquine [10,34]. Ox-
amniquine was used extensively in South America until 10 years ago,
when it was withdrawn due to resistance development [34]. In the
present study, a crystalline polymorph of standard praziquantel, re-
vealing improved physical characteristics, such as increased water so-
lubility and dissolution, together with an appreciable physical stability,
was thoroughly tested, given initial promising in vitro and in vivo
findings [17]. Moreover, we conducted PK studies, for which we suc-
cessfully adapted and validated an LC-MS/MS method for mouse
plasma.
Indeed, different studies have demonstrated that improved prazi-
quantel formulations are able to influence the in vivo drug performance.
For example, a study by El-Feky et al. (2015) [35] showed that a clay-
based nanoformulation praziquantel increased the efficacy of the drug.
Moreover, El-Lakkany et al. (2012) showed an increased efficacy of a
praziquantel–polyvinylpyrrolidone (PVP) solid dispersion, by in-
creasing the bioavailability of praziquantel in a PK study [36].
Our results, based on in vitro and in vivo studies using the S. mansoni
mouse model, show that the polymorph B has no benefit in terms of
efficacy over the current formulation. No significant differences were
observed in the in vitro and in vivo studies, contrary to preliminary in
vitro and in vivo results which showed higher efficacy of the formulation
derivative compared to the standard praziquantel [17].
The ED50 value of 58.45mg/kg for the standard praziquantel cal-
culated in this study is in line with previously reported values for sus-
ceptible S. mansoni strains ranging from 70 to 100mg/kg [35–38] but
lower than the one previously determined in our laboratory (246.5mg/
Table 3
Effect of standard praziquantel and polymorph B on the worm burden in mice harboring a chronic S. mansoni infection.
Worm burden Worm Burden Reduction (WBR %)
Compound Dose (mg/kg) No. of mice Female Male Total Female Male Total (SD)
Control_mice_1 Untreated 8 12.6 12.4 25.0 – – –
Control_mice_2 Untreated 8 10.5 11.5 22.0 – – –
Control_mice_3 Untreated 8 2.1 1.9 4.0 – – –
Polymorph B*** 50 4 10.5 10.5 21.0 13 12 13 (25)
Praziquantel*** 50 3 4.8 4.8 9.5 33 33 33 (58)
Polymorph B** 100 4 3.3 4.3 7.5 69 63 66 (21)
Praziquantel** 100 4 1.5 2.3 3.8 86 80 83 (20)
Polymorph B* 200 4 2.5 8.5 11.0 80 31 56 (33)
Praziquantel* 200 4 3.3 5.5 8.8 74 56 65 (17)
Polymorph B* 300 4 0.8 2.0 2.8 94 84 89 (14)
Praziquantel* 300 4 1.3 2.0 3.3 90 84 87 (5)
Polymorph B* 400 5 3.0 3.4 6.4 76 73 74 (13)
Praziquantel* 400 4 1.5 2.5 4.0 88 80 84 (23)
* Indicates that the WBR was calculated based on mice batch 1.
** Indicates that mice batch 2 was used to calculate the WBR.
*** Indicates that mice batch 3 was used to calculate the WBR. In the group of 50mg/kg praziquantel, one mouse was excluded from the analysis as outlier,
because it was not infected. SD= Standard deviation.
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kg) [39]. While a slightly higher ED50 of 122.61mg/kg was calculated
for the polymorph B (mainly due to a slightly lower activity at 50 mg/
kg) no significant difference was observed between the two treatments
(as aqueous suspensions) at the individual dosages.
One limitation of our study, which might explain this finding, was
the comparison of the two crystalline forms as water suspension: Once
the drugs were suspended in water for the oral administration, the
conformation of the polymorph B might have changed, thereby possibly
altering its properties. To fully exclude this possibility it would have
been advantageous to use the crystalline polymorph and the standard
praziquantel as powders embedded in mini gelatin capsules or loaded in
microparticles suitable for oral administration. However, the high
praziquantel doses required to achieve antischistosomal activity (up to
400mg/kg) are not compatible with mini capsule usage in the mouse
model (the main animal model for research on schistosomiasis [40]),
since the maximum capacity of each commercially available mini-
capsule is 2–4mg. Capsules can only be administered to rodents larger
than 150 g. Therefore, comparison of liquid formulations, as done in
this study, is a widely used approach in drug formulations and delivery
studies in rodents [41].
The praziquantel quantification method in mouse plasma was suc-
cessfully adapted from a human-based validated LC-MS/MS quantifi-
cation method [32,42]. The PK analysis was based on a non-compart-
mental analysis using a trapezoidal linear model, given the small
number of time points used in the study (30, 60, 240min and 24 h). The
trapezoidal linear model was preferred to the log-linear model due to
the general opinion of this model being more accurate in the calculation
for drugs with a fast metabolism [43]. A limitation of the PK study was
the rather small sample size for each treatment arm (four mice) which
could influence the error rate in the study. To limit this experimental
error, the test and the control mice were chosen randomly within the
same infection batch.
The data presented here show that, surprisingly, the polymorph B
has an overall lower exposure profile for both R- and S- enantiomers,
indicating a lower bioavailability of the drug, in comparison with
standard praziquantel. Moreover, the polymorph B shows lower plasma
peak concentrations of the R- and S-enantiomers compared to standard
praziquantel formulation (Table 4). The polymorph B has previously
been shown to have a faster dissolution rate compared to standard
praziquantel [17,44] and therefore a better absorption would have been
expected [45]. However, the fast first pass metabolism typical of pra-
ziquantel, might result in lower disposition profiles of the drug over
time [16,37,46]. Earlier PK sampling time points (e.g. 5 min) should
have been considered to obtain a better picture of the absorption phase.
Though the AUC was 40% lower for the polymorph B compared to
standard praziquantel, the WBR observed was similar (Table 3). No
relationship was observed between AUC and Cmax and WBR
(Supplementary Fig. 2), confirming previous findings from Abla et al.
(2017), hypothesizing that the portal vein drug concentration is pri-
marily responsible for the activity of praziquantel [37].
Similar to other studies a great variability was observed for both
compounds in the PK profiles and parameters among individual mice
[37]. Overall, the short praziquantel Tmax value obtained in this study is
in agreement with other in vivo studies, while in humans the Tmax is
generally ranging between 3 and 4 h [46,47]. The Cmax values we found
(0.21–4.55 µg/mL (0.67 – 14.56 µM) for R-praziquantel) are con-
siderably lower than the ones found in other studies, as for example El-
Feky et al. (2015) and Botros et al. (2006) [35,48], which report values
of 24.36 and 33.33 µg/mL (77.98 and 106.59 µM), respectively, based
on PK analysis of Swiss albino mice’s plasma. However, both groups are
reporting those results following a 500mg/kg dose only, which makes a
direct comparison difficult. The overall lower Cmax observed in our
study could be explained by the different strains and sex of the mice
used in the different studies and, as mentioned, the slightly lower doses
used, but also by other parameters, such as infection rate and mouse
age [16,46,48–50]. However, we obtained a similar Cmax as the re-
ported values from Abla et al. (2017) for the dose of 200mg/kg of
standard praziquantel (about 1.3 µg/mL) and a similar value for the
WBR (about 68%) [37]. However, interestingly the AUC value of R
praziquantel reported by the same group is 2.6 times lower than the
ones reported in this study at the dose of 200mg/kg (median value of
5.93 h*µg/mL in our study compared to 2.2 h*µg/mL reported by Abla
and colleagues) even though experimental conditions were identical
(Table 3 and Table 4).
5. Conclusion
In this study we generated activity and PK data on a new alternative
Table 4
Pharmacokinetic parameters calculated for R- and S-praziquantel following treatment of mice infected with S. mansoni with praziquantel and the polymorph B.
Parameter 50mg/kg 100mg/kg 200mg/kg 300mg/kg 400mg/kg
t1/2 [h] 5.9 (5.3; 9.8) 2.6 (2.3; 3.5) 3.3 (2.7; 6.5) 5.9 (4.1; 8.2) 3.3 (3.0; 3.7) R-Praziquantel
Tmax [h] 0.5 (0.5; 0.5) 0.5 (0.5; 0.5) 0.8 (0.5; 1) 0.5 (0.5; 0.5) 0.8 (0.5; 1)
Cmax [µg/mL] 0.7 (0.2; 1.4) 0.7 (0.4; 1.0) 2.1 (1.2; 4.5) 0.8 (0.7; 0.9) 2.7 (2.1; 3.1)
AUC 0-24h [h*µg/mL] 1.5 (0.8; 3) 1.2 (0.5; 1.9) 5.9 (4.5; 10.4) 2.2 (1.8; 2.4) 6.3 (4.7; 8.1)
AUC∞ [h*µg/mL] 2.2 (1.9; 4.3) 1.3 (0.6; 1.9) 7.1 (6.5; 10.4) 2.5 (1.8; 3.1) 6.4 (4.7; 8.2)
Cl/F_obs (mg)/(µg/mL)/h 22.3 (15; 26.9) 112.8 (51.8; 180.3) 28.1 (23.4; 31.8) 123.9 (98.5; 186.5) 66.3 (49.3; 85)
t1/2 [h] 5.4 (3.3; 7) 10.6 (8.9; 11.1) 3.1 (2.9; 3.6) 4 (3.8; 6.3) 5.3 (4.3; 6.5) R-Polymorph B
Tmax [h] 0.5 (0.5; 0.5) 0.5 (0.5; 0.5) 0.5 (0.5; 0.5) 0.8 (0.5; 1) 0.5 (0.5; 0.9)
Cmax [µg/mL] 0.2 (0.1; 0.3) 0.3 (0.2; 0.4) 0.9 (0.7; 1.1) 0.9 (0.6; 1.3) 1.6 (0.3; 2.7)
AUC 0-24h [h*µg/mL] 0.3 (0.3; 0.5) 1.4 (0.9; 2) 2.9 (1.9; 3.8) 3.1 (2.3; 3.6) 2.5 (1.1; 4.5)
AUC∞ [h*µg/mL] 0.4 (0.3; 0.5) 1.9 (1.3; 2.4) 3 (2.2; 3.9) 3.1 (2.5; 3.7) 3.1 (2.4; 5.1)
Cl/F_obs (mg)/(µg/mL)/h 134.7 (109.3; 147.3) 53.1 (41.4; 113.7) 72.6 (51.9; 91.6) 96.7 (82.8; 125.4) 131.1 (78.3; 170.1)
t1/2 [h] 5.5 (4.7; 6.3) 0.4 (0.4; 0.4) 6 (5.0; 7.0) 6.4 (3.1; 9.7) 4.7 (4.5; 4.8) S-Praziquantel
Tmax [h] 0.5 (0.5; 0.6) 0.5 (0.5; 0.6) 0.8 (0.5; 1.0) 0.5 (0.5; 0.5) 0.8 (0.5; 1)
Cmax [µg/mL] 0.2 (0.1; 0.8) 0.1 (0.1; 0.2) 2.9 (2.4; 3.2) 0.3 (0.2; 0.3) 0.5 (0.4; 0.7)
AUC 0-24h [h*µg/mL] 2.2 (1.0; 3.8) 0.2 (0.1; 0.8) 7.2 (5.0; 9.4) 0.8 (0.6; 0.9) 1.8 (1.3; 2.1)
AUC∞ [h*µg/mL] 3.6 (2.5; 4.7) 0.3 (0.3; 0.3) 11.5 (11.1; 11.9) 1 (0.7; 1.2) 1.9 (1.3; 2.2)
Cl/F_obs (mg)/(µg/mL)/h 22.6 (15.6; 29.6) 316.2 (316.2; 316.2) 17.4 (16.8; 18) 314.3 (251.8; 804.5) 222.4 (182.8; 335.1)
t1/2 [h] 5.4 (1.1; 47.4) 20.4 (17.2; 21.2) 1.5 (1.0; 2.7) 5.4 (4.7; 7) 7.1 (5.1; 13.2) S-Polymorph B
Tmax [h] 0.5 (0.5; 0.6) 0.5 (0.5; 0.5) 0.5 (0.5; 0.5) 0.8 (0.5; 1) 0.5 (0.5; 0.9)
Cmax [µg/mL] 0.1 (0; 0.2) 0.1 (0.1; 0.2) 0.4 (0.2; 0.6) 0.2 (0.2; 0.3) 0.7 (0.2; 0.8)
AUC 0-24h [h*µg/mL] 0.2 (0.1; 0.8) 0.6 (0.6; 1.4) 0.9 (0.4; 1.5) 0.8 (0.5; 1.1) 1.3 (0.5; 1.5)
AUC∞ [h*µg/mL] 0.3 (0.2; 8.2) 1.6 (1.3; 3.2) 1 (0.6; 1.6) 0.9 (0.6; 1.1) 1.5 (1.5; 1.6)
Cl/F_obs (mg)/(µg/mL)/h 196.5 (127; 385.5) 61.7 (41.1; 82.6) 236.1 (129.4; 366.4) 371.5 (271.1; 507.9) 260.8 (245.4; 269.7)
Median values are reported, and an interquartile range is provided: 1st quartile and 3rd quartile.
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praziquantel formulation based on a crystalline polymorph of the ra-
cemic drug, the polymorph B, obtained via a solvent-free process of
neat grinding. The polymorph B showed similar in vivo efficacy to the
standard praziquantel formulation, but in general lower plasma levels.
However, due to the excellent physical stability and doubled water
solubility of the polymorph, this product remains a valid option to
enhance the pharmaceutical performance of the antischistosomal drug
praziquantel. Indeed, the possibility to generate additional praziquantel
solid forms or other suitable formulations may represent new inter-
esting approaches for overcoming the numerous praziquantel pharma-
ceutical and biopharmaceutical drawbacks.
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During my PhD, I had the opportunity to gain insight into the interesting and highly 
relevant field of drug development and to understand drawbacks of the current drug 
screening procedures against NTDs and schistosomiasis. I worked on a collection of 
protocols for drug screening on Schistosoma mansoni, with the aim to spread the 
current methodology that we employ in the laboratory here at Swiss TPH across other 
research settings (Chapter I). We examined the entire procedure and underlined its 
drawbacks. In this thesis we reflect on the drug discovery pipeline for 
schistosomiasis, which is empty due to its many constraints, such as low parasite 
yield, subjective drug screening, and the time-consuming harvest of adult parasites 
which requires an in vivo life cycle that needs 7 weeks to fully develop.   
Here I will discuss a series of projects aimed at solving or lessening some of these 
drawbacks. Solving or reducing some of the problems related to the drug screening 
on S. mansoni might lead to faster drug screenings. Furthermore, solving the issue of 
the drug screening subjectivity would increase the concordance of hits between 
different laboratories, which might be as low as 20% (Panic et al., 2015). These 
improvements in the drug screening against schistosomiasis might contribute to fill the 
empty pipeline with novel promising compounds. Contributing to the empty drug 
pipeline is of fundamental importance, because at the moment praziquantel and -to 
some extent- oxamniquine are the only available active compounds against 
schistosomiasis. Nonetheless, other improvements of the current drug screening 
pipeline can be found in other emerging technologies, such as in silico drug screenings 
and in silico drug development. 
The de facto gold standard approach to find novel drugs -the phenotypic screening- is 
old, maybe a bit out-dated, but due to the relatively small knowledge on all the proteins 
in the eukaryote kingdom, it is still a necessary approach to find novel drugs (Swinney 
and Anthony, 2011). As Swinney reported in a comparative study, phenotypical drug 
screening is the leading method for finding novel first-class drugs. The follower 
compounds are more frequently found by the target screening approach, because 
the biological details have been explained by the discovery of the first-class drug 
(Swinney and Anthony, 2011). The lack of knowledge is evident in the 
antischistosomal drug development field, where the mechanism of action of 
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praziquantel is still unclear. This could stall research and the development of 
praziquantel alternatives (Marxer et al., 2012).  
Parasitic organisms are very complex; they have co-evolved with their hosts 
for millions of years and many parts of their genome are still unknown. Therefore, 
more research is required to find possible new drug targets (Young et al., 2012, 
Berriman et al., 2009). In parasitic diseases, the interactions with human proteins are 
essential for the establishment and development of the parasites (Han et al., 2009, 
Jones, 2014, Schistosoma japonicum Genome and Functional Analysis, 2009). 
There is a new initiative started by Mullard and other researchers - Target 2035 - 
for finding a specific probe for each component of the human proteome within 2035, 
in order to foster the knowledge of all the human protein functions and molecular 
interactions (Mullard, 2019). Some of these proteins might be used to target 
molecular targets of the host required by the parasites for their development. 
The knowledge of the human proteome could lead to an increased usage of 
target-based screening -instead of the phenotypic screening- to find novel first-class 
drug candidates (Mullard, 2019).  
I will discuss the advances in in silico drug discovery to highlight the latest evolutions 
and paradigm shifts in the drug discovery field by employing new technologies, which 
could be used in search for novel compounds (section 1.1). In section 1.2, I will discuss 
the project in which we aim to mitigate the drawbacks of the gold standard drug 
screening method by developing an impedance-based drug screening system. In 
section 1.3 I will discuss the possibility to include a primary human liver microtissue-
based system to expand the current drug screening capacity in order to test prodrugs, 
to evaluate drug metabolites and to analyse drug- related cytotoxicity. Finally, in 
section 1.4, I will discuss and contextualise the project in which we compare the activity 
of a praziquantel polymorph-based derivative to commercial praziquantel. 
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2.1 Advances in in silico drug screenings 
In recent years, with the advance of the computational power and increased knowledge 
of protein structures in freely available public databases (e.g. SwissProt, Expasys), 
drug discovery has been moving more and more to the direction of in silico molecular 
docking, in situ binding and ex-novo design, which are based on advanced 3D 
structural protein models. In this context, drug discovery and drug design for millions 
of possible compounds can be performed in days and not anymore in months/years 
(Wishart et al., 2006, Terstappen and Reggiani, 2001). In the anti-helminthic drug 
discovery field this is very beneficial because an in vitro based screen of thousands of 
compounds is very time-consuming and costly with some ethical aspects to consider. 
Parasites are obtained in low yield and their complex life cycle makes it laborious to 
test many compounds in vitro (Lombardo et al., 2019a, Pasche et al., 2018b, Pasche 
et al., 2018a, Panic et al., 2015). Schistosoma spp. cannot be grown from eggs to 
parasites in vitro, because the parasites require the intermediate and the definitive host 
to mature (Keiser, 2010). The novel technological improvements in machine learning 
and neural networks can greatly help the discovery and design of novel drug entities 
or the remodelling of existing drugs into better compounds by using both structure-
based drug design (SBDD) and ligand-based drug design (LBDD). Those are the two 
types of computer-aided drug design (CADD) (Yu and MacKerell, 2017). The recent 
elucidation of the genomes of Schistosoma mansoni, S. haematobium and S. 
japonicum (Berriman et al., 2009, Schistosoma japonicum Genome and Functional 
Analysis, 2009, Young et al., 2012) makes CADD approaches very useful to 
specifically design a compound targeting the known structural molecular elements of 
the parasites. The freely available databases that offer potential drug targets, such as 
TDR Targets Database, Therapeutic Targets Database (TTD), DrugBank as well as 
the sequenced Schistosoma mansoni and other Schistosoma spp. genomes can be 
used to evaluate potential new drug targets. Identified drug targets can be used to 
screen hundreds of known molecular structures in silico to evaluate potential fits and 
estimate structure activity relations (SAR). For example, Torini et al. structurally 
characterized the key component of the purine salvage pathway, the Adenosine 
Phosphorylase/5’-Methylthioadenosine Phosphorylase, encoded by the gene 
SmMTAP (Torini et al., 2016). This enzyme was predicted to be a good drug target 
because S. mansoni parasites do not have de novo purine pathways but rely on the 
purine salvage pathway (Torini et al., 2016). Therefore, targeting such a pathway would 
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inevitably harm the parasites' ability to synthesise DNA. However, targeting such 
structural elements is challenging, as they often have homologs in the host (Boumis et 
al., 2011).  
The research and development of novel compounds to be used in human medicine 
requires 10-12 years and it is estimated to cost between 500 and 2000 million USD 
(Adams and Brantner, 2006). Therefore, the repurposing strategy coupled by in silico 
prediction of drug candidates already in the market for human medicine for other 
diseases, with the aim to repurpose them against schistosomiasis, would be most 
favourable in the field of NTDs, that, by definition, lacks sufficient funding (Macleod et 
al., 2019). The strategy offers an excellent cost-benefit ratio by diminishing the time 
and money that would otherwise be required for the development of new compounds 
to bring them to the market (Panic et al., 2014).  
There are some examples of in silico drug repurposing for S. mansoni, such as the 
study in which over 20 different compound candidates were identified, targeting 
metabolically active pathways in S. mansoni (Calixto et al., 2019). In silico based drug 
repurposing was used in genomic studies (Ziniel et al., 2016), in which the one member 
of the cytochrome P450 family (SmCYP450) found in S. mansoni was identified as 
potential drug target. Given the essential role of SmCYP450 in the development of the 
parasites, the authors identified miconazole as inhibitor of the SmCYP450 enzyme, 
leading to a high in vitro activity of the compound against S. mansoni parasites (Ziniel 
et al., 2016). In another study, over 115 potential drug candidates were found by in 
silico prediction, 20 of which were confirmed to be active on S. mansoni (Neves et al., 
2015). 
In conclusion, in silico drug screening or in silico drug repurposing can be very 
interesting methods that could be applied to facilitate drug screenings, for example by 
choosing only the most promising compounds out of huge compound libraries. The 
facilitation is of particular importance in a field like schistosomiasis where the funding 
is a problem and where the in vitro model does not allow high throughput screenings 
because of the low parasite yield. However, the in silico drug screenings and 
cheminformatics in general have their limitations. One of the most important limitations 
is the computational power required by such an approach, because oftentimes 
computational facilities providing cloud computing systems are needed and this could 
require big investments that are not possible to all laboratories. Finally, the current 
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algorithms might also predict false positive hits that are not active in vitro, reducing the 
advantages offered by these computational models. However, in silico drug screening 
and in silico drug repurposing would still hold advantages over traditional high 
throughput screening in terms of time and money (Sacan et al., 2012). Ideally, a non-
profit research and development organization, such as Drugs for Neglected Diseases 
initiative (DNDi) would finance and organize the development of a computational 
facility where other partners and laboratories could remotely join and take advantage 
of the novel in silico drug screening and in silico drug design benefits for the 
development of novel drug candidates against schistosomiasis.     
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2.2 EIS-based real time drug screening on Schistosoma mansoni 
One of the most challenging parts of drug screening against schistosomiasis is the lack 
of automation and the subjectivity of the gold standard drug screening method on 
Schistosoma spp., which is based on phenotypic evaluation by visual scoring of NTS 
viability (Keiser, 2010) (Chapter I). In the project further explained in Chapter II, we 
addressed these issues. Together with the Bio Engineering Laboratory (BEL) at the 
ETH in Basel, led by Prof. Andreas Hierlemann, we developed a novel platform to 
evaluate in vitro drug activity on NTS in real time. We employed electrical impedance 
spectroscopy (EIS) for the investigation of the dielectric properties of NTS. The big 
advantage of EIS is that it is a non-destructive technique, it is a label free method and 
it can be integrated into other platforms with relative ease. Those were the main 
reasons for which we decided to use this technology for the development of a novel 
promising way to analyse NTS viability for drug screening. 
To develop the EIS platform, we adopted a polydimethylsiloxan (PDMS) matrix, 
in order to develop a biocompatible prototyping platform to record NTS-viability. 
The EIS based platform helped us evaluate the drug activity onset on NTS in more 
detail and at better time-resolution, providing real time measurement of the 
parasites' motility after drug administration. In addition, the platform allowed for 
microscopical evaluation of the parasites' morphology simultaneous to the EIS 
measurement.  
EIS has been implemented already with a variety of biological samples in solution, 
such as single cells (Sun and Morgan, 2010) and plants for detection of viability of 
seeds (Repo et al., 2002). EIS has been used for organisms such as C. elegans (Zhu 
et al., 2018) and for S. mansoni (Rinaldi et al., 2015). The latter study evaluated the 
use of xCELLigence technology for the assessment of motility in S. mansoni adult 
worms, cercariae and hatching eggs. Although it was possible to determine the motility 
of adult worms, cercariae and hatching eggs, the 96-well plate format of this technique 
precluded accurate assessment of NTS motility. This could likely be explained by 
a lower sensitivity of this platform, due to an increased surface area of 
measurement, in contrast to our platform that has a smaller surface area. Moreover, 
due to the lower sensitivity of the xCELLigence in the evaluation of the parasites’ 
motility, thousands of cercariae or eggs or several adult worms are required. In 
contrast, the EIS platform we developed allows for using 10 times fewer parasites 
than the standard drug screening assay on NTS and hundreds of times less parasites
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than would be necessary with xCELLigence. Moreover, in contrast to the costly 
and non-reusable xCELLigence plates, our EIS based platform can be autoclaved 
and reused multiple times. 
We developed two EIS-based platforms. The first one was used as a method 
validation for the implementation of EIS to evaluate parasite viability. We 
assembled a device that was based on microfluidics, PDMS and EIS (Chawla et al., 
2018). We tested two compounds to compare the EIS-based platform with the 
already established visual scoring (Chapter I) in order to assess the robustness of 
the novel method on NTS. In this device, we were able to record viability 
through motility assessment of NTS, and we used microscopy to evaluate their 
phenotype and number to confirm the findings of the EIS (Chawla et al., 2018) 
(Figure 7). However, with this version of the platform we had some limitations, such 
as the low throughput, because the measurements could not be parallelized 
with more than three chambers simultaneously. In addition, the parasite 
loading was cumbersome, and it could influence the parasites’ viability. A 
recurrent issue with the first platform was that the parasites were not directly co-
cultured with the drug within the platform, but they were transferred into it at 24 and 
72 hour endpoints. At those time-points, the parasites’ motility was measured as a 
proxy for viability. During the parasites’ loading from the inlet port (Figure 7), the 
flow generated within the device did not consistently transport all the NTS into the 
measurement area between the electrodes; many were spread in the channel. 
Furthermore, a lot of handling was required to correctly load the parasites into the 
device and to not make them clog the channel. All these issues led to 
decreased parasite viability already before the measurements. 
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Figure 7: Figure showing the schematic of the first EIS based platform. The two co-
planar electrodes pairs are depicted in orange.  
To solve this first platform’s limitations, we designed a second platform after multiple 
rounds of design changes and testing (Chapter II). The microfluidic component of the 
platform was removed. This ameliorated parasite loading and handling and it allowed 
much more rapid workflows. The larger measurement area -that now more closely 
resembles a standard half-area 96 well plate surface- ensured a higher viability of the 
parasites over time, allowing culturing of the NTS within the platform for over 48 hours. 
The increased measurement area and the absence of constraining structures, as in 
the first platform, were essential for the real-time measurement of the drug’s activity 
on the NTS, since the novel platform layout did not show detrimental effects on the 
overall NTS viability (Figure 8).  
However, the long-term NTS incubation for over 48 hours in the platform introduced a 
new issue: the problem of drug absorption by the PDMS, which is a known 
drawback of the PDMS matrix (Toepke and Beebe, 2006, Van Meer et al., 2016, Sasaki 
et al., 2010). This issue had not been relevant in the previous platform, since the NTS 
motility recordings were only performed at end-points of 24 and 72 hours. Some 
studies analysed intermediate substances that could be used on top of the PDMS to 
reduce its drug absorption: Sasaki et al. used substances such as hydrophobic 
polymers of poly(p-xylylene) –parylene to mitigate the absorption problem, showing a 
drastic reduction in the absorption of rhodamine B, once the parylene matrix was 
deposited on top of PDMS (Sasaki et al., 2010). Therefore, we adopted the same 
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approach as Sasaki et al., by coating the PDMS matrix with parylene. The approach 
was successful and we drastically reduced the absorption of rhodamine B, which is a 
good indicator of the absorption for the compounds we used (Chapter II). 
Figure 8: The schematic of the second platform. The printed circuit board (PCB) is 
illustrated in the left part of the figure; the polydimethylsiloxane (PDMS) chip unit is 
depicted in more detail in the middle and right part of the schematics. On the right side 
of the schematic, the chamber unit and the measurement area on top of the electrodes 
are illustrated. 
For the second EIS-platform we decided to select some compounds with evident, 
yet varying activity in vitro on NTS. In this study with the second platform, we 
aimed to prove the EIS-based platform a good alternative to the standard visual 
scoring. To demonstrate this, we chose a fast acting compound that would kill 
the parasites immediately, such as oxethazaine, and one compound, 
methiothepin, that would increase drastically the parasites’ motility (hypermotility). 
Hypermotility is in fact difficult to be scored by visual scoring (Chapter I). We 
performed in parallel standard visual scoring in 96 well plates for both compounds, 
in order to compare the dose response curves and IC50.  
Oxethazaine showed high and fast activity in vitro, confirming previous findings from 
Panic et al. (2015). With the EIS platform, we observed the compound’s onset of action 
Chip Unit 
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on NTS already at 30 min post drug exposure. Oxethazaine is commonly used in 
human medicine as potent local anaesthetic and as therapy against esophagitis and 
other gastro-intestinal diseases. The mechanism of action of oxethazaine is based on 
reducing the tendency of voltage-dependent sodium channels to activate (PubChem). 
Possibly, the blockage of the sodium voltage dependent channels is the reason for the 
fast activity of the compound on NTS, causing the parasites’ complete paralysis within 
one hour after treatment.  
Methiothepin had a fast onset of action on NTS, but it showed lethality only in the high 
range of the tested concentrations in both EIS and visual scoring on standard plates. 
Methiothepin has a role as an antipsychotic agent by antagonizing serotonin receptors 
(5-HT1, 5-HT2). The onset of activity was observed to be within 15 minutes after co-
incubation of the NTS with the compound. The compound had already been tested 
against the sporocyst stage and adult stage of the S. mansoni parasites as shown by 
Boyle et al. (2000, 2005) (Boyle and Yoshino, 2005, Boyle et al., 2000). Methiothepin 
inhibited the parasites’ movements, according to the authors by blocking serotonin 
intake, which plays a crucial role in the parasitic movements (Boyle et al., 2000). In 
contrast, we observed hypermotility once the drug was tested on NTS, therefore 
indicating an excitatory effect of the methiothepin on the NTS and not inhibition of the 
movements as described by Boyle et al. on the sporocyst stage and adult stage of S. 
mansoni parasites. One possible explanation for this difference could be the 
genetic differences between the S. mansoni Liberian strain used in our experiments 
and the Puerto Rican strain used by Boyle et al., as well as the differences 
between the sporocyst and adult stages of the parasites, as used by Boyle et al., and 
the NTS stage, which we used in our experiments. (Boyle et al., 2000, Boyle and 
Yoshino, 2005). Other studies demonstrated that bromocriptine and rotundine, 
selective inhibitors of 5HT, induced hypermotility on NTS (Chan et al., 2016). They 
showed similar results to the ones we obtained using different compounds 
acting in a similar way as methiothepin on NTS. This might indicate a common 
pathway in which bromocriptine and methiothepin could exert their mechanism of 
action (MOA), maybe by targeting a common receptor for the 5-HT or by targeting 
different parts of the same molecular pathway. In short, methiothepin and 
oxethazaine had different effects on NTS and those could be observed in both the 
EIS platform and visual scoring. However, the EIS platform provided objective 
evaluation; while the standard assay was less precise. In the case of oxethazaine,
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the results were very similar, while the methiothepin results were more discordant 
between the two drug screening methods (Chapter II).  
To make the comparison to the standard assay more complete, we evaluated the effect 
of praziquantel in a side-by-side comparison between the EIS based platform and the 
standard drug screening on NTS. Praziquantel is active in vitro on NTS but not lethal; 
the drug induces changes in the behaviour and morphology of NTS. Among those 
changes, we observed an increase in motility within 30 minutes after drug 
administration, a darkening of the tegument including evident blebs on the parasites’ 
tegument and contractions of the parasites’ length. However, because the effect of 
praziquantel in vitro on juvenile stages of the parasites is mild, praziquantel’s effect in 
vitro is hard to evaluate by visual scoring and it requires a trained operator to score  
the characteristic drug-induced phenotype on NTS accurately. The comparison 
between the two techniques resulted again in a similar precision, but the EIS scoring 
was objective and automated, in contrast to the standard visual scoring. 
The EIS based platform could be useful also in the context of exploration of the 
compound’s MOA, because providing real time information on the compound’s activity 
could help define specific time-points in which the compound can be found bound to 
its molecular target(s) and this could facilitate the identification of those targets. 
Coupling the platform with confocal microscopy and the usage of fluorescent probes 
could help resolve the molecular location(s) to which the compound of interest is 
bound. Another advantage of the EIS platform is the possible selection of very active 
compounds only, because the compound onset of action can be determined in real 
time. Until now, in fact, selecting fast-acting compounds was challenging and required 
a lot of operator time, because the screening time points had to be increased.  
In conclusion, we demonstrated the usage of EIS as a suitable alternative method to 
the standard visual scoring for drug screening on NTS. We obtained similar dose 
response curves and similar IC50 demonstrating the usability of this technology as 
possible replacement for the visual scoring on NTS. The EIS platform we developed 
has many advantages over the standard drug screening assay on NTS as discussed 
above, but it is not free from drawbacks. For example, the cost for the preparation of 
the chips and the necessity of a clean room to prepare the electrodes for 
the measurements can be major constraints for the adoption of this technology in 
other laboratory settings. In addition, the transimpedance recorder can be very 
expensive and out of budget for many laboratories working on NTDs. It is possible to
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reduce the costs related to this platform by plastic fabrication in the future, using for 
example an injection molding. In addition, the transimpedance device can be less 
sensitive than the one we have used in this study, and therefore cheaper. 
However, to reduce the costs associated with the production and the usage of this 
platform, it would need to be mass produced. Further studies are required to assess 
the feasibility of this. At the current stage, the platform allows only the readout of the 
NTS stage of S. mansoni, but it could be potentially adapted to other stages and/or 
parasites, to maximise the cost-usability of the platform. More research on the latter 
point is necessary to establish the EIS platform usage for other parasites and/or 
stages.
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2.3 Incorporation of liver microtissues into the drug screening 
procedure 
Many of the compounds that are tested in our laboratory show interesting activity in 
vitro against NTS and adults, but fail to show activity in vivo. There are many possible 
reasons to explain this phenomenon, such as unknown administration dosage and high 
first pass metabolism that could inactivate the compound before reaching the systemic 
circulation. There are some compounds such as prodrugs that can hardly be pre-
screened in vitro, because they need to be pre-activated by the liver enzymes first. 
Prodrugs can lessen some of the drawbacks commonly seen in standard compounds, 
such as low water solubility, high first pass metabolism and increased resistance to 
pH. Prodrugs are precursors of the API, conjugated with additional chemical groups. 
Once the additional groups are removed from the API by the liver CYPs, the compound 
is active. This strategy is increasingly being considered for novel drug candidates, 
because it can increase the compounds’ bioavailability and it reduces the first pass 
metabolism and at the same time it increases the duration of action of the compounds 
(Ortiz de Montellano, 2013).  
In addition, a liver-based drug screening system could provide important information 
on a compound's cytotoxicity, such as drug induced liver injuries (DILI) evaluation by 
analysis of some of the specific liver-related markers for this condition such as miR-
122 and miR-192. Including liver microtissues into the drug screening process could 
also provide information on the drug metabolism, for example by evidencing the 
compound’s metabolites. Furthermore, such a system can provide information on a 
compound’s cytotoxicity by quantification of intracellular ATP (Proctor et al., 2017, 
Hendriks et al., 2016). The liver human primary microtissues technology extends the 
capability offered by the standard primary liver culture, by prolonging the functionality 
of the cells, thereby extending the stable expression of CYP enzymes for more than 
four weeks, in comparison to just two weeks for flat cell cultures (Proctor et al., 2017, 
Simon et al., 2018). This becomes important when testing long drug exposure effects 
such as DILI, which with the standard cell cultures is not feasible after two weeks 
(Proctor et al., 2017). In addition, liver microtissues resemble the human liver and are 
capable of metabolizing most of the compounds with their high expression of CYPs 
(Bale et al., 2014).  
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We tested primary human liver microtissues to evaluate whether they could bioactivate 
or bioinactivate drugs and prodrugs to test in vitro on S. mansoni NTS. I compared 
the IC50 of the liver microtissues' medium after co-exposure with compounds to the 
IC50 obtained in the standard drug screening assay on NTS to assess the 
functionality of such a platform in drug screening. We evaluated the cytotoxicity of 
praziquantel and the other tested compounds by intracellular ATP quantification. 
In addition, we evaluated the metabolism of praziquantel by LC-MS/MS 
quantification of praziquantel’s main metabolite trans-OH-praziquantel (Chapter III).  
Microtissues with praziquantel were tested to evaluate the liver microtissues' 
metabolism by quantification of the trans-OH-praziquantel metabolite at 24, 48 and 72 
hours post exposure of the liver microtissues to 50, 25, 10, 2 µM of praziquantel. We 
analysed the conditioned medium for quantification of the R- and S- and trans-OH 
praziquantel for every time point by LC-MS/MS. We found that liver microtissues have 
an active metabolism that allows quantifying the trans-OH-praziquantel metabolised. 
We quantified about 250-300 ng/day of trans-OH-praziquantel. The presence of less 
active praziquantel metabolites was notably in contrast with the unchanged IC50 we 
observed after NTS direct co-incubation with liver microtissues. The reason for this 
divergence between expectation and observation could be explained by the fact that 
due to the very low concentration of praziquantel needed to cause a phenotypic change 
in NTS (as low as 2 µM and below could damage the NTS), there would always be 
enough parent compound present in solution so that the operator would score those 
phenotypic changes on NTS with low scores. In addition, the resolution of the visual 
scoring is very low for minimal changes in the parasites’ phenotype, making the exact 
effect evaluation difficult.  
The first step in planning such experiments is to carefully select potentially useful or 
informative drugs and in the following sections I will elaborate on why we chose the 
drugs that eventually were tested. 
Auranofin is in fact a known active compound in vitro and we wanted to test whether 
the exposure to liver microtissues could alter its activity in vitro on NTS. The compound 
had been shown to be inactive in vivo on S. mansoni in infected mice. Perhaps a 
decrease in the compound’s activity in vivo after exposure of the compound to the liver 
CYPs could be predicted in vitro with the microtissues approach. Auranofin is a gold 
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salt that is used in human medicine as disease-modifying antirheumatic drug 
(DMARDs). Its mechanism of action has not been characterized but it is assumed that 
it acts as an inhibitor of kappab kinase and thioredoxin reductase (Roder and 
Thomson, 2015, Harbut et al., 2015). Auranofin is an example of a repurposed drug, 
being originally designed to treat DMARD, its use was expanded to the treatment of 
amoebiasis and tuberculosis (Roder and Thomson, 2015).  
We tested tamoxifen citrate and terfenadine, since their high activity in vitro on NTS 
had previously been shown (Cowan and Keiser, 2015, Panic et al., 2015). We 
evaluated if the liver enzymes could bioactivate or bioinactivate them, thereby reducing 
or increasing their IC50 in vitro on NTS. Tamoxifen citrate is a prodrug classified as an 
essential drug for the treatment of oestrogen-receptor-positive breast cancer. 
Tamoxifen is metabolized by the cytochrome P450 isoforms CYP3A4, CYP2C9, and 
CYP2D6 into two active metabolites afimoxifene and endoxifen, both selective 
oestrogen receptor modulators (Sanchez-Spitman et al., 2019). Terfenadine is used 
as a peripherally selective antihistamine or antagonist of the histamine H1 receptor. It 
is a prodrug, completely metabolized to the active form fexofenadine in the liver by 
the enzyme cytochrome P450 3A4. (Perlmutter et al., 2014, Jeong et al., 2018).  
Some of the main problems of the liver microtissue system are the high costs and the 
difficulty in prediction of pharmacokinetics. In fact, the liver microtissues are spheroids 
in a static medium, and the dynamics of the drug entering inside a sphere are not as 
simple as in flat cell cultures, where there are various models predicting 
pharmacokinetic parameters such as hepatic clearance and half-life (t1/2) (Tóth et al., 
2018). There are currently no models explaining exactly how and if the drug enters in 
the inner part of the liver spheroids and how different the permeability of the 
outer spheroids is from the inner spheroids. Another important factor to consider is 
the liver spheroids' albumin production (10-20 ng/spheroid/day). The albumin in our 
static system, for example, could bind the compounds in solution and retain them 
from permeating the NTS and by doing so, prevent their activity, which could be the 
reason for lower IC50 as we demonstrated for some of the tested compounds, 
such as tamoxifen (Chapter III). However, most likely the influence of the 
albumin produced by the liver microtissue system was negligible, because the 
microtissues only produce 10-20 ng/per day of albumin. 
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Nonetheless, there are solutions to make the system more dynamic. For example, in 
a next study, it would be interesting to integrate the microtissues in a microfluidic device 
with a gravity driven flow or a micro pump. In such a solution, multiple liver microtissues 
could be connected and exchange metabolites and other markers more efficiently 
than by using just one liver spheroid as we did in our study (Lohasz et al., 2017, 
Mittal et al., 2019). Furthermore, in such a platform, the prediction of the drugs' 
behaviour could be easier than in a static microtissue system, because inside 
this microfluidic device the fluid viscosity could resemble the one in the body and 
the albumin level could be adjusted to resemble the physiological plasma 
concentration in blood (45 g/Litre).  
In future studies, the liver microtissue system could be combined with the EIS based 
platform (Chaper II) to gather more information on the compounds’ activity, dynamics 
and cytotoxicity simultaneously. In addition, more studies could help assembling an in 
vitro system resembling closely the in vivo settings of a human being. For example, 
multiple microtissue types, such as cardiac microtissue, lung microtissue and liver 
microtissues could be combined with the EIS technology. This "organ-on-a-chip" 
approach might facilitate the accurate prediction of pharmacokinetics and 
pharmacodynamics and provide information on compound testing more representative 
to human beings than animal models. Furthermore, such a system could be 
established to evaluate compounds' activity in more detail, for example providing 
precise information on the dynamics of action and the compound. Such a platform 
with microtissues from different organs involved in the parasite development, such as 
lungs, endothelial cells, heart and liver, might also be used to study the growth of S. 
mansoni NTS from juvenile into adult stages. This would allow to discover the 
essential unknown factors that do not allow the growth of the parasites in vitro. Growing 
parasites in vitro would increase the drug screening output and more testing could be 
performed on adult S. mansoni, perhaps making high throughput screening on adult 
S. mansoni parasites reality. However, more studies on this technology need to be 
conducted in order to fully exploit the potential offered by this novel cell culture type.  
In conclusion, with this study, we are the first to explore the liver microtissue technology 
as a tool to improve the current drug screening against schistosomiasis. The liver 
microtissue system not only offers information on the effect of the cytochrome P450 
family activity on prodrugs, but it is also able to provide important information on a 
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compound’s toxicity and metabolites simultaneously. By enabling the selection of 
promising, non-toxic compounds for further assessment in vivo, the liver microtissue 
system could lead to a decreased usage of animal models in preclinical studies, 
thereby reducing the costs and the ethical issues related with drug screening and 
development.  
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2.4 Praziquantel and derivatives 
One of the most important breakthroughs in the anthelminthic drug discovery history 
is praziquantel, a compound that complies with the Lipinski rule of five and that belongs 
to the Biopharmaceutics Classification System (BCS) class II compounds, because 
of its low solubility and high permeability. Praziquantel was developed in the early 
‘70s for veterinary usage and used for human medicine a few years later (Alsaqabi, 
2014, Cioli and Pica-Mattoccia, 2003).  
Nowadays, praziquantel is massively used in the mass drug administration (MDA) 
campaigns organised by the WHO, with over 200 million doses of praziquantel given 
to individuals annually since the ‘80s (Wang and Liang, 2015, Olveda et al., 2016). 
This was possible thanks to private companies such as Merck and non-profit 
organisations such as WHO, which donated millions of doses, and the fact that a dose 
of praziquantel can currently be purchased for less than 0.30$ in some countries (Cioli 
and Pica-Mattoccia, 2003). 
Praziquantel has not always been the sole drug candidate against schistosomiasis. 
For over 30 years, oxamniquine was the first-line drug in countries such as Brazil 
(Valentim et al., 2013). The drug was working very well, but in contrast to praziquantel, 
its mechanism of action was specific for Schistosoma mansoni only. This is because 
oxamniquine targets a specific sulfotransferase enzyme present in S. mansoni 
(Valentim et al., 2013). This was likely the main reason why the massive use of 
oxamniquine led to the rise of a resistant strain that rapidly spread across South 
America, making its use obsolete in 2010 (Fallon and Doenhoff, 1994, Bruce et al., 
1987). 
MDA campaigns have the purpose of controlling schistosomiasis to finally achieve 
elimination of the disease by 2020 (Wang and Liang, 2015, Olveda et al., 2016). This 
objective will not be reached. It is more likely that the objective might be achieved by 
2030, as indicated by the sustainable development goals (SDGs) of the United Nations 
(UN) (Knopp et al., 2019). The reasons  for missing the objective was the lack of re-
infection prevention due to the limitations of praziquantel and the lack of proper 
sanitation, which is one of the main drivers of infection and reinfection in the first place 
(Fenwick and Jourdan, 2016, Secor and Montgomery, 2015).  
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Praziquantel is the main drug to fight schistosomiasis, but it is not without 
drawbacks, such as low water solubility and extensive first pass liver 
metabolism that limit the compound’s bioavailability (Olliaro et al., 2014). There 
are reports showing big inter-individual variability, with erratic absorption profiles, as 
reported (Kovac et al., 2018). This finding is confirmed by other comparative studies 
on praziquantel (El-Feky et al., 2015, El-Lakkany et al., 2012), underlining the inter-
individual variability observed in praziquantel-treated individuals (Olliaro et al., 
2014, Schneeberger et al., 2018). Genetic variation of the parasites might 
contribute to this inter-individual variability (Norton et al., 2010, Coeli et al., 
2013). Others have suggested that the human microbiota is involved. (Sady et al., 
2015) (Jenkins et al., 2018, Schneeberger et al., 2018). Generally, the effective time 
of the active pharmaceutical ingredient (API) in the blood circulation (duration of 
action) is short and the AUC (indicating the blood API concentration) is low. 
Praziquantel is rapidly absorbed (80% to 100%), but undergoes extensive first-pass 
hepatic metabolism. This results in inactive metabolites so that most of the 
active drug does not reach the systemic circulation (Secor and Montgomery, 
2015, Kemal et al., 2019, Chan et al., 2017, Colley et al., 2014, McCarthy and Moore, 
2015). Moreover, there are indications that the efficacy of praziquantel against 
schistosomiasis is decreasing, especially in countries where praziquantel has been 
used the longest, such as Egypt and Sudan (Doenhoff et al., 2008, Doenhoff and 
Pica-Mattoccia, 2006). The reason for this could be related to the selection of 
praziquantel resistant Schistosoma spp. in countries where MDA campaigns are 
common, due to the very high selective pressure to which the parasites are exposed 
(Coeli et al., 2013, Sady et al., 2015).  
To alleviate the low water solubility and the extensive first pass metabolism, many 
improvements of the standard praziquantel formulation have been suggested. 
Solubility of praziquantel can be improved by administering a praziquantel 
-polyvinylpyrrolidone solid dispersion, by encapsulating it into clay, by 
using nanoparticles or by co-administration of praziquantel with other drugs that 
could eventually improving praziquantel bioavailability (El-Lakkany et al., 2012, El-
Feky et al., 2015, Elmasry et al., 2017, Campelo et al., 2017). Praziquantel 
derivatives are being developed and tested, such as organometallic derivatives, and 
two praziquantel derivatives conjugated with Cr(CO)3 showed interesting in vitro 
and in vivo results (Hess et al., 2015).  
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Here I elaborate on my research on the effects of a polymorph co-crystal-based 
formulation derivative on S. mansoni. A polymorph is defined as a solid material that 
can have different crystalline forms and different special rearrangements of the crystal 
lattice. The polymorphic crystals differ in their physicochemical properties such as 
dissolution rate, solubility, stability and hygroscopicity compared to their amorphous 
state (Raza, 2014). In this work, we tested the praziquantel derivative in vitro on NTS 
as well as adult worms and in vivo in a side by side comparison with the standard 
praziquantel. We found that the novel compound was less effective than the standard 
praziquantel in terms of absolute WBR. However, we did observe differences in 
pharmacokinetics and pharmacodynamics. In vivo WBR that we observed with the 
polymorph was 60%, while the standard praziquantel had a WBR of 68% overall 
(Figure 9). One of the reasons for this result could be its administration as a solution: 
This might have altered the co-crystal formulation of the compound, perhaps lessening 
its advantages. It might have been advantageous to administer the compound in 
microcapsules in vivo in order to not solubilize the compound before reaching the 
gastro-intestinal (GI) tract. A microcapsule administration of the praziquantel 
polymorph might have prevented the transition to the standard conformation, thereby 
enhancing the water solubility advantage offered by the polymorphic formulation 
(Lombardo et al., 2019b).  
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Figure 9: Worm burden reduction by dose. The box plot indicates the WBR by each 
of the tested concentrations in vivo for the standard praziquantel and polymorph 
praziquantel.  
The praziquantel formulation derivative was absorbed slower than the standard 
praziquantel and the maximum concentration (Cmax) in the circulation did not reach the 
Cmax obtained by the standard praziquantel. We did not find correlations between the 
Cmax and the WBR, which indicates that other factors might be important for the drug 
activity in vivo. For example, in other studies the portal vein drug concentration was 
considered the main parameter for the determination of the effect of praziquantel: the 
portal vein drug concentration can be considered as the active part of the compound 
effectively affecting the blood flukes Schistosoma spp., because the blood flukes 
reside in the mesenteric veins. (Abla et al., 2017).  
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Praziquantel is a racemate in which both R- and S- enantiomers are present at 50%. 
The active principle is the R-praziquantel, while the S-praziquantel is inactive and it is 
responsible for the bitter taste of the formulation. We evaluated the pharmacokinetics 
of the R- and S- praziquantel in murine plasma by LC-MS/MS and found the 
concentration of R-praziquantel to be superior to the one of S-praziquantel in both 
formulations (Figure 4). In humans the opposite trend can be found (Meister et al., 
2016). The different concentration of the API between human and mice could be due 
to different P450 cytochromes and ADME parameters in mice and humans. Humans 
have seven genetic clusters with 27 active genes that encode CYP enzymes; mice 
have 72 active genes distributed in seven clusters (Nelson et al., 2004). It is possible 
that the enzymatic kinetics of some of the enzymes differ between species. More 
research should be conducted in order to establish the exact behaviour of praziquantel 
in mice and in other animal models, in order to better understand its mechanism of 
action.  
In conclusion, polymorphs could represent a valid opportunity to further develop 
existing drugs without undergoing the time and money requirements of developing a 
completely new compound. McCrone’s law states that “every compound has 
different polymorphic forms, and that, in general, the number of forms known for a 
given compound is proportional to the time and money spent in research on that 
compound.”(McCrone, 1965). Praziquantel is the mainstay treatment against 
schistosomiasis. However, its drawbacks and the decrease of the compound efficacy 
in endemic areas indicate the importance to develop novel anthelmintics. In order to 
develop praziquantel derivatives that have an impact on schistosomiasis, it is 
important to accurately define praziquantel's mechanisms of action and identify all the 
molecular targets of the compound. Although the praziquantel polymorph we tested in 
this study had no superior efficacy to the standard praziquantel, polymorphs are still 
an interesting possibility that could be explored for novel drug candidates’ 
development.  
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3. Conclusion and outlook
Drug discovery and development are essential elements for human and animal 
health. Schistosomiasis currently relies on a single drug for treatment of millions of 
people, praziquantel. Since praziquantel has been used for 40 years, the 
emergence of resistance poses a threat to the wellbeing of millions of people, therefore 
there is a necessity to find alternative drugs to accompany and potentially replace the 
only one available at the moment. However, this is quite a challenging task due to the 
complex parasite life cycle, the resulting limited drug screening throughput and the 
socio-economic status of NTDs, being associated with the poorest regions of the 
world. We tried to tackle these issues by providing novel solutions to increase drug 
screening throughput and lower the costs associated with it. 
This work consists of several projects that I worked on: the development of a novel 
drug screening platform; the inclusion of liver microtissues in the drug screening 
process and the testing of a derivative version of praziquantel.  
The EIS based platform can be used to increase the drug screening throughput and 
the objectivity of the drug screening on NTS, which would foster common ground 
between labs working with the same drug screening technology. The EIS based 
platform can be mass-produced by plastic-based injection printing of the current 
template and is reusable, which would make the platform cheap and easy to adopt in 
various research settings. Also, the real-time evaluation of the parasites' viability made 
possible by this platform might expedite the identification of fast acting compounds.  
The human primary liver microtissues based project aimed at extending the output of 
the standard drug screening by making use of the liver P450 cytochromes' metabolism 
to process drugs into metabolites that are active or inactive on NTS. This approach, 
although it could cause considerable costs, would allow simultaneous drug screening, 
hepatotoxicity evaluation and metabolite studies of interesting active compounds. 
Moreover, the liver microtissues, with more research being done on that subject, could 
be used as predictor for potential lead compounds’ pharmacokinetics and dose finding. 
Finally, we worked on a praziquantel polymorph and gained interesting insight on its 
metabolism in the mouse model. We did not find this compound to be more active than 
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the standard praziquantel, but the idea of developing polymorphs could be an 
affordable way to produce more drug candidates with potentially new chemical-
physical properties. Further research on other praziquantel polymorphs or co-crystal 
derivatives might lead to optimisations of the drug's properties, as well as the 
development of novel in vivo formulation strategies, such as nanoformulation.  
With these projects we contributed significantly to the field of helminth drug discovery 
and I am confident that by providing these novel ideas, solutions and proof-of-
concepts, we paved the way for faster, cheaper and more efficient drug screening and 
development against S. mansoni. 
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